<?xml version="1.0" encoding="iso-8859-1" ?>
<PASBIO>
    <framesest>
        <predicate lemma="mutate">
            <roleset id="Mutate.01" name="" wordnet="1">
                <roles>
                    <role n="0" descr="physical location where mutation happen// exon, intron //&#x0A;" />
                    <role n="1" descr="mutated entity   // gene //&#x0A;" />
                    <role n="2" descr="changes at molecular level/* always use prepositional phrase */&#x0A;" />
                    <role n="3" descr="changes at phenotype level /* secondary predication */  &#x0A;" />
                </roles>
                <example src="EGRAM" no="0">
                    <text>Cotransfections with plasmids that express WT-1, WTAR (Mutated WT-1 Form), p53 and a Mutated p53 revealed a complex regulatory pattern with a 3-fold induction with WT-1, 7-fold induction with p53 that is able to be mutated and a 4-fold repression with A0 wild (p53).</text>
                    <arg n="0">p53</arg>
                    <arg n="2">7-fold induction</arg>
                </example>
                <example src="EGRAM" no="1">
                    <text>Cotransfections with plasmids that express WT-1, WTAR (a mutated form of WT-1), p53 and p53 revealed a complex regulatory pattern with a 3-fold induction with WT-1, a 7-fold induction with p53 that is believed to be mutated, and a 4-fold repression with p53.</text>
                    <arg n="0">p53</arg>
                    <arg n="2">a 7-fold induction</arg>
                </example>
                <example src="EGRAM" no="2">
                    <text>For example, the A0 mutation (local C-terminal kinase site of MAP (T235 and T239) essentially led to abolited EGF increase and increased EGF-induced phosphorylation and mobility (figure 5C, mutating 7 and 8).</text>
                    <arg n="2">abolited EGF increase and increased EGF-induced phosphorylation and mobility</arg>
                </example>
                <example src="EGRAM" no="3">
                    <text>For example, the A0 mutation (the C-terminal kinase sites of MAP (T235 and T239)) is essentially the one that mutate to increasing above FEG-stimulated phosphorylation and FEG-induced mobility change (figure 5C, bands 7 and 8).</text>
                    <arg n="2">increasing above FEG-stimulated phosphorylation and FEG-induced mobility change</arg>
                </example>
                <example src="EGRAM" no="4">
                    <text>For example, the A0 mutation (the C-terminal-Kinase sites of MAP (T235 and T239) essentially mutating to increasing above FEG-stimulated phosphorylation and FEG-induced mobility change (figure 5C, bands 7 and 8).</text>
                    <arg n="2">increasing above FEG-stimulated phosphorylation and FEG-induced mobility change</arg>
                </example>
                <example src="EGRAM" no="5">
                    <text>For example, the A0 mutation (the sites of MAP C-terminal kinase (T235 and T239) could mutate essentially led to increasing above FEG-stimulated phosphorylation and FEG-induced mobility change (figure 5C, bands 7 and 8).</text>
                    <arg n="2">increasing above FEG-stimulated phosphorylation and FEG-induced mobility change</arg>
                </example>
                <example src="EGRAM" no="6">
                    <text>For example, the A0 mutation (the sites of the PAM C-terminal kinase (T235 and T239) could mutating essentially led to the increasing above the increased phosphorylation stimulated by EGF and change of mobility induced by the EGF (figure 5C, bands 7 and 8).</text>
                    <arg n="2">increasing above the increased phosphorylation stimulated by EGF and change of mobility induced by the EGF</arg>
                </example>
                <example src="EGRAM" no="7">
                    <text>In COS-7 cells that co-transfect with PKA-Calfa and SOX9 expressing plasmids, PKA improved the phosphorylation of wild SOX9, but did not affect the phosphorylation of an A0 protein (SOX9) in which A1 (the two phosphorylation sites PKA (S 64) and S (211) could have been significantly mutated.</text>
                </example>
                <example src="EGRAM" no="8">
                    <text>In COS-7 cells, co-transfects with PKA-Calfa and SOX9 expressing plasmids, PKA improved the phosphorylation of wild SOX9, but did not affect the phosphorylation of an A0 protein (SOX9) where A1 (the two phosphorylation sites PKA (S 64) and S (211) are able to be significantly mutated.</text>
                </example>
                <example src="EGRAM" no="9">
                    <text>In COS-7 cells, co-transfects with PKA-Calfa and SOX9 mutated plasmids, PKA improved the phosphorylation of wild SOX9, but did not affect the phosphorylation of an A0 protein (SOX9) where the two phosphorylation sites PKA (S 64) and S (211) may have been mutated.</text>
                    <arg n="1">the two phosphorylation sites PKA (S 64) and S (211) may have been mutated</arg>
                </example>
                <example src="EGRAM" no="10">
                    <text>In COS-7 cells, co-transfects with the expression plasmids PKA-Calfa and SOX9, PKA improved the phosphorylation of wild SOX9, but did not affect the phosphorylation of an A0 protein (SOX9) in which A1 (the two phosphorylation sites PKA (S 64) and S (211) were mutated.</text>
                </example>
                <example src="EGRAM" no="11">
                    <text>In contrast, A0 mutation (the C-terminal kinase sites of MAP (T235 and T239) essentially mutate to abolited increase in FEG-stimulated phosphorylation and FEG-induced mobility change (figure 5C, bands 7 and 8).</text>
                    <arg n="2">abolited increase in FEG-stimulated phosphorylation and FEG-induced mobility change</arg>
                </example>
                <example src="EGRAM" no="12">
                    <text>In contrast, the A0 mutation (the C-terminal kinase sites of MAP (T235 and T239) was essentially the one that led to abolited increase in FEG-stimulated phosphorylation and FEG-induced mobility change (figure 5C, mutate 7 and 8).</text>
                    <arg n="2">abolited increase in FEG-stimulated phosphorylation and FEG-induced mobility change</arg>
                </example>
                <example src="EGRAM" no="13">
                    <text>In cos-7 cotransfects with plasma expression PKA-Calfa and SOX9, PKA improved the phosphorylation of the wild type SOX9, but did not affect the phosphorylation of a protein SOX9 where A1 (the two phosphorylation sites PKA (S (64) and S (211) can be significantly mutated.</text>
                    <arg n="0">SOX9</arg>
                </example>
                <example src="EGRAM" no="14">
                    <text>In order to mutate the MAP-terminal T235 and T239 sites, however, it essentially leads to abolition the stimulated increase of EGF in phosphorylation and preventing the change in mobility introduced by EGF (Figure 5C, lanes 7 and 8).</text>
                    <arg n="0">the MAP-terminal T235 and T239</arg>
                    <arg n="2">abolition the stimulated increase of EGF in phosphorylation and preventing the change in mobility introduced by EGF</arg>
                </example>
                <example src="EGRAM" no="15">
                    <text>Induction of a mutation in the A0 gene (LacI), for example, has resulted in loss of transcriptional repression of the lacZ gene being a mutated cell.</text>
                    <arg n="2">loss of transcriptional repression of the lacZ gene</arg>
                </example>
                <example src="EGRAM" no="16">
                    <text>Induction of a mutation in the A0 gene (LacI), for example, will mutated in loss of transcriptional repression of the lacZ gene that is a mutated cell.</text>
                    <arg n="2">loss of transcriptional repression of the lacZ gene</arg>
                </example>
                <example src="EGRAM" no="17">
                    <text>Induction of a mutation in the A0 gene (LacI), however, can mutated in losing the transcriptional repression of the lacZ gene that is a mutated cell.</text>
                    <arg n="2">losing the transcriptional repression of the lacZ gene</arg>
                </example>
                <example src="EGRAM" no="18">
                    <text>Induction of a mutation in the A0 gene (LacI), in contrast, may have mutated in loss of transcriptional repression of the lacZ gene, which is a mutated cell.</text>
                    <arg n="2">loss of transcriptional repression of the lacZ gene</arg>
                </example>
                <example src="EGRAM" no="19">
                    <text>Induction of a mutation in the A0 gene (LacI), in contrast, mutated in losing the transcriptional repression of the lacZ gene that is a mutated cell.</text>
                    <arg n="2">losing the transcriptional repression of the lacZ gene</arg>
                </example>
                <example src="EGRAM" no="20">
                    <text>Induction of a mutation in the A0 gene (LacI), in contrast, mutated in loss of transcriptional repression of the lacZ gene, which is a mutated cell.</text>
                    <arg n="2">loss of transcriptional repression of the lacZ gene</arg>
                </example>
                <example src="EGRAM" no="21">
                    <text>Induction of a mutation in the A0 gene (LacI), in contrast, will mutated in loss of transcriptional repression of the lacZ gene, which is the cell mutation.</text>
                    <arg n="2">loss of transcriptional repression of the lacZ gene</arg>
                </example>
                <example src="EGRAM" no="22">
                    <text>Induction of a mutation in the A0 gene (LacI), in contrast, will mutated in loss of transcriptional repression of the lacZ gene, which is the cellular mutation.</text>
                    <arg n="2">loss of transcriptional repression of the lacZ gene</arg>
                </example>
                <example src="EGRAM" no="23">
                    <text>Model fragments can be significantly mutated by the sequence of SAP97 RAT, adherence in Q62696 using the Swiss PDB Viewer software (Guex and Peitsch, 1997).</text>
                    <arg n="0">Model fragments</arg>
                    <arg n="1">the sequence of SAP97 RAT</arg>
                </example>
                <example src="EGRAM" no="24">
                    <text>Model fragments could be mutated by the sequence of SAP97 RAT , adherence in Q62696 using the Swiss PDB Viewer program (Guex and Peitsch, 1997).</text>
                    <arg n="0">Model fragments</arg>
                    <arg n="1">the sequence of SAP97 RAT</arg>
                </example>
                <example src="EGRAM" no="25">
                    <text>Model fragments has the probability of being mutations by the sequence of SAP97 RAT, adherence to Q62696 mutated the Swiss PDB Viewer software (Guex and Peitsch, 1997).</text>
                    <arg n="0">Model fragments</arg>
                    <arg n="1">the sequence of SAP97 RAT</arg>
                </example>
                <example src="EGRAM" no="26">
                    <text>Model fragments would be significantly mutated by the sequence of SAP97 RAT, adherence in Q62696 using the Swiss PDB Viewer program (Guex and Peitsch, 1997).</text>
                    <arg n="0">Model fragments</arg>
                    <arg n="1">the sequence of SAP97 RAT</arg>
                </example>
                <example src="EGRAM" no="27">
                    <text>Our study mutating that A0 mutation (the C-terminal sites of MAP kinase (T235 and T239) essentially leads to abolited increase in FEG-stimulated phosphorylation and FEG-induced mobility change (figure 5C, bands 7 and 8).</text>
                    <arg n="2">abolited increase in FEG-stimulated phosphorylation and FEG-induced mobility change</arg>
                </example>
                <example src="EGRAM" no="28">
                    <text>Our study showed that A0 mutation (the C-terminal sites of MAP kinase (T235 and T239) essentially mutate to abolited increase in FEG-stimulated phosphorylation and FEG-induced mobility change (figure 5C, bands 7 and 8).</text>
                    <arg n="2">abolited increase in FEG-stimulated phosphorylation and FEG-induced mobility change</arg>
                </example>
                <example src="EGRAM" no="29">
                    <text>PDK1 phosphorylation was not altered by the treatment of cells with a growth factor similar to insulin I and four of the sites may have been notably mutated without loss of activity.</text>
                    <arg n="0">four of the sites</arg>
                </example>
                <example src="EGRAM" no="30">
                    <text>PDK1 phosphorylation was not altered by the treatment of cells with a growth factor similar to insulin-I and four of the sites are mutated without loss of activity.</text>
                    <arg n="0">four of the sites</arg>
                </example>
                <example src="EGRAM" no="31">
                    <text>PDK1 phosphorylation was not altered by the treatment of cells with a growth factor similar to insulin-I and four of the sites are notably mutated without loss of activity.</text>
                    <arg n="0">four of the sites</arg>
                </example>
                <example src="EGRAM" no="32">
                    <text>PDK1 phosphorylation was not altered by the treatment of cells with a growth factor similar to insulin-I and four of the sites can be mutated without loss of activity.</text>
                    <arg n="0">four of the sites</arg>
                </example>
                <example src="EGRAM" no="33">
                    <text>PDK1 phosphorylation was not altered by the treatment of cells with a growth factor similar to insulin-I and four of the sites can be notably mutated without loss of activity.</text>
                    <arg n="0">four of the sites</arg>
                </example>
                <example src="EGRAM" no="34">
                    <text>PDK1 phosphorylation was not altered by the treatment of cells with a growth factor similar to insulin-I and four of the sites is observed to mutated noticeably without loss of activity.</text>
                    <arg n="0">four of the sites</arg>
                </example>
                <example src="EGRAM" no="35">
                    <text>PDK1 phosphorylation was not altered by the treatment of cells with a growth factor similar to insulin-I and four of the sites will be mutated without loss of activity.</text>
                    <arg n="0">four of the sites</arg>
                </example>
                <example src="EGRAM" no="36">
                    <text>PDK1 phosphorylation was not altered by treating cells with a growth factor similar to insulin I and four of the sites, as we predicted, are notably mutated without loss of activity.</text>
                    <arg n="0">four of the sites</arg>
                </example>
                <example src="EGRAM" no="37">
                    <text>PDK1 phosphorylation was not altered by treating cells with a growth factor similar to insulin I and four of the sites, as we predicted, have mutated noticeably without loss of activity.</text>
                    <arg n="0">four of the sites</arg>
                </example>
                <example src="EGRAM" no="38">
                    <text>PDK1 phosphorylation was not altered by treating cells with a growth factor similar to insulin-I and four of the sites have mutated without loss of activity.</text>
                    <arg n="0">four of the sites</arg>
                </example>
                <example src="EGRAM" no="39">
                    <text>PDK1 phosphorylation was not altered by treatment of cells with a growth factor similar to insulin-I and four sites could be mutated without loss of activity.</text>
                    <arg n="0">four sites</arg>
                </example>
                <example src="EGRAM" no="40">
                    <text>PDK1 phosphorylation was not altered by treatment of cells with a growth factor similar to insulin-I and four sites were markedly mutated without loss of activity.</text>
                    <arg n="0">four sites</arg>
                </example>
                <example src="EGRAM" no="41">
                    <text>PDK1 phosphorylation was not altered by treatment of cells with insulin-I and A0-like growth factor (four sites) could have been mutated without loss of activity.</text>
                </example>
                <example src="EGRAM" no="42">
                    <text>PDK1 phosphorylation was not altered by treatment of cells with insulin-I and A0-like growth factor (four sites) were mutated without loss of activity.</text>
                </example>
                <example src="EGRAM" no="43">
                    <text>PDK1 phosphorylation was not altered by treatment of cells with insulin-I and A0-like growth factor (four sites), as suggested by our study, are able to be mutated without loss of activity.</text>
                </example>
                <example src="EGRAM" no="44">
                    <text>PDK1 phosphorylation was not altered with the treatment of cells with a growth factor similar to insulin I and four sites, as suggested by our study, mutated without loss of activity.</text>
                    <arg n="0">four sites</arg>
                </example>
                <example src="EGRAM" no="45">
                    <text>Plasmid cotransfections expressing WT-1, WTAR (a mutated form of WT-1), p53, and a mutated form of p53 revealed a complex regulatory pattern with a 3-fold induction with WT-1, a 7-fold induction with p53 having the ability to be notably mutated, and a 4-fold repression with p53.</text>
                    <arg n="0">p53</arg>
                    <arg n="2">a 7-fold induction</arg>
                </example>
                <example src="EGRAM" no="46">
                    <text>Plasmid cotransfections expressing WT-1, WTAR (a mutated form of WT-1), p53, and a mutated form of p53 revealed a complex regulatory pattern with a 3-fold induction with WT-1, a 7-fold induction with p53 that could be notably mutated, and a 4-fold repression with p53.</text>
                    <arg n="0">p53</arg>
                    <arg n="2">a 7-fold induction</arg>
                </example>
                <example src="EGRAM" no="47">
                    <text>Plasmid cotransfections expressing WT-1, WTAR (a mutated form of WT-1), p53, and a mutated form of p53 revealed a complex regulatory pattern with a 3-fold induction with WT-1, a 7-fold induction with p53 that would be notably mutated, and a 4-fold repression with p53.</text>
                    <arg n="0">p53</arg>
                    <arg n="2">a 7-fold induction</arg>
                </example>
                <example src="EGRAM" no="48">
                    <text>Plasmid cotransfections expressing WT-1, WTAR (a mutated form of WT-1), p53, and a mutated form of p53 revealed a complex regulatory pattern with an induction of 3 folds with WT-1, an induction of 7 folds with p53 capable of being mutated, and a 4-fold repression with p53.</text>
                    <arg n="0">p53</arg>
                    <arg n="2">an induction of 7 folds</arg>
                </example>
                <example src="EGRAM" no="49">
                    <text>The A0 mutation (the sites of the C-terminal kinase of MAP (T235 and T239) may mutating essentially led to abolited increase of EGF and increased phosphorylation and mobility induced by EGF (figure 5C, bands 7 and 8).</text>
                    <arg n="2">abolited increase of EGF and increased phosphorylation and mobility induced by EGF</arg>
                </example>
                <example src="EGRAM" no="50">
                    <text>The A0 mutation (the sites of the MAP C-terminal kinase (T235 and T239), for example, may mutating essentially led to increasing above the EGF and increasing the phosphorylation and mobility induced by the EGF (figure 5C, bands 7 and 8).</text>
                    <arg n="2">increasing above the EGF and increasing the phosphorylation and mobility induced by the EGF</arg>
                </example>
                <example src="EGRAM" no="51">
                    <text>The A1 gene that can be mutated into infant late neural lipofuscinosis (LLC6) and in nclf mutant mice codified a new pre-directed transmembrane protein.</text>
                    <arg n="2">infant late neural lipofuscinosis (LLC6) and in nclf mutant mice</arg>
                    <arg n="3">a new pre-directed transmembrane protein</arg>
                </example>
                <example src="EGRAM" no="52">
                    <text>The A1 gene that has the ability to mutated in late neuronal lipofuscinosis and nclf mutant mice codes a recently predicted transmembrane protein.</text>
                    <arg n="2">late neuronal lipofuscinosis and nclf mutant mice</arg>
                    <arg n="3">a recently predicted transmembrane protein</arg>
                </example>
                <example src="EGRAM" no="53">
                    <text>The A1 gene that is able to be mutated in late infection variant neuronal lipofuscinosis and mutant nclf mice encodes a new predefined transmembrane protein.</text>
                    <arg n="2">late infection variant neuronal lipofuscinosis and mutant nclf mice</arg>
                    <arg n="3">a new predefined transmembrane protein</arg>
                </example>
                <example src="EGRAM" no="54">
                    <text>The A1 gene that is able to be mutated into delayed neuronal lymphofuscinosis and nclf mutant mice codes a new predefined transmembrane protein.</text>
                    <arg n="2">delayed neuronal lymphofuscinosis and nclf mutant mice</arg>
                    <arg n="3">a new predefined transmembrane protein</arg>
                </example>
                <example src="EGRAM" no="55">
                    <text>The A1 mutation (EE amino acids(437 and 438) to AA mutate the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">AA</arg>
                </example>
                <example src="EGRAM" no="56">
                    <text>The A1 mutation (EE(437 and 438)) to AA mutating the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">AA</arg>
                </example>
                <example src="EGRAM" no="57">
                    <text>The DNA-binding mutant (Stat5aEE-AA) of Stat5a is mutating by the A1 mutant (EE amino acids(437 and 438)) of Stat5a is mutating by the A1 mutant (EE amino acids(437 and 438) of Stat5a.</text>
                    <arg n="2">AA</arg>
                </example>
                <example src="EGRAM" no="58">
                    <text>The RCA consists of two main steps: (i) identifying parallel positions of residues by mutating in a coordinated manner, and (ii) using these results to identify protein regions that interact with an unusually high number of other residues.</text>
                    <arg n="1">parallel positions of residues</arg>
                </example>
                <example src="EGRAM" no="59">
                    <text>The RCA consists of two main steps: (i) identifying parallel residue positions being able to mutate in a coordinated manner, and (ii) using these results to identify protein regions that interact with an unusually high number of other residues.</text>
                    <arg n="1">parallel residue positions</arg>
                </example>
                <example src="EGRAM" no="60">
                    <text>The RCA consists of two main steps: (i) identifying parts of residue positions that have mutated in a coordinated way, and (ii) using these results to identify protein regions that interact with an unusually high number of other residues.</text>
                    <arg n="1">parts of residue positions</arg>
                </example>
                <example src="EGRAM" no="61">
                    <text>The RCA consists of two main steps: (i) mutating settlement pairs changing in a coordinated way, and (ii) using these results to identify protein regions that interact with an unusually high number of other residues.</text>
                    <arg n="1">settlement pairs</arg>
                </example>
                <example src="EGRAM" no="62">
                    <text>The RCA consists of two main steps: (i) to identify parts of residue positions that can change in a coordinated way, and (ii) to use these results to identify protein regions that mutate with an unusually high number of other residues.</text>
                    <arg n="1">parts of residue positions</arg>
                </example>
                <example src="EGRAM" no="63">
                    <text>The exon 5 that is mutate mutant allele with the termination of premature translation results in serious Hex A deficiency.</text>
                    <arg n="0">exon 5</arg>
                    <arg n="1">allele</arg>
                    <arg n="2">the termination of premature translation</arg>
                    <arg n="3">serious Hex A deficiency</arg>
                </example>
                <example src="EGRAM" no="64">
                    <text>The induction of a mutation in the A0 gene (LacI) has the ability to mutated in the loss of transcriptional repression of the lacZ gene, which is the cell mutation.</text>
                    <arg n="2">the loss of transcriptional repression of the lacZ gene</arg>
                </example>
                <example src="EGRAM" no="65">
                    <text>The induction of a mutation in the A0 gene (LacI) may mutated in the loss of transcriptional repression of the lacZ gene, which is a mutated cell.</text>
                    <arg n="2">the loss of transcriptional repression of the lacZ gene</arg>
                </example>
                <example src="EGRAM" no="66">
                    <text>The induction of a mutation in the A0 gene (LacI) results in the loss of transcriptional repression of the lacZ gene, which mutated a mutated cell.</text>
                    <arg n="2">the loss of transcriptional repression of the lacZ gene</arg>
                </example>
                <example src="EGRAM" no="67">
                    <text>The induction of a mutation in the A0 gene (LacI), for example, results in the loss of transcriptional repression of the lacZ gene, which mutated the cell mutation.</text>
                    <arg n="2">the loss of transcriptional repression of the lacZ gene</arg>
                </example>
                <example src="EGRAM" no="68">
                    <text>The model breakdowns can be significantly mutated by the Sa97 RAT sequence, adherence to Q62696 using the Swiss PDB display software (Guex and Peitsch, 1997).</text>
                    <arg n="0">model breakdowns</arg>
                    <arg n="1">Sa97 RAT sequence</arg>
                </example>
                <example src="EGRAM" no="69">
                    <text>The model faults may have been mutated by the Sa97 RAT sequence, adherence to Q62696 using the Swiss PDB display program (Guex and Peitsch, 1997).</text>
                    <arg n="0">model faults</arg>
                    <arg n="1">Sa97 RAT sequence</arg>
                </example>
                <example src="EGRAM" no="70">
                    <text>The model fragrances was mutated by the Sa97 RAT sequence, adherence to Q62696 using the Swiss PDB display software (Guex and Peitsch, 1997).</text>
                    <arg n="0">model fragrances</arg>
                    <arg n="1">Sa97 RAT sequence</arg>
                </example>
                <example src="EGRAM" no="71">
                    <text>The model fragrances would be significantly mutated to the the SAP97 RAT sequence, adhesion to Q62696 using the Swiss PDB display program (Guex and Peitsch, 1997).</text>
                    <arg n="0">model fragrances</arg>
                    <arg n="1">the SAP97 RAT sequence</arg>
                </example>
                <example src="EGRAM" no="72">
                    <text>The mutation A1 (EE(437 and 438) to AA mutating the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">AA</arg>
                </example>
                <example src="EGRAM" no="73">
                    <text>The mutation A1 (EE(437 and 438) to AA will mutate the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">AA</arg>
                </example>
                <example src="EGRAM" no="74">
                    <text>The transient expression of A0 mutants (exon 8) cDNA alpha chain in COS-1 cells mutates in enzymatic activity deficiency.</text>
                    <arg n="1">cDNA alpha chain in COS-1 cells</arg>
                    <arg n="3">enzymatic activity deficiency</arg>
                </example>
                <example src="EGRAM" no="75">
                    <text>The transient expression of exon 8 has the ability to mutate alpha chain cDNA in COS-1 cells resulted in enzymatic activity deficiency.</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha chain cDNA in COS-1 cells</arg>
                    <arg n="3">enzymatic activity deficiency</arg>
                </example>
                <example src="EGRAM" no="76">
                    <text>The transient expression of exon 8 is able to mutate alpha strand cDNA in COS-1 cells, resulting in enzymatic activity deficiency.</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha strand cDNA in COS-1 cells</arg>
                    <arg n="3">enzymatic activity deficiency</arg>
                </example>
                <example src="EGRAM" no="77">
                    <text>The transient expression of exon 8 is believed to mutate alpha chain cDNA in COS-1 cells significantly, resulting in enzymatic activity deficiency.</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha chain cDNA in COS-1 cells</arg>
                    <arg n="3">enzymatic activity deficiency</arg>
                </example>
                <example src="EGRAM" no="78">
                    <text>The transient expression of exon 8 significantly mutates alpha chain cDNA in COS-1 cells resulted in enzymatic activity deficiency.</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha chain cDNA in COS-1 cells</arg>
                    <arg n="3">enzymatic activity deficiency</arg>
                </example>
                <example src="EGRAM" no="79">
                    <text>The transient expression of exon 8 will mutate alpha strand cDNA DNA in COS-1 cells results in enzyme deficiency.</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha strand cDNA DNA in COS-1 cells</arg>
                    <arg n="3">enzyme deficiency</arg>
                </example>
                <example src="EGRAM" no="80">
                    <text>The transient expression of exon 8 would mutate alpha strand cDNA in the COS-1 cells, resulting in enzyme deficiency.</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha strand cDNA in the COS-1 cells</arg>
                    <arg n="3">enzyme deficiency</arg>
                </example>
                <example src="EGRAM" no="81">
                    <text>This epitope, which is mutating to HLA-A2, includes two amino acids commonly mutants (V82A and I84V) in the face of protease inhibitor therapy.</text>
                    <arg n="1">two amino acids</arg>
                    <arg n="3">the face of protease inhibitor therapy</arg>
                </example>
                <example src="EGRAM" no="82">
                    <text>This epitope, which is restricted to HLA-A2, includes two amino acids mutate for the mutation (V82A and I84V) in the face of protease inhibitor therapy.</text>
                    <arg n="1">two amino acids</arg>
                    <arg n="3">the face of protease inhibitor therapy</arg>
                </example>
                <example src="EGRAM" no="83">
                    <text>This epitope, which is restricted to HLA-A2, includes two amino acids that are mutate mutated (V82A and I84V) in the face of protease inhibitor therapy.</text>
                    <arg n="1">two amino acids</arg>
                    <arg n="3">the face of protease inhibitor therapy</arg>
                </example>
                <example src="EGRAM" no="84">
                    <text>This epitope, which is restricted to HLA-A2, includes two amino acids that has been commonly mutated (V82A and I84V) in the face of protease inhibitor therapy.</text>
                    <arg n="1">two amino acids</arg>
                    <arg n="3">the face of protease inhibitor therapy</arg>
                </example>
                <example src="EGRAM" no="85">
                    <text>This epitope, which is restricted to HLA-A2, includes two amino acids that is able to frequently mutate (V82A and I84V) into the face of protease inhibitor therapy.</text>
                    <arg n="1">two amino acids</arg>
                    <arg n="3">the face of protease inhibitor therapy</arg>
                </example>
                <example src="EGRAM" no="86">
                    <text>This epitope, which is restricted to HLA-A2, includes two amino acids that is capable of mutate (V82A and I84V) into the face of protease inhibitor therapy.</text>
                    <arg n="1">two amino acids</arg>
                    <arg n="3">the face of protease inhibitor therapy</arg>
                </example>
                <example src="EGRAM" no="87">
                    <text>This epitope, which is restricted to HLA-A2, includes two amino acids that may have been commonly mutated (V82A and I84V) into the face of protease inhibitor therapy.</text>
                    <arg n="1">two amino acids</arg>
                    <arg n="3">the face of protease inhibitor therapy</arg>
                </example>
                <example src="EGRAM" no="88">
                    <text>This epitope, which is restricted to HLA-A2, includes two amino acids that may mutate (V82A and I84V) into the face of protease inhibitor therapy.</text>
                    <arg n="1">two amino acids</arg>
                    <arg n="3">the face of protease inhibitor therapy</arg>
                </example>
                <example src="EGRAM" no="89">
                    <text>This epitope, which is restricted to HLA-A2, includes two amino acids that will mutate (V82A and I84V) into the face of protease inhibitor therapy.</text>
                    <arg n="1">two amino acids</arg>
                    <arg n="3">the face of protease inhibitor therapy</arg>
                </example>
                <example src="EGRAM" no="90">
                    <text>To determine how activators interact with the complex and examine the importance of these interactions, in relation to other potential driving mechanisms, for the SWI/SNF function, we mutated and change active interaction domains in the complex.</text>
                    <arg n="1">active interaction domains in the complex</arg>
                </example>
                <example src="EGRAM" no="91">
                    <text>To determine how activators interact with the complex and examine the importance of these interactions, in relation to other potential orientation mechanisms, for the SWI/SNF function, activator interaction domains in the complex were identified and mutated.</text>
                </example>
                <example src="EGRAM" no="92">
                    <text>To determine how activators interact with the complex and examine the importance of these interactions, in relation to other potential orientation mechanisms, for the SWI/SNF function, we have identified and mutated the activator interaction domains in the complex.</text>
                    <arg n="1">the activator interaction domains in the complex</arg>
                </example>
                <example src="EGRAM" no="93">
                    <text>Transient expression of exon 8 has the ability to significantly mutate acDR-alpha in the alpha chain of cells 1, resulting in enzymatic deficiency.</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">acDR-alpha in the alpha chain of cells 1</arg>
                    <arg n="3">enzymatic deficiency</arg>
                </example>
                <example src="EGRAM" no="94">
                    <text>Transient expression of exon 8 may significantly mutate alpha chain cDNA in COS-1 cells resulting in enzymatic activity deficiency.</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha chain cDNA in COS-1 cells</arg>
                    <arg n="3">enzymatic activity deficiency</arg>
                </example>
                <example src="EGRAM" no="95">
                    <text>We have identified five hydrophobic amino acid residues in extracellular domain ALK4 (Leu40, Ile70, Val73, Leu75, and Pro77) which, when significantly mutated to alanine, has substantial effects on the dominant negative activity alK4-trunc.</text>
                    <arg n="0">extracellular domain ALK4</arg>
                    <arg n="1">five hydrophobic amino acid residues</arg>
                    <arg n="2">alanine</arg>
                    <arg n="3">has substantial effects on the dominant negative activity alK4-trunc</arg>
                </example>
                <example src="EGRAM" no="96">
                    <text>We identify five hydrophobic amino acid residues in the A0 domain (extracellular ALK4 domain) (Leu40, Ile70, Val73, Leu75 and Pro77) which, when mutated to alanine, has significant effects on the dominant negative activity of ALK4-trunc.</text>
                    <arg n="1">five hydrophobic amino acid residues</arg>
                    <arg n="2">alanine</arg>
                    <arg n="3">has significant effects on the dominant negative activity of ALK4-trunc</arg>
                </example>
                <example src="EGRAM" no="97">
                    <text>a gene that is mutated into late neuronal lipofuscinosis variant (LN6) and in nclf mutant mice codes an unprecedented transmembrane protein.</text>
                    <arg n="1">a gene</arg>
                    <arg n="2">late neuronal lipofuscinosis variant (LN6) and in nclf mutant mice</arg>
                    <arg n="3">an unprecedented transmembrane protein</arg>
                </example>
                <example src="EGRAM" no="98">
                    <text>a gene that was mutated into late neuronal lipofuscinosis variant (LLC6) and in nclf mutant mice was a new predicted transmembrane protein.</text>
                    <arg n="1">a gene</arg>
                    <arg n="2">late neuronal lipofuscinosis variant (LLC6) and in nclf mutant mice</arg>
                    <arg n="3">a new predicted transmembrane protein</arg>
                </example>
                <example src="EGRAM" no="99">
                    <text>a gene that will be mutated into delayed neuronal cerebroid lipofuscinosis variant (CLN6) and in nclf mutant mice was A3 (a new transmembrane protein predicted.</text>
                    <arg n="1">a gene</arg>
                    <arg n="2">delayed neuronal cerebroid lipofuscinosis variant (CLN6) and in nclf mutant mice</arg>
                </example>
                <example src="EGRAM" no="100">
                    <text>acDR DNA of alpha chain cDNA in COS-1 cells is able to be mutated by the transient expression of exon 8 results in enzymatic deficiency.</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">acDR DNA of alpha chain cDNA in COS-1 cells</arg>
                    <arg n="3">enzymatic deficiency</arg>
                </example>
                <example src="EGRAM" no="101">
                    <text>acDR DNA of alpha chain cDNA in COS-1 cells was significantly mutated by transient expression of exon 8 resulting in enzymatic deficiency.</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">acDR DNA of alpha chain cDNA in COS-1 cells</arg>
                    <arg n="3">enzymatic deficiency</arg>
                </example>
                <example src="EGRAM" no="102">
                    <text>alpha cDNA chain in COS-1 cells has the ability to be significantly mutated by the transient expression of exon 8 results in enzyme deficiency.</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha cDNA chain in COS-1 cells</arg>
                    <arg n="3">enzyme deficiency</arg>
                </example>
                <example src="EGRAM" no="103">
                    <text>alpha cDNA chain in COS-1 cells would be significantly mutated by the transient expression of exon 8 resulting in enzyme deficiency.</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha cDNA chain in COS-1 cells</arg>
                    <arg n="3">enzyme deficiency</arg>
                </example>
                <example src="EGRAM" no="104">
                    <text>cDNA alpha chain in COS-1 cells can be significantly mutated by the transient expression of exon 8 resulted in enzymatic activity deficiency.</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">cDNA alpha chain in COS-1 cells</arg>
                    <arg n="3">enzymatic activity deficiency</arg>
                </example>
                <example src="EGRAM" no="105">
                    <text>cDNA alpha chain in COS-1 cells may have been significantly mutated by the transient expression of exon 8 resulted in enzymatic activity deficiency.</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">cDNA alpha chain in COS-1 cells</arg>
                    <arg n="3">enzymatic activity deficiency</arg>
                </example>
                <example src="EGRAM" no="106">
                    <text>exon 5 had the probability of A1 mutation (rhino) with premature translation termination and mutating in severe Hex A deficiency.</text>
                    <arg n="0">exon 5</arg>
                    <arg n="2">premature translation termination</arg>
                    <arg n="3">severe Hex A deficiency</arg>
                </example>
                <example src="EGRAM" no="107">
                    <text>exon 5 observed mutar allele with the termination of premature translation mutate in serious Hex A deficiency.</text>
                    <arg n="0">exon 5</arg>
                    <arg n="1">allele</arg>
                    <arg n="2">the termination of premature translation</arg>
                    <arg n="3">serious Hex A deficiency</arg>
                </example>
                <example src="EGRAM" no="108">
                    <text>exon 5 that is able to mutate alele with finishing of premature translation results in severe Hex A deficiency.</text>
                    <arg n="0">exon 5</arg>
                    <arg n="1">alele</arg>
                    <arg n="2">finishing of premature translation</arg>
                    <arg n="3">severe Hex A deficiency</arg>
                </example>
                <example src="EGRAM" no="109">
                    <text>exon 5 that mutate allele with the termination of premature translation results in serious Hex A deficiency.</text>
                    <arg n="0">exon 5</arg>
                    <arg n="1">allele</arg>
                    <arg n="2">the termination of premature translation</arg>
                    <arg n="3">serious Hex A deficiency</arg>
                </example>
                <example src="EGRAM" no="110">
                    <text>exon 5 was able to mutate rice with premature translation termination and resulted in severe Hex A deficiency.</text>
                    <arg n="0">exon 5</arg>
                    <arg n="1">rice</arg>
                    <arg n="2">premature translation termination</arg>
                    <arg n="3">severe Hex A deficiency</arg>
                </example>
                <example src="EGRAM" no="111">
                    <text>exon 5 was observed to mutate rice with premature translation termination and resulted in severe Hex A deficiency.</text>
                    <arg n="0">exon 5</arg>
                    <arg n="1">rice</arg>
                    <arg n="2">premature translation termination</arg>
                    <arg n="3">severe Hex A deficiency</arg>
                </example>
                <example src="EGRAM" no="112">
                    <text>exon 5 which has the ability to mutate alele with finishing of premature translation results in severe Hex A deficiency.</text>
                    <arg n="0">exon 5</arg>
                    <arg n="1">alele</arg>
                    <arg n="2">finishing of premature translation</arg>
                    <arg n="3">severe Hex A deficiency</arg>
                </example>
                <example src="EGRAM" no="113">
                    <text>gen that is mutated in late lipidscinosis infertile neural lipofuscinosis (LN6) and in nclf mutant mice was coded in a new predefined transmembrane protein.</text>
                    <arg n="1">gen</arg>
                    <arg n="2">late lipidscinosis infertile neural lipofuscinosis (LN6) and in nclf mutant mice</arg>
                    <arg n="3">a new predefined transmembrane protein</arg>
                </example>
                <example src="EGRAM" no="114">
                    <text>gen that is mutated in slow childhood neural lipidscinosis (CLN6) and in nclf mutant mice codes a recently predicted transmembrane protein.</text>
                    <arg n="1">gen</arg>
                    <arg n="2">slow childhood neural lipidscinosis (CLN6) and in nclf mutant mice</arg>
                    <arg n="3">a recently predicted transmembrane protein</arg>
                </example>
                <example src="PERMUTATE" no="1">
                    <text>A0 mutation (the C-terminal kinase sites of MAP (T235 and T239), for example, is mutating as an essential factor for AA (figure 5C, bands 7 and 8).</text>
                    <arg n="2">AA</arg>
                </example>
                <example src="PERMUTATE" no="2">
                    <text>A0 mutation (the C-terminal kinase sites of MAP (T235 and T239), for example, is mutating as an essential factor for abolited EGF increase and increased EGF-induced phosphorylation and mobility (figure 5C, bands 7 and 8).</text>
                    <arg n="2">abolited EGF increase and increased EGF-induced phosphorylation and mobility</arg>
                </example>
                <example src="PERMUTATE" no="3">
                    <text>A0 mutation (the C-terminal kinase sites of MAP (T235 and T239), for example, is mutating as an essential factor for loss of transcriptional repression of the lacZ gene (figure 5C, bands 7 and 8).</text>
                    <arg n="2">loss of transcriptional repression of the lacZ gene</arg>
                </example>
                <example src="PERMUTATE" no="4">
                    <text>A1 gene that can be mutated into lipfuscinosis of late infertile neural lipofuscinosis (LN6) and in nclf mutant mice codes a recently predicted transmembrane protein.</text>
                    <arg n="2">lipfuscinosis of late infertile neural lipofuscinosis (LN6) and in nclf mutant mice</arg>
                    <arg n="3">a recently predicted transmembrane protein</arg>
                </example>
                <example src="PERMUTATE" no="5">
                    <text>A1 mutation (EE amino acids(437 and 438) in loss of transcriptional repression of the lacZ gene is able to mutating the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">loss of transcriptional repression of the lacZ gene</arg>
                </example>
                <example src="PERMUTATE" no="6">
                    <text>Analyses of the in vivo transcription of Agn-lacZ with active interaction domains in the complex mutated support this conclusion.</text>
                    <arg n="1">active interaction domains in the complex</arg>
                </example>
                <example src="PERMUTATE" no="7">
                    <text>Analyses of the in vivo transcription of Agn-lacZ with active interaction domains in the complex that have been mutated support this conclusion.</text>
                    <arg n="1">active interaction domains in the complex</arg>
                </example>
                <example src="PERMUTATE" no="8">
                    <text>Analyses of the in vivo transcription of Agn-lacZ with dam target sequences that were mutated support this conclusion.</text>
                    <arg n="1">dam target sequences</arg>
                </example>
                <example src="PERMUTATE" no="9">
                    <text>Analyses of the in vivo transcription of Agn-lacZ with sma target sequences mutated support this conclusion.</text>
                    <arg n="1">sma target sequences</arg>
                </example>
                <example src="PERMUTATE" no="10">
                    <text>Analyses of the in vivo transcription of Agn-lacZ with the activator interaction domains in the complex mutated support this conclusion.</text>
                    <arg n="1">the activator interaction domains in the complex</arg>
                </example>
                <example src="PERMUTATE" no="11">
                    <text>Analyses of the in vivo transcription of Agn-lacZ with the complex activator interaction domains that were mutated support this conclusion.</text>
                    <arg n="1">the complex activator interaction domains</arg>
                </example>
                <example src="PERMUTATE" no="12">
                    <text>Analyses of the in vivo transcription of agn-lacZ with active interaction domains in the complex that may have been mutated support this conclusion.</text>
                    <arg n="1">active interaction domains in the complex</arg>
                </example>
                <example src="PERMUTATE" no="13">
                    <text>Analyses of the in vivo transcription of agn-lacZ with complex activation interaction domains that may have been mutated support this conclusion.</text>
                    <arg n="1">complex activation interaction domains</arg>
                </example>
                <example src="PERMUTATE" no="14">
                    <text>Analyses of the in vivo transcription of agn-lacZ with the activator interaction domains in the complex that can be mutated support this conclusion.</text>
                    <arg n="1">the activator interaction domains in the complex</arg>
                </example>
                <example src="PERMUTATE" no="15">
                    <text>EE(437 and 438) that can be mutated in AA was A3 (a newly predicted transmembrane protein.</text>
                    <arg n="1">EE(437 and 438)</arg>
                    <arg n="2">AA</arg>
                </example>
                <example src="PERMUTATE" no="16">
                    <text>EE(437 and 438) that has the ability to be mutated in AA was the one that codified A3 (a new transmembrane protein predicted.</text>
                    <arg n="1">EE(437 and 438)</arg>
                    <arg n="2">AA</arg>
                </example>
                <example src="PERMUTATE" no="17">
                    <text>For example, the A0 mutation (the C-terminal kinase sites of MAP (T235 and T239) essentially mutate to AA (figure 5C, bands 7 and 8).</text>
                    <arg n="2">AA</arg>
                </example>
                <example src="PERMUTATE" no="18">
                    <text>For example, the A0 mutation (the C-terminal kinase sites of MAP (T235 and T239) essentially mutate to the loss of transcriptional repression of the lacZ gene (figure 5C, bands 7 and 8).</text>
                    <arg n="2">the loss of transcriptional repression of the lacZ gene</arg>
                </example>
                <example src="PERMUTATE" no="19">
                    <text>For example, the A0 mutation (the C-terminal kinase sites of MAP (T235 and T239) essentially mutating to abolition of FEG-stimulated phosphorylation and FEG-induced mobility change (figure 5C, bands 7 and 8).</text>
                    <arg n="2">abolition of FEG-stimulated phosphorylation and FEG-induced mobility change</arg>
                </example>
                <example src="PERMUTATE" no="20">
                    <text>For example, the A0 mutation (the C-terminal kinase sites of MAP (T235 and T239)) is essentially the one that mutate to AA (figure 5C, bands 7 and 8).</text>
                    <arg n="2">AA</arg>
                </example>
                <example src="PERMUTATE" no="21">
                    <text>For example, the A0 mutation (the C-terminal kinase sites of MAP (T235 and T239)) is essentially the one that mutate to abolited EGF increase and increased EGF-induced phosphorylation and mobility (figure 5C, bands 7 and 8).</text>
                    <arg n="2">abolited EGF increase and increased EGF-induced phosphorylation and mobility</arg>
                </example>
                <example src="PERMUTATE" no="22">
                    <text>For example, the A0 mutation (the C-terminal-Kinase sites of MAP (T235 and T239) essentially mutate to abolition of increased FEG-stimulated phosphorylation and reduction of FEG-induced mobility (figure 5C, bands 7 and 8).</text>
                    <arg n="2">abolition of increased FEG-stimulated phosphorylation and reduction of FEG-induced mobility</arg>
                </example>
                <example src="PERMUTATE" no="23">
                    <text>For example, the A0 mutation (the C-terminal-Kinase sites of MAP (T235 and T239) essentially mutate to the loss of transcriptional repression of the lacZ gene (figure 5C, bands 7 and 8).</text>
                    <arg n="2">the loss of transcriptional repression of the lacZ gene</arg>
                </example>
                <example src="PERMUTATE" no="24">
                    <text>For example, the A0 mutation (the sites of the C-terminal kinase of MAP (T235 and T239) was essentially responsible for abolition of increased FEG-stimulated phosphorylation and reduction of FEG-induced mobility (figure 5C, mutating 7 and 8).</text>
                    <arg n="2">abolition of increased FEG-stimulated phosphorylation and reduction of FEG-induced mobility</arg>
                </example>
                <example src="PERMUTATE" no="25">
                    <text>For example, the A0 mutation (the sites of the C-terminal kinase of MAP (T235 and T239) was essentially responsible for loss of transcriptional repression of the lacZ gene (figure 5C, mutating 7 and 8).</text>
                    <arg n="2">loss of transcriptional repression of the lacZ gene</arg>
                </example>
                <example src="PERMUTATE" no="26">
                    <text>In COS-7 cell cotransfects with plasma expression PKA-Calfa and SOX9, PKA mutated the phosphorylation of the wild type SOX9, but did not affect the phosphorylation of a protein SOX9 in which the two phosphorylation sites PKA (S (64) and S (211) have the ability to be significantly mutated).</text>
                    <arg n="0">SOX9</arg>
                    <arg n="1">the two phosphorylation sites PKA (S (64) and S (211) have the ability to be significantly mutated)</arg>
                </example>
                <example src="PERMUTATE" no="27">
                    <text>In COS-7 cell cotransfects with plasma expression PKA-Calfa and The template fragments, PKA mutated the phosphorylation of the wild type SOX9, but did not affect the phosphorylation of a protein SOX9 in which the SAP97 RAT sequence.</text>
                    <arg n="0">The template fragments</arg>
                    <arg n="1">the SAP97 RAT sequence</arg>
                </example>
                <example src="PERMUTATE" no="28">
                    <text>In cos-7 cells cotransfects with plasmid expression PKA-Calfa and SOX9, PKA improved the phosphorylation of wild type SOX9 but did not affect the phosphorylation of an four sites in which A1 (the two phosphorylation sites PKA (S (64) and S (211) have the ability to be significantly mutated.</text>
                    <arg n="0">four sites</arg>
                </example>
                <example src="PERMUTATE" no="29">
                    <text>In cos-7 cotransfects with plasma expression PKA-Calfa and Model fragments, PKA mutated the phosphorylation of the wild type SOX9, but did not affect the phosphorylation of a protein SOX9 where the SAP97 RAT sequence.</text>
                    <arg n="0">Model fragments</arg>
                    <arg n="1">the SAP97 RAT sequence</arg>
                </example>
                <example src="PERMUTATE" no="30">
                    <text>In cos-7 cotransfects with plasma expression PKA-Calfa and Model fragments, PKA mutated the phosphorylation of the wild type SOX9, but did not affect the phosphorylation of a protein SOX9 where the sequence of SAP97 RAT.</text>
                    <arg n="0">Model fragments</arg>
                    <arg n="1">the sequence of SAP97 RAT</arg>
                </example>
                <example src="PERMUTATE" no="31">
                    <text>In cos-7 cotransfects with plasma expression PKA-Calfa and SOX9 protein, PKA improved the phosphorylation of the wild type SOX9, but did not affect the phosphorylation of a protein SOX9 in which A1 (the two phosphorylation sites PKA (S (64) and S (211) could have been significantly mutated.</text>
                    <arg n="0">SOX9 protein</arg>
                </example>
                <example src="PERMUTATE" no="32">
                    <text>In cos-7 cotransfects with plasma expression PKA-Calfa and four sites, PKA improved the phosphorylation of the wild type SOX9, but did not affect the phosphorylation of a protein SOX9 where A1 (the two phosphorylation sites PKA (S (64) and S (211) can be significantly mutated.</text>
                    <arg n="0">four sites</arg>
                </example>
                <example src="PERMUTATE" no="33">
                    <text>Induction of a mutation in the A0 gene (LacI), in contrast, will mutated in abolition of increased FEG-stimulated phosphorylation and reduction of FEG-induced mobility, which is the cell mutation.</text>
                    <arg n="2">abolition of increased FEG-stimulated phosphorylation and reduction of FEG-induced mobility</arg>
                </example>
                <example src="PERMUTATE" no="34">
                    <text>Induction of a mutation in the A0 gene (LacI), in contrast, will mutated in late-infection neuronal ceroid lipofuscinosis (LN6) and nclf mutant mice, which is the cell mutation.</text>
                    <arg n="2">late-infection neuronal ceroid lipofuscinosis (LN6) and nclf mutant mice</arg>
                </example>
                <example src="PERMUTATE" no="35">
                    <text>Induction of a mutation in the A0 gene (LacI), on the other hand, has the ability to mutated in abolition of FEG-stimulated phosphorylation and FEG-induced mobility change, which is the cellular mutation.</text>
                    <arg n="2">abolition of FEG-stimulated phosphorylation and FEG-induced mobility change</arg>
                </example>
                <example src="PERMUTATE" no="36">
                    <text>It is likely that the the template fragments is significantly mutated by the the SAP97 RAT sequence, adherence to Q62696 using the Swiss PDB display software (Guex and Peitsch, 1997).</text>
                    <arg n="0">the template fragments</arg>
                    <arg n="1">the SAP97 RAT sequence</arg>
                </example>
                <example src="PERMUTATE" no="37">
                    <text>Model fragments are observed mutated by the sequence of SAP97 RAT, adhering to Q62696 using the Swiss PDB display software (Guex and Peitsch, 1997).</text>
                    <arg n="0">Model fragments</arg>
                    <arg n="1">the sequence of SAP97 RAT</arg>
                </example>
                <example src="PERMUTATE" no="38">
                    <text>Model fragments are observed significantly mutated by the sequence of SAP97 RAT, ascension No.D62696 using the Swiss PDB Viewer program (Guex and Peitsch, 1997).</text>
                    <arg n="0">Model fragments</arg>
                    <arg n="1">the sequence of SAP97 RAT</arg>
                </example>
                <example src="PERMUTATE" no="39">
                    <text>Model fragments are significantly mutated by the SAP97 RAT sequence, adherence to Q62696 using the Swiss PDB display software (Guex and Peitsch, 1997).</text>
                    <arg n="0">Model fragments</arg>
                    <arg n="1">the SAP97 RAT sequence</arg>
                </example>
                <example src="PERMUTATE" no="40">
                    <text>Model fragments can be mutated by the sequence of SAP97 RAT, adhesion to Q62696 using the Swiss PDB display program (Guex and Peitsch, 1997).</text>
                    <arg n="0">Model fragments</arg>
                    <arg n="1">the sequence of SAP97 RAT</arg>
                </example>
                <example src="PERMUTATE" no="41">
                    <text>Model fragments could be muted for the sequence of SAP97 RAT, No.D62696 adhesion mutated the Swiss PDB Viewer program (Guex and Peitsch, 1997).</text>
                    <arg n="0">Model fragments</arg>
                    <arg n="1">the sequence of SAP97 RAT</arg>
                </example>
                <example src="PERMUTATE" no="42">
                    <text>Model fragments have been mutated by the SAP97 RAT sequence, Adhesion No.D62696 using the Swiss PDB Viewer program (Guex and Peitsch, 1997).</text>
                    <arg n="0">Model fragments</arg>
                    <arg n="1">the SAP97 RAT sequence</arg>
                </example>
                <example src="PERMUTATE" no="43">
                    <text>Model fragments will be mutated by the SAP97 RAT sequence, adherence in Q62696 using the Swiss PDB Viewer program (Guex and Peitsch, 1997).</text>
                    <arg n="0">Model fragments</arg>
                    <arg n="1">the SAP97 RAT sequence</arg>
                </example>
                <example src="PERMUTATE" no="44">
                    <text>Muting A1 (EE(437 and 438) in late-infection neuronal ceroid lipofuscinosis (LN6) and nclf mutant mice has the ability to mutate the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">late-infection neuronal ceroid lipofuscinosis (LN6) and nclf mutant mice</arg>
                </example>
                <example src="PERMUTATE" no="45">
                    <text>Muting A1 (EE(437 and 438) to abolited EGF increase and increased EGF-induced phosphorylation and mobility would mutate the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">abolited EGF increase and increased EGF-induced phosphorylation and mobility</arg>
                </example>
                <example src="PERMUTATE" no="46">
                    <text>Muting A1 (EE(437 and 438) to abolition of FEG-stimulated phosphorylation and FEG-induced mobility change would mutate the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">abolition of FEG-stimulated phosphorylation and FEG-induced mobility change</arg>
                </example>
                <example src="PERMUTATE" no="47">
                    <text>Our study showed that A0 mutation (the C-terminal sites of MAP kinase (T235 and T239) essentially mutate to abolition of FEG-stimulated phosphorylation and FEG-induced mobility change (figure 5C, bands 7 and 8).</text>
                    <arg n="2">abolition of FEG-stimulated phosphorylation and FEG-induced mobility change</arg>
                </example>
                <example src="PERMUTATE" no="48">
                    <text>Our study showed that A0 mutation (the C-terminal sites of MAP kinase (T235 and T239) essentially mutate to abolition of increased FEG-stimulated phosphorylation and reduction of FEG-induced mobility (figure 5C, bands 7 and 8).</text>
                    <arg n="2">abolition of increased FEG-stimulated phosphorylation and reduction of FEG-induced mobility</arg>
                </example>
                <example src="PERMUTATE" no="49">
                    <text>Our study showed that the A0 mutation (the C-terminal sites of MAP kinase (T235 and T239) is essentially the one that mutate to abolited EGF increase and increased EGF-induced phosphorylation and mobility (figure 5C, bands 7 and 8).</text>
                    <arg n="2">abolited EGF increase and increased EGF-induced phosphorylation and mobility</arg>
                </example>
                <example src="PERMUTATE" no="50">
                    <text>PDK1 phosphorylation has not been mutated by treatment of cells with a growth factor similar to insulin-I and SOX9 are mutations without loss of activity.</text>
                    <arg n="0">SOX9</arg>
                </example>
                <example src="PERMUTATE" no="51">
                    <text>PDK1 phosphorylation was not mutated with the treatment of cells with a growth factor similar to insulin I and SOX9 protein, as suggested by our study, it will change without loss of activity.</text>
                    <arg n="0">SOX9 protein</arg>
                </example>
                <example src="PERMUTATE" no="52">
                    <text>SOX9 are mutated by the two phosphorylation sites PKA (S (64) and S (211) could have already been mutated), adhesion in Q62696 using the Swiss PDB display software (Guex and Peitsch, 1997).</text>
                    <arg n="0">SOX9</arg>
                    <arg n="1">the two phosphorylation sites PKA (S (64) and S (211) could have already been mutated)</arg>
                </example>
                <example src="PERMUTATE" no="53">
                    <text>SOX9 are mutated by the two phosphorylation sites PKA (S (64) and S (211) have already been mutated), adhesion in Q62696 using the Swiss PDB display software (Guex and Peitsch, 1997).</text>
                    <arg n="0">SOX9</arg>
                    <arg n="1">the two phosphorylation sites PKA (S (64) and S (211) have already been mutated)</arg>
                </example>
                <example src="PERMUTATE" no="54">
                    <text>SOX9 are mutated by the two phosphorylation sites PKA (S (64) and S (211) have the ability to be significantly mutated), adhesion in Q62696 using the Swiss PDB display software (Guex and Peitsch, 1997).</text>
                    <arg n="0">SOX9</arg>
                    <arg n="1">the two phosphorylation sites PKA (S (64) and S (211) have the ability to be significantly mutated)</arg>
                </example>
                <example src="PERMUTATE" no="55">
                    <text>SOX9 are observed significantly mutated by the two phosphorylation sites PKA (S (64) and S (211) could have already been mutated), adherence to Q62696 using the Swiss PDB display software (Guex and Peitsch, 1997).</text>
                    <arg n="0">SOX9</arg>
                    <arg n="1">the two phosphorylation sites PKA (S (64) and S (211) could have already been mutated)</arg>
                </example>
                <example src="PERMUTATE" no="56">
                    <text>SOX9 are observed significantly mutated by the two phosphorylation sites PKA (S (64) and S (211) have the ability to be significantly mutated), ascension No.D62696 using the Swiss PDB Viewer program (Guex and Peitsch, 1997).</text>
                    <arg n="0">SOX9</arg>
                    <arg n="1">the two phosphorylation sites PKA (S (64) and S (211) have the ability to be significantly mutated)</arg>
                </example>
                <example src="PERMUTATE" no="57">
                    <text>SOX9 are significantly mutated by the two phosphorylation sites PKA (S (64) and S (211) could have already been mutated), adherence in Q62696 using the Swiss PDB Viewer software (Guex and Peitsch, 1997).</text>
                    <arg n="0">SOX9</arg>
                    <arg n="1">the two phosphorylation sites PKA (S (64) and S (211) could have already been mutated)</arg>
                </example>
                <example src="PERMUTATE" no="58">
                    <text>SOX9 can be mutated by the two phosphorylation sites PKA (S (64) and S (211) have the ability to be significantly mutated), adherence in Q62696 using the Swiss PDB Viewer program (Guex and Peitsch, 1997).</text>
                    <arg n="0">SOX9</arg>
                    <arg n="1">the two phosphorylation sites PKA (S (64) and S (211) have the ability to be significantly mutated)</arg>
                </example>
                <example src="PERMUTATE" no="59">
                    <text>SOX9 can be significantly mutated by the two phosphorylation sites PKA (S (64) and S (211) could have already been mutated), adhesion in Q62696 using the Swiss PDB display software (Guex and Peitsch, 1997).</text>
                    <arg n="0">SOX9</arg>
                    <arg n="1">the two phosphorylation sites PKA (S (64) and S (211) could have already been mutated)</arg>
                </example>
                <example src="PERMUTATE" no="60">
                    <text>SOX9 can be significantly mutated by the two phosphorylation sites PKA (S (64) and S (211) have already been mutated), adhesion in Q62696 using the Swiss PDB display software (Guex and Peitsch, 1997).</text>
                    <arg n="0">SOX9</arg>
                    <arg n="1">the two phosphorylation sites PKA (S (64) and S (211) have already been mutated)</arg>
                </example>
                <example src="PERMUTATE" no="61">
                    <text>SOX9 can be significantly mutated by the two phosphorylation sites PKA (S (64) and S (211) have the ability to be significantly mutated), adherence in Q62696 using the Swiss PDB Viewer software (Guex and Peitsch, 1997).</text>
                    <arg n="0">SOX9</arg>
                    <arg n="1">the two phosphorylation sites PKA (S (64) and S (211) have the ability to be significantly mutated)</arg>
                </example>
                <example src="PERMUTATE" no="62">
                    <text>SOX9 could be significantly mutated by the two phosphorylation sites PKA (S (64) and S (211) have already been mutated), adherence in Q62696 using the Swiss PDB Viewer program (Guex and Peitsch, 1997).</text>
                    <arg n="0">SOX9</arg>
                    <arg n="1">the two phosphorylation sites PKA (S (64) and S (211) have already been mutated)</arg>
                </example>
                <example src="PERMUTATE" no="63">
                    <text>SOX9 could be significantly mutated by the two phosphorylation sites PKA (S (64) and S (211) have already been mutated), adherence to Q62696 using the Swiss PDB display program (Guex and Peitsch, 1997).</text>
                    <arg n="0">SOX9</arg>
                    <arg n="1">the two phosphorylation sites PKA (S (64) and S (211) have already been mutated)</arg>
                </example>
                <example src="PERMUTATE" no="64">
                    <text>SOX9 could have been significantly mutated by the two phosphorylation sites PKA (S (64) and S (211) have the ability to be significantly mutated), adherence no.Q62696 using the Swiss PDB Viewer program (Guex and Peitsch, 1997).</text>
                    <arg n="0">SOX9</arg>
                    <arg n="1">the two phosphorylation sites PKA (S (64) and S (211) have the ability to be significantly mutated)</arg>
                </example>
                <example src="PERMUTATE" no="65">
                    <text>SOX9 is able to be mutated by the two phosphorylation sites PKA (S (64) and S (211) have already been mutated), adherence in Q62696 using the Swiss PDB Viewer program (Guex and Peitsch, 1997).</text>
                    <arg n="0">SOX9</arg>
                    <arg n="1">the two phosphorylation sites PKA (S (64) and S (211) have already been mutated)</arg>
                </example>
                <example src="PERMUTATE" no="66">
                    <text>SOX9 is likely to be significantly mutated by the two phosphorylation sites PKA (S (64) and S (211) have already been mutated), ascension No.D62696 using the Swiss PDB Viewer program (Guex and Peitsch, 1997).</text>
                    <arg n="0">SOX9</arg>
                    <arg n="1">the two phosphorylation sites PKA (S (64) and S (211) have already been mutated)</arg>
                </example>
                <example src="PERMUTATE" no="67">
                    <text>SOX9 would be mutated by the two phosphorylation sites PKA (S (64) and S (211) have the ability to be significantly mutated) , adherence in Q62696 using the Swiss PDB Viewer software (Guex and Peitsch, 1997).</text>
                    <arg n="0">SOX9</arg>
                    <arg n="1">the two phosphorylation sites PKA (S (64) and S (211) have the ability to be significantly mutated)</arg>
                </example>
                <example src="PERMUTATE" no="68">
                    <text>Snippets of template are able to be significantly mutated by the SAP97 RAT sequence, adherence no.Q62696 using the Swiss PDB Viewer program (Guex and Peitsch, 1997).</text>
                    <arg n="0">Snippets of template</arg>
                    <arg n="1">the SAP97 RAT sequence</arg>
                </example>
                <example src="PERMUTATE" no="69">
                    <text>Snippets of template are observed significantly mutated by the SAP97 RAT sequence, adherence to Q62696 using the Swiss PDB display software (Guex and Peitsch, 1997).</text>
                    <arg n="0">Snippets of template</arg>
                    <arg n="1">the SAP97 RAT sequence</arg>
                </example>
                <example src="PERMUTATE" no="70">
                    <text>Snippets of template could be muted for the SAP97 RAT sequence, No.D62696 adhesion mutated the Swiss PDB Viewer program (Guex and Peitsch, 1997).</text>
                    <arg n="0">Snippets of template</arg>
                    <arg n="1">the SAP97 RAT sequence</arg>
                </example>
                <example src="PERMUTATE" no="71">
                    <text>Snippets of template have been significantly mutated by the SAP97 RAT sequence, ascent No. 62696 using the Swiss PDB Viewer program (Guex and Peitsch, 1997).</text>
                    <arg n="0">Snippets of template</arg>
                    <arg n="1">the SAP97 RAT sequence</arg>
                </example>
                <example src="PERMUTATE" no="72">
                    <text>Snippets of template may have been mutated by the SAP97 RAT sequence, Adhesion No.D62696 using the Swiss PDB Viewer program (Guex and Peitsch, 1997).</text>
                    <arg n="0">Snippets of template</arg>
                    <arg n="1">the SAP97 RAT sequence</arg>
                </example>
                <example src="PERMUTATE" no="73">
                    <text>Snippets of template would be mutated by the SAP97 RAT sequence , adherence in Q62696 using the Swiss PDB Viewer software (Guex and Peitsch, 1997).</text>
                    <arg n="0">Snippets of template</arg>
                    <arg n="1">the SAP97 RAT sequence</arg>
                </example>
                <example src="PERMUTATE" no="74">
                    <text>The A0 mutation (the sites of the C-terminal kinase of MAP (T235 and T239), for example, essentially mutate to AA (figure 5C, bands 7 and 8).</text>
                    <arg n="2">AA</arg>
                </example>
                <example src="PERMUTATE" no="75">
                    <text>The A1 gene that can be mutated in Slow childhood neural lipfuscinosis (CLN6) and in nclf mutant mice was a recently predicted transmembrane protein.</text>
                    <arg n="2">Slow childhood neural lipfuscinosis (CLN6) and in nclf mutant mice</arg>
                    <arg n="3">a recently predicted transmembrane protein</arg>
                </example>
                <example src="PERMUTATE" no="76">
                    <text>The A1 gene that can be mutated in infant late neural lipofuscinosis (LLC6) and in nclf mutant mice was a new pre-directed transmembrane protein.</text>
                    <arg n="2">infant late neural lipofuscinosis (LLC6) and in nclf mutant mice</arg>
                    <arg n="3">a new pre-directed transmembrane protein</arg>
                </example>
                <example src="PERMUTATE" no="77">
                    <text>The A1 gene that can be mutated into Slow childhood neural lipfuscinosis (CLN6) and in nclf mutant mice codes a recently predicted transmembrane protein.</text>
                    <arg n="2">Slow childhood neural lipfuscinosis (CLN6) and in nclf mutant mice</arg>
                    <arg n="3">a recently predicted transmembrane protein</arg>
                </example>
                <example src="PERMUTATE" no="78">
                    <text>The A1 gene that can be mutated into delayed neuronal lymphofuscinosis and nclf mutant mice codified a new predefined transmembrane protein.</text>
                    <arg n="2">delayed neuronal lymphofuscinosis and nclf mutant mice</arg>
                    <arg n="3">a new predefined transmembrane protein</arg>
                </example>
                <example src="PERMUTATE" no="79">
                    <text>The A1 gene that can be mutated into infectantyl lipofuscinosis neural lipofuscinosis (CLN6) and in nclf mutant mice codified a new predefined transmembrane protein.</text>
                    <arg n="2">infectantyl lipofuscinosis neural lipofuscinosis (CLN6) and in nclf mutant mice</arg>
                    <arg n="3">a new predefined transmembrane protein</arg>
                </example>
                <example src="PERMUTATE" no="80">
                    <text>The A1 gene that can be mutated into last infertile neural lipofuscinosis (LN6) and in nclf mutant mice codes a new predefined transmembrane protein.</text>
                    <arg n="2">last infertile neural lipofuscinosis (LN6) and in nclf mutant mice</arg>
                    <arg n="3">a new predefined transmembrane protein</arg>
                </example>
                <example src="PERMUTATE" no="81">
                    <text>The A1 gene that can be mutated into last infertile neural lipofuscinosis (LN6) and in nclf mutant mice codified a new predefined transmembrane protein.</text>
                    <arg n="2">last infertile neural lipofuscinosis (LN6) and in nclf mutant mice</arg>
                    <arg n="3">a new predefined transmembrane protein</arg>
                </example>
                <example src="PERMUTATE" no="82">
                    <text>The A1 gene that can be mutated into late neuronal lipofuscinosis and nclf mutant mice codes a recently predicted transmembrane protein.</text>
                    <arg n="2">late neuronal lipofuscinosis and nclf mutant mice</arg>
                    <arg n="3">a recently predicted transmembrane protein</arg>
                </example>
                <example src="PERMUTATE" no="83">
                    <text>The A1 gene that can be mutated into variations of late infection in neuronal lipofuscinosis and nclf mice codes a new predefined transmembrane protein.</text>
                    <arg n="2">variations of late infection in neuronal lipofuscinosis and nclf mice</arg>
                    <arg n="3">a new predefined transmembrane protein</arg>
                </example>
                <example src="PERMUTATE" no="84">
                    <text>The A1 gene that has the ability to be mutated in late infection neuronal lipofuscinosis variant (LN6) and in nclf mutant mice codes a recently predicted transmembrane protein.</text>
                    <arg n="2">late infection neuronal lipofuscinosis variant (LN6) and in nclf mutant mice</arg>
                    <arg n="3">a recently predicted transmembrane protein</arg>
                </example>
                <example src="PERMUTATE" no="85">
                    <text>The A1 gene that has the ability to mutated into delayed neuronal lymphofuscinosis and nclf mutant mice codified a new predefined transmembrane protein.</text>
                    <arg n="2">delayed neuronal lymphofuscinosis and nclf mutant mice</arg>
                    <arg n="3">a new predefined transmembrane protein</arg>
                </example>
                <example src="PERMUTATE" no="86">
                    <text>The A1 gene that is able to be mutated into late infection neuronal lipofuscinosis variant (LN6) and in nclf mutant mice codes a recently predicted transmembrane protein.</text>
                    <arg n="2">late infection neuronal lipofuscinosis variant (LN6) and in nclf mutant mice</arg>
                    <arg n="3">a recently predicted transmembrane protein</arg>
                </example>
                <example src="PERMUTATE" no="87">
                    <text>The A1 gene that is mutated in ceroid variety of late infertile neural diffuscosis (CLN6) and in nclf mutant mice was a new predefined transmembrane protein.</text>
                    <arg n="2">ceroid variety of late infertile neural diffuscosis (CLN6) and in nclf mutant mice</arg>
                    <arg n="3">a new predefined transmembrane protein</arg>
                </example>
                <example src="PERMUTATE" no="88">
                    <text>The A1 gene that may have been mutated in delayed neuronal lymphofuscinosis and nclf mutant mice codes a new predefined transmembrane protein.</text>
                    <arg n="2">delayed neuronal lymphofuscinosis and nclf mutant mice</arg>
                    <arg n="3">a new predefined transmembrane protein</arg>
                </example>
                <example src="PERMUTATE" no="89">
                    <text>The A1 gene that may have been mutated in infectantyl lipofuscinosis neural lipofuscinosis (CLN6) and in nclf mutant mice codes a new predefined transmembrane protein.</text>
                    <arg n="2">infectantyl lipofuscinosis neural lipofuscinosis (CLN6) and in nclf mutant mice</arg>
                    <arg n="3">a new predefined transmembrane protein</arg>
                </example>
                <example src="PERMUTATE" no="90">
                    <text>The A1 mutation (EE amino acids(437 and 438) in late-infection neuronal ceroid lipofuscinosis (LN6) and nclf mutant mice mutating the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">late-infection neuronal ceroid lipofuscinosis (LN6) and nclf mutant mice</arg>
                </example>
                <example src="PERMUTATE" no="91">
                    <text>The A1 mutation (EE amino acids(437 and 438) to abolited EGF increase and increased EGF-induced phosphorylation and mobility mutate the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">abolited EGF increase and increased EGF-induced phosphorylation and mobility</arg>
                </example>
                <example src="PERMUTATE" no="92">
                    <text>The A1 mutation (EE amino acids(437 and 438) to abolition of FEG-stimulated phosphorylation and FEG-induced mobility change mutate the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">abolition of FEG-stimulated phosphorylation and FEG-induced mobility change</arg>
                </example>
                <example src="PERMUTATE" no="93">
                    <text>The A1 mutation (EE amino acids(437 and 438) to abolition of increased FEG-stimulated phosphorylation and reduction of FEG-induced mobility would mutate the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">abolition of increased FEG-stimulated phosphorylation and reduction of FEG-induced mobility</arg>
                </example>
                <example src="PERMUTATE" no="94">
                    <text>The A1 mutation (EE amino acids(437 and 438)) to loss of transcriptional repression of the lacZ gene is able to mutate the DNA-binding mutant (Stat5aEE-AA) of Stat5a.</text>
                    <arg n="2">loss of transcriptional repression of the lacZ gene</arg>
                </example>
                <example src="PERMUTATE" no="95">
                    <text>The A1 mutation (EE amino acids(437 and 438)) to the loss of transcriptional repression of the lacZ gene is able to mutate the DNA-binding mutant (Stat5aEE-AA) of Stat5a.</text>
                    <arg n="2">the loss of transcriptional repression of the lacZ gene</arg>
                </example>
                <example src="PERMUTATE" no="96">
                    <text>The A1 mutation (EE(437 and 438) to abolited EGF increase and increased EGF-induced phosphorylation and mobility amino acids will mutate the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">abolited EGF increase and increased EGF-induced phosphorylation and mobility</arg>
                </example>
                <example src="PERMUTATE" no="97">
                    <text>The A1 mutation (EE(437 and 438) to late-infection neuronal ceroid lipofuscinosis (LN6) and nclf mutant mice will mutating the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">late-infection neuronal ceroid lipofuscinosis (LN6) and nclf mutant mice</arg>
                </example>
                <example src="PERMUTATE" no="98">
                    <text>The A1 mutation (EE(437 and 438) to loss of transcriptional repression of the lacZ gene amino acids) can mutating the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">loss of transcriptional repression of the lacZ gene</arg>
                </example>
                <example src="PERMUTATE" no="99">
                    <text>The A1 mutation (EE(437 and 438) to the loss of transcriptional repression of the lacZ gene amino acids) can mutating the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">the loss of transcriptional repression of the lacZ gene</arg>
                </example>
                <example src="PERMUTATE" no="100">
                    <text>The A1 mutation (EE(437 and 438)) to abolited EGF increase and increased EGF-induced phosphorylation and mobility may mutate the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">abolited EGF increase and increased EGF-induced phosphorylation and mobility</arg>
                </example>
                <example src="PERMUTATE" no="101">
                    <text>The A1 mutation (EE(437 and 438)) to abolited increase in FEG-stimulated phosphorylation and FEG-induced mobility change may mutating the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">abolited increase in FEG-stimulated phosphorylation and FEG-induced mobility change</arg>
                </example>
                <example src="PERMUTATE" no="102">
                    <text>The A1 mutation (EE(437 and 438)) to abolition of FEG-stimulated phosphorylation and FEG-induced mobility change could mutate the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">abolition of FEG-stimulated phosphorylation and FEG-induced mobility change</arg>
                </example>
                <example src="PERMUTATE" no="103">
                    <text>The A1 mutation (EE(437 and 438)) to abolition of FEG-stimulated phosphorylation and FEG-induced mobility change is observed to mutate the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">abolition of FEG-stimulated phosphorylation and FEG-induced mobility change</arg>
                </example>
                <example src="PERMUTATE" no="104">
                    <text>The A1 mutation (EE(437 and 438)) to abolition of FEG-stimulated phosphorylation and FEG-induced mobility change may mutating the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">abolition of FEG-stimulated phosphorylation and FEG-induced mobility change</arg>
                </example>
                <example src="PERMUTATE" no="105">
                    <text>The A1 mutation (EE(437 and 438)) to abolition of FEG-stimulated phosphorylation and FEG-induced mobility change would mutating the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">abolition of FEG-stimulated phosphorylation and FEG-induced mobility change</arg>
                </example>
                <example src="PERMUTATE" no="106">
                    <text>The A1 mutation (EE(437 and 438)) to increasing above FEG-stimulated phosphorylation and FEG-induced mobility change could have mutating the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">increasing above FEG-stimulated phosphorylation and FEG-induced mobility change</arg>
                </example>
                <example src="PERMUTATE" no="107">
                    <text>The A1 mutation (EE(437 and 438)) to increasing above FEG-stimulated phosphorylation and FEG-induced mobility change may have mutate the DNA-binding mutant (Stat5aEE-AA of Stat5a may have been caused by the DNA mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">increasing above FEG-stimulated phosphorylation and FEG-induced mobility change</arg>
                </example>
                <example src="PERMUTATE" no="108">
                    <text>The A1 mutation (EE(437 and 438)) to increasing above FEG-stimulated phosphorylation and FEG-induced mobility change may mutate the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">increasing above FEG-stimulated phosphorylation and FEG-induced mobility change</arg>
                </example>
                <example src="PERMUTATE" no="109">
                    <text>The A1 mutation (EE(437 and 438)) to late-infection neuronal ceroid lipofuscinosis (LN6) and nclf mutant mice could mutate the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">late-infection neuronal ceroid lipofuscinosis (LN6) and nclf mutant mice</arg>
                </example>
                <example src="PERMUTATE" no="110">
                    <text>The A1 mutation (EE(437 and 438)) to late-infection neuronal ceroid lipofuscinosis (LN6) and nclf mutant mice could mutating the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">late-infection neuronal ceroid lipofuscinosis (LN6) and nclf mutant mice</arg>
                </example>
                <example src="PERMUTATE" no="111">
                    <text>The A1 mutation (EE(437 and 438)) to late-infection neuronal ceroid lipofuscinosis (LN6) and nclf mutant mice is able to mutating the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">late-infection neuronal ceroid lipofuscinosis (LN6) and nclf mutant mice</arg>
                </example>
                <example src="PERMUTATE" no="112">
                    <text>The A1 mutation (EE(437 and 438)) to late-infection neuronal ceroid lipofuscinosis (LN6) and nclf mutant mice is observed to mutate the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">late-infection neuronal ceroid lipofuscinosis (LN6) and nclf mutant mice</arg>
                </example>
                <example src="PERMUTATE" no="113">
                    <text>The A1 mutation (EE(437 and 438)) to late-infection neuronal ceroid lipofuscinosis (LN6) and nclf mutant mice may mutate the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">late-infection neuronal ceroid lipofuscinosis (LN6) and nclf mutant mice</arg>
                </example>
                <example src="PERMUTATE" no="114">
                    <text>The A1 mutation (EE(437 and 438)) to loss of transcriptional repression of the lacZ gene could mutate the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">loss of transcriptional repression of the lacZ gene</arg>
                </example>
                <example src="PERMUTATE" no="115">
                    <text>The A1 mutation (EE(437 and 438)) to loss of transcriptional repression of the lacZ gene may have mutating the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">loss of transcriptional repression of the lacZ gene</arg>
                </example>
                <example src="PERMUTATE" no="116">
                    <text>The A1 mutation (EE(437 and 438)) to loss of transcriptional repression of the lacZ gene may mutate the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">loss of transcriptional repression of the lacZ gene</arg>
                </example>
                <example src="PERMUTATE" no="117">
                    <text>The A1 mutation (EE(437 and 438)) to loss of transcriptional repression of the lacZ gene may mutating the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">loss of transcriptional repression of the lacZ gene</arg>
                </example>
                <example src="PERMUTATE" no="118">
                    <text>The A1 mutation (EE(437 and 438)) to the loss of transcriptional repression of the lacZ gene could have mutating the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">the loss of transcriptional repression of the lacZ gene</arg>
                </example>
                <example src="PERMUTATE" no="119">
                    <text>The A1 mutation (EE(437 and 438)) to the loss of transcriptional repression of the lacZ gene mutating the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">the loss of transcriptional repression of the lacZ gene</arg>
                </example>
                <example src="PERMUTATE" no="120">
                    <text>The DNA-binding mutant (Stat5aEE-abolition of FEG-stimulated phosphorylation and FEG-induced mobility change) of Stat5a is observed to be mutating by the A1 mutation (EE amino acids(437 and 438)) to AA.</text>
                    <arg n="2">abolition of FEG-stimulated phosphorylation and FEG-induced mobility change</arg>
                </example>
                <example src="PERMUTATE" no="121">
                    <text>The DNA-binding mutant (Stat5aEE-increasing above FEG-stimulated phosphorylation and FEG-induced mobility change) of Stat5a can be mutating by the A1 mutation (EE amino acids(437 and 438)) to AA.</text>
                    <arg n="2">increasing above FEG-stimulated phosphorylation and FEG-induced mobility change</arg>
                </example>
                <example src="PERMUTATE" no="122">
                    <text>The DNA-binding mutant (Stat5aEE-late-infection neuronal ceroid lipofuscinosis (LN6) and nclf mutant mice) of Stat5a can be mutating by the A1 mutation (EE amino acids(437 and 438)) to AA.</text>
                    <arg n="2">late-infection neuronal ceroid lipofuscinosis (LN6) and nclf mutant mice</arg>
                </example>
                <example src="PERMUTATE" no="123">
                    <text>The Model fragments may have been mutated by the the SAP97 RAT sequence, adherence to Q62696 using the Swiss PDB display program (Guex and Peitsch, 1997).</text>
                    <arg n="0">Model fragments</arg>
                    <arg n="1">the SAP97 RAT sequence</arg>
                </example>
                <example src="PERMUTATE" no="124">
                    <text>The Model fragments may have been mutated by the the sequence of SAP97 RAT, adherence to Q62696 using the Swiss PDB display software (Guex and Peitsch, 1997).</text>
                    <arg n="0">Model fragments</arg>
                    <arg n="1">the sequence of SAP97 RAT</arg>
                </example>
                <example src="PERMUTATE" no="125">
                    <text>The Model fragments was significantly mutated by the the sequence of SAP97 RAT, adherence to Q62696 using the Swiss PDB display software (Guex and Peitsch, 1997).</text>
                    <arg n="0">Model fragments</arg>
                    <arg n="1">the sequence of SAP97 RAT</arg>
                </example>
                <example src="PERMUTATE" no="126">
                    <text>The Model fragments will be mutated by the the SAP97 RAT sequence, adherence to Q62696 using the Swiss PDB display program (Guex and Peitsch, 1997).</text>
                    <arg n="0">Model fragments</arg>
                    <arg n="1">the SAP97 RAT sequence</arg>
                </example>
                <example src="PERMUTATE" no="127">
                    <text>The Model fragments would be significantly mutated to the the SAP97 RAT sequence, adhesion to Q62696 using the Swiss PDB display program (Guex and Peitsch, 1997).</text>
                    <arg n="0">Model fragments</arg>
                    <arg n="1">the SAP97 RAT sequence</arg>
                </example>
                <example src="PERMUTATE" no="128">
                    <text>The SOX9 could have been significantly mutated by the the two phosphorylation sites PKA (S (64) and S (211) could have already been mutated), the adherence no.D62696 using the Swiss PDB display program (Guex and Peitsch, 1997).</text>
                    <arg n="0">SOX9</arg>
                    <arg n="1">the two phosphorylation sites PKA (S (64) and S (211) could have already been mutated)</arg>
                </example>
                <example src="PERMUTATE" no="129">
                    <text>The SOX9 may have been mutated by the the two phosphorylation sites PKA (S (64) and S (211) have the ability to be significantly mutated), adherence to Q62696 using the Swiss PDB display software (Guex and Peitsch, 1997).</text>
                    <arg n="0">SOX9</arg>
                    <arg n="1">the two phosphorylation sites PKA (S (64) and S (211) have the ability to be significantly mutated)</arg>
                </example>
                <example src="PERMUTATE" no="130">
                    <text>The SOX9 may have been significantly mutated by the the two phosphorylation sites PKA (S (64) and S (211) have already been mutated), adhering to Q62696 using the Swiss PDB display software (Guex and Peitsch, 1997).</text>
                    <arg n="0">SOX9</arg>
                    <arg n="1">the two phosphorylation sites PKA (S (64) and S (211) have already been mutated)</arg>
                </example>
                <example src="PERMUTATE" no="131">
                    <text>The Snippets of template was mutated by the the SAP97 RAT sequence, adherence to Q62696 using the Swiss PDB display software (Guex and Peitsch, 1997).</text>
                    <arg n="0">Snippets of template</arg>
                    <arg n="1">the SAP97 RAT sequence</arg>
                </example>
                <example src="PERMUTATE" no="132">
                    <text>The Snippets of template would be mutated by the the SAP97 RAT sequence, adherence to Q62696 using the Swiss PDB display software (Guex and Peitsch, 1997).</text>
                    <arg n="0">Snippets of template</arg>
                    <arg n="1">the SAP97 RAT sequence</arg>
                </example>
                <example src="PERMUTATE" no="133">
                    <text>The The template fragments could have been significantly mutated by the the SAP97 RAT sequence, the adherence no.D62696 using the Swiss PDB display program (Guex and Peitsch, 1997).</text>
                    <arg n="0">The template fragments</arg>
                    <arg n="1">the SAP97 RAT sequence</arg>
                </example>
                <example src="PERMUTATE" no="134">
                    <text>The The template fragments may have been significantly mutated by the the SAP97 RAT sequence, adhering to Q62696 using the Swiss PDB display software (Guex and Peitsch, 1997).</text>
                    <arg n="0">The template fragments</arg>
                    <arg n="1">the SAP97 RAT sequence</arg>
                </example>
                <example src="PERMUTATE" no="135">
                    <text>The induction of a mutation in the A0 gene (LacI) has the ability to mutated in abolited EGF increase and increased EGF-induced phosphorylation and mobility, which is the cell mutation.</text>
                    <arg n="2">abolited EGF increase and increased EGF-induced phosphorylation and mobility</arg>
                </example>
                <example src="PERMUTATE" no="136">
                    <text>The induction of a mutation in the A0 gene (LacI) has the ability to mutated in late-infection neuronal ceroid lipofuscinosis (LN6) and nclf mutant mice, which is the cell mutation.</text>
                    <arg n="2">late-infection neuronal ceroid lipofuscinosis (LN6) and nclf mutant mice</arg>
                </example>
                <example src="PERMUTATE" no="137">
                    <text>The induction of a mutation in the A0 gene (LacI) has the ability to mutated in loss of transcriptional repression of the lacZ gene, which is the cell mutation.</text>
                    <arg n="2">loss of transcriptional repression of the lacZ gene</arg>
                </example>
                <example src="PERMUTATE" no="138">
                    <text>The induction of a mutation in the A0 gene (LacI) will mutated in abolition of FEG-stimulated phosphorylation and FEG-induced mobility change, which is the cell mutation.</text>
                    <arg n="2">abolition of FEG-stimulated phosphorylation and FEG-induced mobility change</arg>
                </example>
                <example src="PERMUTATE" no="139">
                    <text>The induction of a mutation in the A0 gene (LacI) will mutated in abolition of increased FEG-stimulated phosphorylation and reduction of FEG-induced mobility, which is the cell mutation.</text>
                    <arg n="2">abolition of increased FEG-stimulated phosphorylation and reduction of FEG-induced mobility</arg>
                </example>
                <example src="PERMUTATE" no="140">
                    <text>The induction of a mutation in the A0 gene (LacI), for example, will mutated in abolited increase in FEG-stimulated phosphorylation and FEG-induced mobility change, which is the cell mutation.</text>
                    <arg n="2">abolited increase in FEG-stimulated phosphorylation and FEG-induced mobility change</arg>
                </example>
                <example src="PERMUTATE" no="141">
                    <text>The model breakdowns would be mutated by the Sa97 RAT sequence, adherence to Q62696 using the Swiss PDB display software (Guex and Peitsch, 1997).</text>
                    <arg n="0">model breakdowns</arg>
                    <arg n="1">Sa97 RAT sequence</arg>
                </example>
                <example src="PERMUTATE" no="142">
                    <text>The model faults may have been mutated by the the SAP97 RAT sequence, adherence to Q62696 using the Swiss PDB display program (Guex and Peitsch, 1997).</text>
                    <arg n="0">model faults</arg>
                    <arg n="1">the SAP97 RAT sequence</arg>
                </example>
                <example src="PERMUTATE" no="143">
                    <text>The model faults would be mutated by the Sa97 RAT sequence, adherence to Q62696 using the Swiss PDB display software (Guex and Peitsch, 1997).</text>
                    <arg n="0">model faults</arg>
                    <arg n="1">Sa97 RAT sequence</arg>
                </example>
                <example src="PERMUTATE" no="144">
                    <text>The model fragrances would be mutated by the Sa97 RAT sequence, adherence to Q62696 using the Swiss PDB display software (Guex and Peitsch, 1997).</text>
                    <arg n="0">model fragrances</arg>
                    <arg n="1">Sa97 RAT sequence</arg>
                </example>
                <example src="PERMUTATE" no="145">
                    <text>The mutation A1 (EE(437 and 438) to abolited EGF increase and increased EGF-induced phosphorylation and mobility has the ability to mutating the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">abolited EGF increase and increased EGF-induced phosphorylation and mobility</arg>
                </example>
                <example src="PERMUTATE" no="146">
                    <text>The mutation A1 (EE(437 and 438) to abolition of FEG-stimulated phosphorylation and FEG-induced mobility change may have mutate the DNA-binding mutant (Stat5aEE-AA of Stat5a may have been caused by the DNA mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">abolition of FEG-stimulated phosphorylation and FEG-induced mobility change</arg>
                </example>
                <example src="PERMUTATE" no="147">
                    <text>The mutation A1 (EE(437 and 438) to abolition of FEG-stimulated phosphorylation and FEG-induced mobility change will mutating the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">abolition of FEG-stimulated phosphorylation and FEG-induced mobility change</arg>
                </example>
                <example src="PERMUTATE" no="148">
                    <text>The mutation A1 (EE(437 and 438) to abolition of increased FEG-stimulated phosphorylation and reduction of FEG-induced mobility can mutate the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">abolition of increased FEG-stimulated phosphorylation and reduction of FEG-induced mobility</arg>
                </example>
                <example src="PERMUTATE" no="149">
                    <text>The mutation A1 (EE(437 and 438) to abolition of increased FEG-stimulated phosphorylation and reduction of FEG-induced mobility may have mutating the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">abolition of increased FEG-stimulated phosphorylation and reduction of FEG-induced mobility</arg>
                </example>
                <example src="PERMUTATE" no="150">
                    <text>The mutation A1 (EE(437 and 438) to increasing above FEG-stimulated phosphorylation and FEG-induced mobility change could mutate the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">increasing above FEG-stimulated phosphorylation and FEG-induced mobility change</arg>
                </example>
                <example src="PERMUTATE" no="151">
                    <text>The mutation A1 (EE(437 and 438) to late-infection neuronal ceroid lipofuscinosis (LN6) and nclf mutant mice could mutating the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">late-infection neuronal ceroid lipofuscinosis (LN6) and nclf mutant mice</arg>
                </example>
                <example src="PERMUTATE" no="152">
                    <text>The mutation A1 (EE(437 and 438) to late-infection neuronal ceroid lipofuscinosis (LN6) and nclf mutant mice may have mutate the DNA-binding mutant (Stat5aEE-AA of Stat5a may have been caused by the DNA mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">late-infection neuronal ceroid lipofuscinosis (LN6) and nclf mutant mice</arg>
                </example>
                <example src="PERMUTATE" no="153">
                    <text>The mutation A1 (EE(437 and 438) to late-infection neuronal ceroid lipofuscinosis (LN6) and nclf mutant mice may have mutate the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">late-infection neuronal ceroid lipofuscinosis (LN6) and nclf mutant mice</arg>
                </example>
                <example src="PERMUTATE" no="154">
                    <text>The mutation A1 (EE(437 and 438) to late-infection neuronal ceroid lipofuscinosis (LN6) and nclf mutant mice mutating the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">late-infection neuronal ceroid lipofuscinosis (LN6) and nclf mutant mice</arg>
                </example>
                <example src="PERMUTATE" no="155">
                    <text>The mutation A1 (EE(437 and 438) to late-infection neuronal ceroid lipofuscinosis (LN6) and nclf mutant mice will mutating the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">late-infection neuronal ceroid lipofuscinosis (LN6) and nclf mutant mice</arg>
                </example>
                <example src="PERMUTATE" no="156">
                    <text>The mutation A1 (EE(437 and 438) to late-infection neuronal ceroid lipofuscinosis (LN6) and nclf mutant mice would mutating the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">late-infection neuronal ceroid lipofuscinosis (LN6) and nclf mutant mice</arg>
                </example>
                <example src="PERMUTATE" no="157">
                    <text>The mutation A1 (EE(437 and 438) to loss of transcriptional repression of the lacZ gene can mutating the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">loss of transcriptional repression of the lacZ gene</arg>
                </example>
                <example src="PERMUTATE" no="158">
                    <text>The mutation A1 (EE(437 and 438) to loss of transcriptional repression of the lacZ gene mutating the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">loss of transcriptional repression of the lacZ gene</arg>
                </example>
                <example src="PERMUTATE" no="159">
                    <text>The mutation A1 (EE(437 and 438) to loss of transcriptional repression of the lacZ gene will mutate the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">loss of transcriptional repression of the lacZ gene</arg>
                </example>
                <example src="PERMUTATE" no="160">
                    <text>The mutation A1 (EE(437 and 438) to the loss of transcriptional repression of the lacZ gene will mutate the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">the loss of transcriptional repression of the lacZ gene</arg>
                </example>
                <example src="PERMUTATE" no="161">
                    <text>The mutation A1 (EE(437 and 438) to the loss of transcriptional repression of the lacZ gene will mutating the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">the loss of transcriptional repression of the lacZ gene</arg>
                </example>
                <example src="PERMUTATE" no="162">
                    <text>The template fragments are observed mutated by the SAP97 RAT sequence, adhering to Q62696 using the Swiss PDB display software (Guex and Peitsch, 1997).</text>
                    <arg n="0">The template fragments</arg>
                    <arg n="1">the SAP97 RAT sequence</arg>
                </example>
                <example src="PERMUTATE" no="163">
                    <text>The template fragments are observed significantly mutated by the SAP97 RAT sequence, adherence to Q62696 using the Swiss PDB display software (Guex and Peitsch, 1997).</text>
                    <arg n="0">The template fragments</arg>
                    <arg n="1">the SAP97 RAT sequence</arg>
                </example>
                <example src="PERMUTATE" no="164">
                    <text>The template fragments can be mutated by the sequence the SAP97 RAT sequence, adherence no.D62696 using the Swiss PDB Viewer software (Guex and Peitsch, 1997).</text>
                    <arg n="0">The template fragments</arg>
                    <arg n="1">the SAP97 RAT sequence</arg>
                </example>
                <example src="PERMUTATE" no="165">
                    <text>The template fragments can be significantly mutated by the SAP97 RAT sequence, adherence in Q62696 using the Swiss PDB Viewer software (Guex and Peitsch, 1997).</text>
                    <arg n="0">The template fragments</arg>
                    <arg n="1">the SAP97 RAT sequence</arg>
                </example>
                <example src="PERMUTATE" no="166">
                    <text>The template fragments could be significantly mutated by the SAP97 RAT sequence, adherence in Q62696 using the Swiss PDB Viewer program (Guex and Peitsch, 1997).</text>
                    <arg n="0">The template fragments</arg>
                    <arg n="1">the SAP97 RAT sequence</arg>
                </example>
                <example src="PERMUTATE" no="167">
                    <text>The template fragments is able to be mutated by the SAP97 RAT sequence, adherence in Q62696 using the Swiss PDB Viewer program (Guex and Peitsch, 1997).</text>
                    <arg n="0">The template fragments</arg>
                    <arg n="1">the SAP97 RAT sequence</arg>
                </example>
                <example src="PERMUTATE" no="168">
                    <text>The template fragments is likely to be significantly mutated by the SAP97 RAT sequence, ascension No.D62696 using the Swiss PDB Viewer program (Guex and Peitsch, 1997).</text>
                    <arg n="0">The template fragments</arg>
                    <arg n="1">the SAP97 RAT sequence</arg>
                </example>
                <example src="PERMUTATE" no="169">
                    <text>The the template fragments could have been significantly mutated by the the SAP97 RAT sequence, the adherence no.D62696 using the Swiss PDB display program (Guex and Peitsch, 1997).</text>
                    <arg n="0">the template fragments</arg>
                    <arg n="1">the SAP97 RAT sequence</arg>
                </example>
                <example src="PERMUTATE" no="170">
                    <text>The the template fragments may have been mutated by the the SAP97 RAT sequence, adherence to Q62696 using the Swiss PDB display software (Guex and Peitsch, 1997).</text>
                    <arg n="0">the template fragments</arg>
                    <arg n="1">the SAP97 RAT sequence</arg>
                </example>
                <example src="PERMUTATE" no="171">
                    <text>The the template fragments may have been significantly mutated by the the SAP97 RAT sequence, adhering to Q62696 using the Swiss PDB display software (Guex and Peitsch, 1997).</text>
                    <arg n="0">the template fragments</arg>
                    <arg n="1">the SAP97 RAT sequence</arg>
                </example>
                <example src="PERMUTATE" no="172">
                    <text>The transient expression of exon 8 may have mutation alpha strand cDNA in COS-1 cells mutated in enzyme deficiency.</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha strand cDNA in COS-1 cells</arg>
                    <arg n="3">enzyme deficiency</arg>
                </example>
                <example src="PERMUTATE" no="173">
                    <text>The transient expression of exon 8 significantly changes alpha chain DNA in cells 1, mutates in enzymatic deficiency.</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha chain DNA in cells 1</arg>
                    <arg n="3">enzymatic deficiency</arg>
                </example>
                <example src="PERMUTATE" no="174">
                    <text>This epitope, which is mutate to HLA-A2, includes cDNA alpha chain in COS-1 cells that is able to commonly change (V82A and I84V) in enzymatic activity deficiency.</text>
                    <arg n="1">cDNA alpha chain in COS-1 cells</arg>
                    <arg n="3">enzymatic activity deficiency</arg>
                </example>
                <example src="PERMUTATE" no="175">
                    <text>This epitope, which is restricted to HLA-A2, includes cDNA alpha chain in COS-1 cells observed to frequently mutate (V82A and I84V) in enzymatic activity deficiency.</text>
                    <arg n="1">cDNA alpha chain in COS-1 cells</arg>
                    <arg n="3">enzymatic activity deficiency</arg>
                </example>
                <example src="PERMUTATE" no="176">
                    <text>This epitope, which is restricted to HLA-A2, includes cDNA alpha chain in COS-1 cells that are mutate for mutation (V82A and I84V) in enzymatic activity deficiency.</text>
                    <arg n="1">cDNA alpha chain in COS-1 cells</arg>
                    <arg n="3">enzymatic activity deficiency</arg>
                </example>
                <example src="PERMUTATE" no="177">
                    <text>This epitope, which is restricted to HLA-A2, includes cDNA alpha chain in COS-1 cells that are observed to mutate (V82A and I84V) in enzymatic activity deficiency.</text>
                    <arg n="1">cDNA alpha chain in COS-1 cells</arg>
                    <arg n="3">enzymatic activity deficiency</arg>
                </example>
                <example src="PERMUTATE" no="178">
                    <text>This epitope, which is restricted to HLA-A2, includes cDNA alpha chain in COS-1 cells that have been commonly mutated (V82A and I84V) in enzymatic activity deficiency.</text>
                    <arg n="1">cDNA alpha chain in COS-1 cells</arg>
                    <arg n="3">enzymatic activity deficiency</arg>
                </example>
                <example src="PERMUTATE" no="179">
                    <text>This epitope, which is restricted to HLA-A2, includes cDNA alpha chain in COS-1 cells that have been mutated (V82A and I84V) in enzymatic activity deficiency.</text>
                    <arg n="1">cDNA alpha chain in COS-1 cells</arg>
                    <arg n="3">enzymatic activity deficiency</arg>
                </example>
                <example src="PERMUTATE" no="180">
                    <text>This epitope, which is restricted to HLA-A2, includes cDNA alpha chain in COS-1 cells that may have been mutated (V82A and I84V) into enzymatic activity deficiency.</text>
                    <arg n="1">cDNA alpha chain in COS-1 cells</arg>
                    <arg n="3">enzymatic activity deficiency</arg>
                </example>
                <example src="PERMUTATE" no="181">
                    <text>This epitope, which is restricted to HLA-A2, includes cDNA alpha chain in COS-1 cells that normally mutate (V82A and I84V) to enzymatic activity deficiency.</text>
                    <arg n="1">cDNA alpha chain in COS-1 cells</arg>
                    <arg n="3">enzymatic activity deficiency</arg>
                </example>
                <example src="PERMUTATE" no="182">
                    <text>This epitope, which is restricted to HLA-A2, includes cDNA alpha chain in COS-1 cells which is able to mutate (V82A and I84V) in enzymatic activity deficiency.</text>
                    <arg n="1">cDNA alpha chain in COS-1 cells</arg>
                    <arg n="3">enzymatic activity deficiency</arg>
                </example>
                <example src="PERMUTATE" no="183">
                    <text>This epitope, which is restricted to HLA-A2, includes cDNA alpha chain in COS-1 cells which may mutate (V82A and I84V) in enzymatic activity deficiency.</text>
                    <arg n="1">cDNA alpha chain in COS-1 cells</arg>
                    <arg n="3">enzymatic activity deficiency</arg>
                </example>
                <example src="PERMUTATE" no="184">
                    <text>To determine how activators interact with the complex and examine the importance of these interactions, in relation to other potential driving mechanisms, for the SWI/SNF function, dam target sequences was identified and mutated.</text>
                    <arg n="1">dam target sequences</arg>
                </example>
                <example src="PERMUTATE" no="185">
                    <text>To determine how activators interact with the complex and examine the importance of these interactions, in relation to other potential orientation mechanisms, for the SWI/SNF function, sequences of Dam targets have been identified and mutated.</text>
                    <arg n="1">sequences of Dam targets</arg>
                </example>
                <example src="PERMUTATE" no="186">
                    <text>To determine how activators interact with the complex and examine the importance of these interactions, in relation to other potential orientation mechanisms, for the SWI/SNF function, the complex activator interaction domains have been identified and mutated.</text>
                    <arg n="1">the complex activator interaction domains</arg>
                </example>
                <example src="PERMUTATE" no="187">
                    <text>To determine how activators interact with the complex and examine the importance of these interactions, in relation to other potential orientation mechanisms, for the SWI/SNF function, we found to identify and mutate the complex activator interaction domains.</text>
                    <arg n="1">the complex activator interaction domains</arg>
                </example>
                <example src="PERMUTATE" no="188">
                    <text>To determine how activators interact with the complex and examine the importance of these interactions, in relation to other potential orientation mechanisms, for the SWI/SNF function, we have identified and mutated complex activation interaction domains.</text>
                    <arg n="1">complex activation interaction domains</arg>
                </example>
                <example src="PERMUTATE" no="189">
                    <text>To determine how activators interact with the complex and examine the importance of these interactions, in relation to other potential orientation mechanisms, for the SWI/SNF function, we identify and mutated active interaction domains in the complex.</text>
                    <arg n="1">active interaction domains in the complex</arg>
                </example>
                <example src="PERMUTATE" no="190">
                    <text>We have identified alele in exon 5 (Leu40, Ile70, Val73, Leu75, and Pro77) which, when completely mutated to finishing of premature translation, severe Hex A deficiency.</text>
                    <arg n="0">exon 5</arg>
                    <arg n="1">alele</arg>
                    <arg n="2">finishing of premature translation</arg>
                    <arg n="3">severe Hex A deficiency</arg>
                </example>
                <example src="PERMUTATE" no="191">
                    <text>We have identified allele in exon 5 (Leu40, Ile70, Val73, Leu75, and Pro77) which, when mutated to the termination of the premature translation, serious Hex A deficiency.</text>
                    <arg n="0">exon 5</arg>
                    <arg n="1">allele</arg>
                    <arg n="2">the termination of the premature translation</arg>
                    <arg n="3">serious Hex A deficiency</arg>
                </example>
                <example src="PERMUTATE" no="192">
                    <text>We identify a gene in the A0 domain (extracellular ALK4 domain) (Leu40, Ile70, Val73, Leu75 and Pro77) which, when completely mutated to late neuronal lipofuscinosis variant (LLC6) and in nclf mutant mice, a new predicted transmembrane protein.</text>
                    <arg n="1">a gene</arg>
                    <arg n="2">late neuronal lipofuscinosis variant (LLC6) and in nclf mutant mice</arg>
                    <arg n="3">a new predicted transmembrane protein</arg>
                </example>
                <example src="PERMUTATE" no="193">
                    <text>We identify a gene in the A0 domain (extracellular ALK4 domain) (Leu40, Ile70, Val73, Leu75 and Pro77) which, when completely mutated to variate to the variant of cerebroide neuronal lipofuscinosis (CLN6) and nclf mutant mice, a new predefined transmembrane protein.</text>
                    <arg n="1">a gene</arg>
                    <arg n="2">variate to the variant of cerebroide neuronal lipofuscinosis (CLN6) and nclf mutant mice</arg>
                    <arg n="3">a new predefined transmembrane protein</arg>
                </example>
                <example src="PERMUTATE" no="194">
                    <text>We identify a gene in the A0 domain (extracellular ALK4 domain) (Leu40, Ile70, Val73, Leu75 and Pro77) which, when mutated to late neuronal lipofuscinosis variant (LLC6) and in nclf mutant mice, a new transmembrane protein predicted.</text>
                    <arg n="1">a gene</arg>
                    <arg n="2">late neuronal lipofuscinosis variant (LLC6) and in nclf mutant mice</arg>
                    <arg n="3">a new transmembrane protein predicted</arg>
                </example>
                <example src="PERMUTATE" no="195">
                    <text>We identify gene in the A0 domain (extracellular ALK4 domain) (Leu40, Ile70, Val73, Leu75 and Pro77) which, when mutated to delayed neuronal cerebroid lipofuscinosis variant (CLN6) and in nclf mutant mice, a new transmembrane protein predicted.</text>
                    <arg n="1">gene</arg>
                    <arg n="2">delayed neuronal cerebroid lipofuscinosis variant (CLN6) and in nclf mutant mice</arg>
                    <arg n="3">a new transmembrane protein predicted</arg>
                </example>
                <example src="PERMUTATE" no="196">
                    <text>a gene mutated in late neuronal lipofuscinosis variant (LLC6) and in nclf mutant mice was coded in an unprecedented transmembrane protein.</text>
                    <arg n="1">a gene</arg>
                    <arg n="2">late neuronal lipofuscinosis variant (LLC6) and in nclf mutant mice</arg>
                    <arg n="3">an unprecedented transmembrane protein</arg>
                </example>
                <example src="PERMUTATE" no="197">
                    <text>a gene mutated in variant under the neural lipofuscinosis variant cerebroide (CLN6) and in nclf mutant mice was A3 (a newly predicted transmembrane protein.</text>
                    <arg n="1">a gene</arg>
                    <arg n="2">variant under the neural lipofuscinosis variant cerebroide (CLN6) and in nclf mutant mice</arg>
                </example>
                <example src="PERMUTATE" no="198">
                    <text>a gene mutated in variate to the variant of cerebroide neuronal lipofuscinosis (CLN6) and nclf mutant mice was coded in a new predefined transmembrane protein.</text>
                    <arg n="1">a gene</arg>
                    <arg n="2">variate to the variant of cerebroide neuronal lipofuscinosis (CLN6) and nclf mutant mice</arg>
                    <arg n="3">a new predefined transmembrane protein</arg>
                </example>
                <example src="PERMUTATE" no="199">
                    <text>a gene that can be mutated in delayed neuronal cerebroid lipofuscinosis variant (CLN6) and in nclf mutant mice was A3 (a newly predicted transmembrane protein.</text>
                    <arg n="1">a gene</arg>
                    <arg n="2">delayed neuronal cerebroid lipofuscinosis variant (CLN6) and in nclf mutant mice</arg>
                </example>
                <example src="PERMUTATE" no="200">
                    <text>a gene that is mutated in late neuronal lipofuscinosis variant (LLC6) and in nclf mutant mice was coded in a new predicted transmembrane protein.</text>
                    <arg n="1">a gene</arg>
                    <arg n="2">late neuronal lipofuscinosis variant (LLC6) and in nclf mutant mice</arg>
                    <arg n="3">a new predicted transmembrane protein</arg>
                </example>
                <example src="PERMUTATE" no="201">
                    <text>a gene that is mutated in late neuronal lipofuscinosis variant (LN6) and in nclf mutant mice codes an unprecedented transmembrane protein.</text>
                    <arg n="1">a gene</arg>
                    <arg n="2">late neuronal lipofuscinosis variant (LN6) and in nclf mutant mice</arg>
                    <arg n="3">an unprecedented transmembrane protein</arg>
                </example>
                <example src="PERMUTATE" no="202">
                    <text>a gene that is mutated in variate to the variant of cerebroide neuronal lipofuscinosis (CLN6) and nclf mutant mice codes a new predefined transmembrane protein.</text>
                    <arg n="1">a gene</arg>
                    <arg n="2">variate to the variant of cerebroide neuronal lipofuscinosis (CLN6) and nclf mutant mice</arg>
                    <arg n="3">a new predefined transmembrane protein</arg>
                </example>
                <example src="PERMUTATE" no="203">
                    <text>a gene that is mutated into late neuronal lipofuscinosis variant (LLC6) and in nclf mutant mice codes a new predicted transmembrane protein.</text>
                    <arg n="1">a gene</arg>
                    <arg n="2">late neuronal lipofuscinosis variant (LLC6) and in nclf mutant mice</arg>
                    <arg n="3">a new predicted transmembrane protein</arg>
                </example>
                <example src="PERMUTATE" no="204">
                    <text>a gene that was mutated into late neuronal lipofuscinosis variant (LLC6) and in nclf mutant mice codes an unprecedented transmembrane protein.</text>
                    <arg n="1">a gene</arg>
                    <arg n="2">late neuronal lipofuscinosis variant (LLC6) and in nclf mutant mice</arg>
                    <arg n="3">an unprecedented transmembrane protein</arg>
                </example>
                <example src="PERMUTATE" no="205">
                    <text>a gene that will be mutated into late neuronal lipofuscinosis variant (LLC6) and in nclf mutant mice codes a new transmembrane protein predicted.</text>
                    <arg n="1">a gene</arg>
                    <arg n="2">late neuronal lipofuscinosis variant (LLC6) and in nclf mutant mice</arg>
                    <arg n="3">a new transmembrane protein predicted</arg>
                </example>
                <example src="PERMUTATE" no="206">
                    <text>a gene that will be mutated into variant under the neural lipofuscinosis variant cerebroide (CLN6) and in nclf mutant mice codes a new predefined transmembrane protein.</text>
                    <arg n="1">a gene</arg>
                    <arg n="2">variant under the neural lipofuscinosis variant cerebroide (CLN6) and in nclf mutant mice</arg>
                    <arg n="3">a new predefined transmembrane protein</arg>
                </example>
                <example src="PERMUTATE" no="207">
                    <text>a gene that will mutated in late neuronal lipofuscinosis variant (LLC6) and in nclf mutant mice was a new predicted transmembrane protein.</text>
                    <arg n="1">a gene</arg>
                    <arg n="2">late neuronal lipofuscinosis variant (LLC6) and in nclf mutant mice</arg>
                    <arg n="3">a new predicted transmembrane protein</arg>
                </example>
                <example src="PERMUTATE" no="208">
                    <text>a gene was mutated into late neuronal lipofuscinosis variant (LLC6) and in nclf mutant mice and coded into an unprecedented transmembrane protein.</text>
                    <arg n="1">a gene</arg>
                    <arg n="2">late neuronal lipofuscinosis variant (LLC6) and in nclf mutant mice</arg>
                    <arg n="3">an unprecedented transmembrane protein</arg>
                </example>
                <example src="PERMUTATE" no="209">
                    <text>a gene was mutated into late neuronal lipofuscinosis variant (LN6) and in nclf mutant mice coding an unprecedented transmembrane protein.</text>
                    <arg n="1">a gene</arg>
                    <arg n="2">late neuronal lipofuscinosis variant (LN6) and in nclf mutant mice</arg>
                    <arg n="3">an unprecedented transmembrane protein</arg>
                </example>
                <example src="PERMUTATE" no="210">
                    <text>exon 5 observed mutar allele with the termination of the premature translation mutate in serious Hex A deficiency.</text>
                    <arg n="0">exon 5</arg>
                    <arg n="1">allele</arg>
                    <arg n="2">the termination of the premature translation</arg>
                    <arg n="3">serious Hex A deficiency</arg>
                </example>
                <example src="PERMUTATE" no="211">
                    <text>five hydrophobic amino acid residues that is mutated in alanine codes has significant effects on the dominant negative activity of ALK4-trunc.</text>
                    <arg n="1">five hydrophobic amino acid residues</arg>
                    <arg n="2">alanine</arg>
                    <arg n="3">has significant effects on the dominant negative activity of ALK4-trunc</arg>
                </example>
                <example src="PERMUTATE" no="212">
                    <text>five hydrophobic amino acid residues that is mutated in alanine was coded in has significant effects on the dominant negative activity of ALK4-trunc.</text>
                    <arg n="1">five hydrophobic amino acid residues</arg>
                    <arg n="2">alanine</arg>
                    <arg n="3">has significant effects on the dominant negative activity of ALK4-trunc</arg>
                </example>
                <example src="PERMUTATE" no="213">
                    <text>five hydrophobic amino acid residues that is mutated into alanine codes has significant effects on the dominant negative activity of ALK4-trunc.</text>
                    <arg n="1">five hydrophobic amino acid residues</arg>
                    <arg n="2">alanine</arg>
                    <arg n="3">has significant effects on the dominant negative activity of ALK4-trunc</arg>
                </example>
                <example src="PERMUTATE" no="214">
                    <text>five hydrophobic amino acid residues that was mutated into alanine codes has significant effects on the dominant negative activity of ALK4-trunc.</text>
                    <arg n="1">five hydrophobic amino acid residues</arg>
                    <arg n="2">alanine</arg>
                    <arg n="3">has significant effects on the dominant negative activity of ALK4-trunc</arg>
                </example>
                <example src="PERMUTATE" no="215">
                    <text>five hydrophobic amino acid residues that was mutated into alanine was has significant effects on the dominant negative activity of ALK4-trunc.</text>
                    <arg n="1">five hydrophobic amino acid residues</arg>
                    <arg n="2">alanine</arg>
                    <arg n="3">has significant effects on the dominant negative activity of ALK4-trunc</arg>
                </example>
                <example src="PERMUTATE" no="216">
                    <text>five hydrophobic amino acid residues that will mutated in alanine was has significant effects on the dominant negative activity of ALK4-trunc.</text>
                    <arg n="1">five hydrophobic amino acid residues</arg>
                    <arg n="2">alanine</arg>
                    <arg n="3">has significant effects on the dominant negative activity of ALK4-trunc</arg>
                </example>
                <example src="PERMUTATE" no="217">
                    <text>five hydrophobic amino acid residues was mutated into alanine coding has significant effects on the dominant negative activity of ALK4-trunc.</text>
                    <arg n="1">five hydrophobic amino acid residues</arg>
                    <arg n="2">alanine</arg>
                    <arg n="3">has significant effects on the dominant negative activity of ALK4-trunc</arg>
                </example>
                <example src="PERMUTATE" no="218">
                    <text>five residues of hydrophobic amino acids that is mutated in alanine was coded in has significant effects on the dominant negative activity of ALK4-trunc.</text>
                    <arg n="1">five residues of hydrophobic amino acids</arg>
                    <arg n="2">alanine</arg>
                    <arg n="3">has significant effects on the dominant negative activity of ALK4-trunc</arg>
                </example>
                <example src="PERMUTATE" no="219">
                    <text>five residues of hydrophobic amino acids was mutated into alanine coding has significant effects on the dominant negative activity of ALK4-trunc.</text>
                    <arg n="1">five residues of hydrophobic amino acids</arg>
                    <arg n="2">alanine</arg>
                    <arg n="3">has significant effects on the dominant negative activity of ALK4-trunc</arg>
                </example>
                <example src="PERMUTATE" no="220">
                    <text>gen that has been mutated into infant-child neural lipofuscinosis (CLN6) and in nclf mutant mice codes a recently predicted transmembrane protein.</text>
                    <arg n="1">gen</arg>
                    <arg n="2">infant-child neural lipofuscinosis (CLN6) and in nclf mutant mice</arg>
                    <arg n="3">a recently predicted transmembrane protein</arg>
                </example>
                <example src="PERMUTATE" no="221">
                    <text>gen that is able to be mutated in late lipidscinosis infertile neural lipofuscinosis (LN6) and in nclf mutant mice codes a new predefined transmembrane protein.</text>
                    <arg n="1">gen</arg>
                    <arg n="2">late lipidscinosis infertile neural lipofuscinosis (LN6) and in nclf mutant mice</arg>
                    <arg n="3">a new predefined transmembrane protein</arg>
                </example>
                <example src="PERMUTATE" no="222">
                    <text>gen that is mutated in infant-child neural lipofuscinosis (CLN6) and in nclf mutant mice codes a recently predicted transmembrane protein.</text>
                    <arg n="1">gen</arg>
                    <arg n="2">infant-child neural lipofuscinosis (CLN6) and in nclf mutant mice</arg>
                    <arg n="3">a recently predicted transmembrane protein</arg>
                </example>
                <example src="PERMUTATE" no="223">
                    <text>gen that is mutated in slow childhood neural lipidscinosis (CLN6) and in nclf mutant mice was coded in a recently predicted transmembrane protein.</text>
                    <arg n="1">gen</arg>
                    <arg n="2">slow childhood neural lipidscinosis (CLN6) and in nclf mutant mice</arg>
                    <arg n="3">a recently predicted transmembrane protein</arg>
                </example>
                <example src="PERMUTATE" no="224">
                    <text>gen that is mutated in the variant of late infant neural lipofuscinosis (LN6) and in nclf mutant mice codes a new predefined transmembrane protein.</text>
                    <arg n="1">gen</arg>
                    <arg n="2">the variant of late infant neural lipofuscinosis (LN6) and in nclf mutant mice</arg>
                    <arg n="3">a new predefined transmembrane protein</arg>
                </example>
                <example src="PERMUTATE" no="225">
                    <text>gen that may have been mutated in the variant of late infant neural lipofuscinosis (LN6) and in nclf mutant mice was a new predefined transmembrane protein.</text>
                    <arg n="1">gen</arg>
                    <arg n="2">the variant of late infant neural lipofuscinosis (LN6) and in nclf mutant mice</arg>
                    <arg n="3">a new predefined transmembrane protein</arg>
                </example>
                <example src="PERMUTATE" no="226">
                    <text>gen that was mutated into infant-child neural lipofuscinosis (CLN6) and in nclf mutant mice codes a recently predicted transmembrane protein.</text>
                    <arg n="1">gen</arg>
                    <arg n="2">infant-child neural lipofuscinosis (CLN6) and in nclf mutant mice</arg>
                    <arg n="3">a recently predicted transmembrane protein</arg>
                </example>
                <example src="PERMUTATE" no="227">
                    <text>gen that was mutated into slow childhood neural lipidscinosis (CLN6) and in nclf mutant mice codes a recently predicted transmembrane protein.</text>
                    <arg n="1">gen</arg>
                    <arg n="2">slow childhood neural lipidscinosis (CLN6) and in nclf mutant mice</arg>
                    <arg n="3">a recently predicted transmembrane protein</arg>
                </example>
                <example src="PERMUTATE" no="228">
                    <text>gen that was mutated into the variant of late infant neural lipofuscinosis (LN6) and in nclf mutant mice codes a new predefined transmembrane protein.</text>
                    <arg n="1">gen</arg>
                    <arg n="2">the variant of late infant neural lipofuscinosis (LN6) and in nclf mutant mice</arg>
                    <arg n="3">a new predefined transmembrane protein</arg>
                </example>
                <example src="PERMUTATE" no="229">
                    <text>gen was mutated into late lipidscinosis infertile neural lipofuscinosis (LN6) and in nclf mutant mice coding a new predefined transmembrane protein.</text>
                    <arg n="1">gen</arg>
                    <arg n="2">late lipidscinosis infertile neural lipofuscinosis (LN6) and in nclf mutant mice</arg>
                    <arg n="3">a new predefined transmembrane protein</arg>
                </example>
                <example src="PERMUTATE" no="230">
                    <text>gen was mutated into the variant of late infant neural lipofuscinosis (LN6) and in nclf mutant mice and coded into a new predefined transmembrane protein.</text>
                    <arg n="1">gen</arg>
                    <arg n="2">the variant of late infant neural lipofuscinosis (LN6) and in nclf mutant mice</arg>
                    <arg n="3">a new predefined transmembrane protein</arg>
                </example>
                <example src="PERMUTATE" no="231">
                    <text>gene mutated in delayed neuronal cerebroid lipofuscinosis variant (CLN6) and in nclf mutant mice was coded in a new transmembrane protein predicted.</text>
                    <arg n="1">gene</arg>
                    <arg n="2">delayed neuronal cerebroid lipofuscinosis variant (CLN6) and in nclf mutant mice</arg>
                    <arg n="3">a new transmembrane protein predicted</arg>
                </example>
                <example src="PERMUTATE" no="232">
                    <text>gene mutated in late neuronal lipofuscinosis variant (LN6) and in nclf mutant mice was coded in an unprecedented transmembrane protein.</text>
                    <arg n="1">gene</arg>
                    <arg n="2">late neuronal lipofuscinosis variant (LN6) and in nclf mutant mice</arg>
                    <arg n="3">an unprecedented transmembrane protein</arg>
                </example>
                <example src="PERMUTATE" no="233">
                    <text>gene that can be mutated in delayed neuronal cerebroid lipofuscinosis variant (CLN6) and in nclf mutant mice was A3 (a newly predicted transmembrane protein.</text>
                    <arg n="1">gene</arg>
                    <arg n="2">delayed neuronal cerebroid lipofuscinosis variant (CLN6) and in nclf mutant mice</arg>
                </example>
                <example src="PERMUTATE" no="234">
                    <text>gene that has been mutated into late neuronal lipofuscinosis variant (LN6) and in nclf mutant mice codes an unprecedented transmembrane protein.</text>
                    <arg n="1">gene</arg>
                    <arg n="2">late neuronal lipofuscinosis variant (LN6) and in nclf mutant mice</arg>
                    <arg n="3">an unprecedented transmembrane protein</arg>
                </example>
                <example src="PERMUTATE" no="235">
                    <text>gene that is able to be mutated in late neuronal lipofuscinosis variant (LN6) and in nclf mutant mice codes an unprecedented transmembrane protein.</text>
                    <arg n="1">gene</arg>
                    <arg n="2">late neuronal lipofuscinosis variant (LN6) and in nclf mutant mice</arg>
                    <arg n="3">an unprecedented transmembrane protein</arg>
                </example>
                <example src="PERMUTATE" no="236">
                    <text>gene that is mutated in delayed neuronal cerebroid lipofuscinosis variant (CLN6) and in nclf mutant mice was coded in a new transmembrane protein predicted.</text>
                    <arg n="1">gene</arg>
                    <arg n="2">delayed neuronal cerebroid lipofuscinosis variant (CLN6) and in nclf mutant mice</arg>
                    <arg n="3">a new transmembrane protein predicted</arg>
                </example>
                <example src="PERMUTATE" no="237">
                    <text>gene that may have been mutated in delayed neuronal cerebroid lipofuscinosis variant (CLN6) and in nclf mutant mice was A3 (a new transmembrane protein predicted.</text>
                    <arg n="1">gene</arg>
                    <arg n="2">delayed neuronal cerebroid lipofuscinosis variant (CLN6) and in nclf mutant mice</arg>
                </example>
                <example src="PERMUTATE" no="238">
                    <text>gene was mutated into late neuronal lipofuscinosis variant (LN6) and in nclf mutant mice and coded into an unprecedented transmembrane protein.</text>
                    <arg n="1">gene</arg>
                    <arg n="2">late neuronal lipofuscinosis variant (LN6) and in nclf mutant mice</arg>
                    <arg n="3">an unprecedented transmembrane protein</arg>
                </example>
                <example src="PERMUTATE" no="239">
                    <text>gene was mutated into late neuronal lipofuscinosis variant (LN6) and in nclf mutant mice coding an unprecedented transmembrane protein.</text>
                    <arg n="1">gene</arg>
                    <arg n="2">late neuronal lipofuscinosis variant (LN6) and in nclf mutant mice</arg>
                    <arg n="3">an unprecedented transmembrane protein</arg>
                </example>
                <example src="PERMUTATE" no="240">
                    <text>genus that has the ability to be mutated in dissipated neural lipofuscinosis induced by cerebro-cerebro (CLN6) variant and in nclf mutant mice was the one that codified A3 (a new transmembrane protein predicted.</text>
                    <arg n="1">genus</arg>
                    <arg n="2">dissipated neural lipofuscinosis induced by cerebro-cerebro (CLN6) variant and in nclf mutant mice</arg>
                </example>
                <example src="PERMUTATE" no="241">
                    <text>model breakdowns are observed as mutated by Sa97 RAT sequence, adherence to Q62696 using the Swiss PDB Viewer software (Guex and Peitsch, 1997).</text>
                    <arg n="0">model breakdowns</arg>
                    <arg n="1">Sa97 RAT sequence</arg>
                </example>
                <example src="PERMUTATE" no="242">
                    <text>model breakdowns are observed mutated by Sa97 RAT sequence, adhering to Q62696 using the Swiss PDB display software (Guex and Peitsch, 1997).</text>
                    <arg n="0">model breakdowns</arg>
                    <arg n="1">Sa97 RAT sequence</arg>
                </example>
                <example src="PERMUTATE" no="243">
                    <text>model breakdowns are significantly mutated by Sa97 RAT sequence, adherence to Q62696 using the Swiss PDB display software (Guex and Peitsch, 1997).</text>
                    <arg n="0">model breakdowns</arg>
                    <arg n="1">Sa97 RAT sequence</arg>
                </example>
                <example src="PERMUTATE" no="244">
                    <text>model breakdowns can be mutated by Sa97 RAT sequence, adhesion to Q62696 using the Swiss PDB display program (Guex and Peitsch, 1997).</text>
                    <arg n="0">model breakdowns</arg>
                    <arg n="1">Sa97 RAT sequence</arg>
                </example>
                <example src="PERMUTATE" no="245">
                    <text>model breakdowns could have been mutated by Sa97 RAT sequence, adherence in Q62696 using the Swiss PDB Viewer program (Guex and Peitsch, 1997).</text>
                    <arg n="0">model breakdowns</arg>
                    <arg n="1">Sa97 RAT sequence</arg>
                </example>
                <example src="PERMUTATE" no="246">
                    <text>model breakdowns have been significantly mutated by Sa97 RAT sequence, ascent No. 62696 using the Swiss PDB Viewer program (Guex and Peitsch, 1997).</text>
                    <arg n="0">model breakdowns</arg>
                    <arg n="1">Sa97 RAT sequence</arg>
                </example>
                <example src="PERMUTATE" no="247">
                    <text>model breakdowns may have been mutated by Sa97 RAT sequence, Adhesion No.D62696 using the Swiss PDB Viewer program (Guex and Peitsch, 1997).</text>
                    <arg n="0">model breakdowns</arg>
                    <arg n="1">Sa97 RAT sequence</arg>
                </example>
                <example src="PERMUTATE" no="248">
                    <text>model breakdowns would be mutated by Sa97 RAT sequence , adherence in Q62696 using the Swiss PDB Viewer software (Guex and Peitsch, 1997).</text>
                    <arg n="0">model breakdowns</arg>
                    <arg n="1">Sa97 RAT sequence</arg>
                </example>
                <example src="PERMUTATE" no="249">
                    <text>model faults are significantly mutated by Sa97 RAT sequence, adherence to Q62696 using the Swiss PDB display software (Guex and Peitsch, 1997).</text>
                    <arg n="0">model faults</arg>
                    <arg n="1">Sa97 RAT sequence</arg>
                </example>
                <example src="PERMUTATE" no="250">
                    <text>model faults are significantly mutated by the SAP97 RAT sequence, adherence in Q62696 using the Swiss PDB Viewer software (Guex and Peitsch, 1997).</text>
                    <arg n="0">model faults</arg>
                    <arg n="1">the SAP97 RAT sequence</arg>
                </example>
                <example src="PERMUTATE" no="251">
                    <text>model faults can be mutated by the SAP97 RAT sequence, adherence in Q62696 using the Swiss PDB Viewer program (Guex and Peitsch, 1997).</text>
                    <arg n="0">model faults</arg>
                    <arg n="1">the SAP97 RAT sequence</arg>
                </example>
                <example src="PERMUTATE" no="252">
                    <text>model faults can be mutated by the sequence Sa97 RAT sequence, adherence no.D62696 using the Swiss PDB Viewer software (Guex and Peitsch, 1997).</text>
                    <arg n="0">model faults</arg>
                    <arg n="1">Sa97 RAT sequence</arg>
                </example>
                <example src="PERMUTATE" no="253">
                    <text>model faults can be significantly mutated by Sa97 RAT sequence, adhesion in Q62696 using the Swiss PDB display software (Guex and Peitsch, 1997).</text>
                    <arg n="0">model faults</arg>
                    <arg n="1">Sa97 RAT sequence</arg>
                </example>
                <example src="PERMUTATE" no="254">
                    <text>model faults could be mutated by the SAP97 RAT sequence , adherence in Q62696 using the Swiss PDB Viewer program (Guex and Peitsch, 1997).</text>
                    <arg n="0">model faults</arg>
                    <arg n="1">the SAP97 RAT sequence</arg>
                </example>
                <example src="PERMUTATE" no="255">
                    <text>model faults is likely to be significantly mutated by Sa97 RAT sequence, ascension No.D62696 using the Swiss PDB Viewer program (Guex and Peitsch, 1997).</text>
                    <arg n="0">model faults</arg>
                    <arg n="1">Sa97 RAT sequence</arg>
                </example>
                <example src="PERMUTATE" no="256">
                    <text>model faults will be mutated by Sa97 RAT sequence, adherence in Q62696 using the Swiss PDB Viewer program (Guex and Peitsch, 1997).</text>
                    <arg n="0">model faults</arg>
                    <arg n="1">Sa97 RAT sequence</arg>
                </example>
                <example src="PERMUTATE" no="257">
                    <text>model faults will be significantly mutated by Sa97 RAT sequence, adherence in Q62696 using the Swiss PDB Viewer program (Guex and Peitsch, 1997).</text>
                    <arg n="0">model faults</arg>
                    <arg n="1">Sa97 RAT sequence</arg>
                </example>
                <example src="PERMUTATE" no="258">
                    <text>model fragrances are observed significantly mutated by Sa97 RAT sequence, adherence to Q62696 using the Swiss PDB display software (Guex and Peitsch, 1997).</text>
                    <arg n="0">model fragrances</arg>
                    <arg n="1">Sa97 RAT sequence</arg>
                </example>
                <example src="PERMUTATE" no="259">
                    <text>model fragrances can be mutated by the SAP97 RAT sequence, No.D62696 adhesion using the Swiss PDB Viewer program (Guex and Peitsch, 1997).</text>
                    <arg n="0">model fragrances</arg>
                    <arg n="1">the SAP97 RAT sequence</arg>
                </example>
                <example src="PERMUTATE" no="260">
                    <text>model fragrances can be mutated by the sequence Sa97 RAT sequence, adherence no.D62696 using the Swiss PDB Viewer software (Guex and Peitsch, 1997).</text>
                    <arg n="0">model fragrances</arg>
                    <arg n="1">Sa97 RAT sequence</arg>
                </example>
                <example src="PERMUTATE" no="261">
                    <text>model fragrances can be significantly mutated by Sa97 RAT sequence, adherence in Q62696 using the Swiss PDB Viewer software (Guex and Peitsch, 1997).</text>
                    <arg n="0">model fragrances</arg>
                    <arg n="1">Sa97 RAT sequence</arg>
                </example>
                <example src="PERMUTATE" no="262">
                    <text>model fragrances can be significantly mutated by the SAP97 RAT sequence, adherence in Q62696 using the Swiss PDB Viewer software (Guex and Peitsch, 1997).</text>
                    <arg n="0">model fragrances</arg>
                    <arg n="1">the SAP97 RAT sequence</arg>
                </example>
                <example src="PERMUTATE" no="263">
                    <text>model fragrances could be muted for the SAP97 RAT sequence, No.D62696 adhesion mutated the Swiss PDB Viewer program (Guex and Peitsch, 1997).</text>
                    <arg n="0">model fragrances</arg>
                    <arg n="1">the SAP97 RAT sequence</arg>
                </example>
                <example src="PERMUTATE" no="264">
                    <text>model fragrances could be significantly mutated by the SAP97 RAT sequence, adherence in Q62696 using the Swiss PDB Viewer program (Guex and Peitsch, 1997).</text>
                    <arg n="0">model fragrances</arg>
                    <arg n="1">the SAP97 RAT sequence</arg>
                </example>
                <example src="PERMUTATE" no="265">
                    <text>model fragrances have been mutated by Sa97 RAT sequence, Adhesion No.D62696 using the Swiss PDB Viewer program (Guex and Peitsch, 1997).</text>
                    <arg n="0">model fragrances</arg>
                    <arg n="1">Sa97 RAT sequence</arg>
                </example>
                <example src="PERMUTATE" no="266">
                    <text>model fragrances have been significantly mutated by Sa97 RAT sequence, ascent No. 62696 using the Swiss PDB Viewer program (Guex and Peitsch, 1997).</text>
                    <arg n="0">model fragrances</arg>
                    <arg n="1">Sa97 RAT sequence</arg>
                </example>
                <example src="PERMUTATE" no="267">
                    <text>model fragrances may have been mutated by Sa97 RAT sequence, Adhesion No.D62696 using the Swiss PDB Viewer program (Guex and Peitsch, 1997).</text>
                    <arg n="0">model fragrances</arg>
                    <arg n="1">Sa97 RAT sequence</arg>
                </example>
                <example src="PERMUTATE" no="268">
                    <text>snippets of template are observed mutated by sAP97 RAT, adhering to Q62696 using the Swiss PDB display software (Guex and Peitsch, 1997).</text>
                    <arg n="0">snippets of template</arg>
                    <arg n="1">sAP97 RAT</arg>
                </example>
                <example src="PERMUTATE" no="269">
                    <text>snippets of template are significantly mutated by sAP97 RAT, adherence in Q62696 using the Swiss PDB Viewer software (Guex and Peitsch, 1997).</text>
                    <arg n="0">snippets of template</arg>
                    <arg n="1">sAP97 RAT</arg>
                </example>
                <example src="PERMUTATE" no="270">
                    <text>snippets of template is likely to be mutated by sAP97 RAT, ascension No.D62696 using the Swiss PDB Viewer program (Guex and Peitsch, 1997).</text>
                    <arg n="0">snippets of template</arg>
                    <arg n="1">sAP97 RAT</arg>
                </example>
                <example src="PERMUTATE" no="271">
                    <text>snippets of template is likely to be significantly mutated by sAP97 RAT, ascension No.D62696 using the Swiss PDB Viewer program (Guex and Peitsch, 1997).</text>
                    <arg n="0">snippets of template</arg>
                    <arg n="1">sAP97 RAT</arg>
                </example>
                <example src="PERMUTATE" no="272">
                    <text>the template fragments are significantly mutated by the SAP97 RAT sequence, adherence to Q62696 using the Swiss PDB display software (Guex and Peitsch, 1997).</text>
                    <arg n="0">the template fragments</arg>
                    <arg n="1">the SAP97 RAT sequence</arg>
                </example>
                <example src="PERMUTATE" no="273">
                    <text>the template fragments can be mutated by the SAP97 RAT sequence, No.D62696 adhesion using the Swiss PDB Viewer program (Guex and Peitsch, 1997).</text>
                    <arg n="0">the template fragments</arg>
                    <arg n="1">the SAP97 RAT sequence</arg>
                </example>
                <example src="PERMUTATE" no="274">
                    <text>the template fragments is likely to be significantly mutated by the SAP97 RAT sequence, ascension No.D62696 using the Swiss PDB Viewer program (Guex and Peitsch, 1997).</text>
                    <arg n="0">the template fragments</arg>
                    <arg n="1">the SAP97 RAT sequence</arg>
                </example>
                <example src="PERMUTATE" no="275">
                    <text>the template fragments would be mutated by the SAP97 RAT sequence , adherence in Q62696 using the Swiss PDB Viewer software (Guex and Peitsch, 1997).</text>
                    <arg n="0">the template fragments</arg>
                    <arg n="1">the SAP97 RAT sequence</arg>
                </example>
                <example src="REPLACE" no="1">
                    <text>A0 mutation (the C-terminal kinase sites of MAP (T235 and T239), for example, essentially mutating to late infectious variant neuronal lipofuscinosis (CLN6) and mutant nclf mice (figure 5C, bands 7 and 8).</text>
                    <arg n="2">late infectious variant neuronal lipofuscinosis (CLN6) and mutant nclf mice</arg>
                </example>
                <example src="REPLACE" no="2">
                    <text>A0 mutation (the C-terminal kinase sites of MAP (T235 and T239), for example, is mutating as an essential factor for abolition of FEG-stimulated phosphorylation and prevented FEG-induced mobility (figure 5C, bands 7 and 8).</text>
                    <arg n="2">abolition of FEG-stimulated phosphorylation and prevented FEG-induced mobility</arg>
                </example>
                <example src="REPLACE" no="3">
                    <text>A0 mutation (the C-terminal kinase sites of MAP (T235 and T239), for example, is mutating as an essential factor for ceroid lipofuscinosis neural ceroid variation (CLN6) and in mutant mice nclf (figure 5C, bands 7 and 8).</text>
                    <arg n="2">ceroid lipofuscinosis neural ceroid variation (CLN6) and in mutant mice nclf</arg>
                </example>
                <example src="REPLACE" no="4">
                    <text>A0 mutation (the C-terminal kinase sites of MAP (T235 and T239), for example, is mutating as an essential factor for ceroid variant of late infertile neural diffufuscinosis (CLN6) and in nclf mutant mice (figure 5C, bands 7 and 8).</text>
                    <arg n="2">ceroid variant of late infertile neural diffufuscinosis (CLN6) and in nclf mutant mice</arg>
                </example>
                <example src="REPLACE" no="5">
                    <text>A0 mutation (the C-terminal kinase sites of MAP (T235 and T239), for example, is mutating as an essential factor for increasing above the EGF and increasing the phosphorylation and mobility induced by the EGF (figure 5C, bands 7 and 8).</text>
                    <arg n="2">increasing above the EGF and increasing the phosphorylation and mobility induced by the EGF</arg>
                </example>
                <example src="REPLACE" no="6">
                    <text>A0 mutation (the C-terminal kinase sites of MAP (T235 and T239), for example, is mutating as an essential factor for late infection variant ceroid neuronal lipofuscinosis (CLN6) and mutant nclf mice (figure 5C, bands 7 and 8).</text>
                    <arg n="2">late infection variant ceroid neuronal lipofuscinosis (CLN6) and mutant nclf mice</arg>
                </example>
                <example src="REPLACE" no="7">
                    <text>A0 mutation (the C-terminal kinase sites of MAP (T235 and T239), for example, is mutating as an essential factor for late infection variant neuronal lipofuscinosis and mutant nclf mice (figure 5C, bands 7 and 8).</text>
                    <arg n="2">late infection variant neuronal lipofuscinosis and mutant nclf mice</arg>
                </example>
                <example src="REPLACE" no="8">
                    <text>A1 gene that can be mutated into late infection variations in neuronal lipofuscinosis and nclf mice codes a new predefined transmembrane protein.</text>
                    <arg n="2">late infection variations in neuronal lipofuscinosis and nclf mice</arg>
                    <arg n="3">a new predefined transmembrane protein</arg>
                </example>
                <example src="REPLACE" no="9">
                    <text>A1 gene that can be mutated into late neuronal lipofuscinosis and mutant nclf mice codes a newly predicted transmembrane protein.</text>
                    <arg n="2">late neuronal lipofuscinosis and mutant nclf mice</arg>
                    <arg n="3">a newly predicted transmembrane protein</arg>
                </example>
                <example src="REPLACE" no="10">
                    <text>A1 mutation (EE amino acids(437 and 438) in abolited increase of EGF and increased phosphorylation and mobility induced by EGF is able to mutating the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">abolited increase of EGF and increased phosphorylation and mobility induced by EGF</arg>
                </example>
                <example src="REPLACE" no="11">
                    <text>A1 mutation (EE amino acids(437 and 438) in ceroid lipofuscinosis neural ceroid variation (CLN6) and in mutant mice nclf is able to mutating the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">ceroid lipofuscinosis neural ceroid variation (CLN6) and in mutant mice nclf</arg>
                </example>
                <example src="REPLACE" no="12">
                    <text>A1 mutation (EE amino acids(437 and 438) in increasing above the EGF and increasing the phosphorylation and mobility induced by the EGF is able to mutating the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">increasing above the EGF and increasing the phosphorylation and mobility induced by the EGF</arg>
                </example>
                <example src="REPLACE" no="13">
                    <text>A1 mutation (EE amino acids(437 and 438) in increasing above the EGF increase and increasing the phosphorylation and mobility induced by the EGF is able to mutating the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">increasing above the EGF increase and increasing the phosphorylation and mobility induced by the EGF</arg>
                </example>
                <example src="REPLACE" no="14">
                    <text>Analyses of the in vivo transcription of Agn-lacZ with a mutated gene mutated support this conclusion.</text>
                    <arg n="1">a mutated gene</arg>
                </example>
                <example src="REPLACE" no="15">
                    <text>Analyses of the in vivo transcription of Agn-lacZ with parallel of residue positions mutated support this conclusion.</text>
                    <arg n="1">parallel of residue positions</arg>
                </example>
                <example src="REPLACE" no="16">
                    <text>Analyses of the in vivo transcription of Agn-lacZ with parallel positions of residues that are mutated support this conclusion.</text>
                    <arg n="1">parallel positions of residues</arg>
                </example>
                <example src="REPLACE" no="17">
                    <text>Analyses of the in vivo transcription of Agn-lacZ with parallel residue positions that are mutated support this conclusion.</text>
                    <arg n="1">parallel residue positions</arg>
                </example>
                <example src="REPLACE" no="18">
                    <text>Analyses of the in vivo transcription of Agn-lacZ with pars of residue positions that have been mutated support this conclusion.</text>
                    <arg n="1">pars of residue positions</arg>
                </example>
                <example src="REPLACE" no="19">
                    <text>Analyses of the in vivo transcription of Agn-lacZ with settlement pairs mutated support this conclusion.</text>
                    <arg n="1">settlement pairs</arg>
                </example>
                <example src="REPLACE" no="20">
                    <text>Analyses of the in vivo transcription of Agn-lacZ with settlement pairs that were mutated support this conclusion.</text>
                    <arg n="1">settlement pairs</arg>
                </example>
                <example src="REPLACE" no="21">
                    <text>Analyses of the in vivo transcription of Agn-lacZ with the two phosphorylation sites PKA (S 64) and S (211) have already been mutated mutated support this conclusion.</text>
                    <arg n="1">the two phosphorylation sites PKA (S 64) and S (211) have already been mutated</arg>
                </example>
                <example src="REPLACE" no="22">
                    <text>Analyses of the in vivo transcription of Agn-lacZ with the two phosphorylation sites PKA (S 64) and S (211) may have been mutated that were mutated support this conclusion.</text>
                    <arg n="1">the two phosphorylation sites PKA (S 64) and S (211) may have been mutated</arg>
                </example>
                <example src="REPLACE" no="23">
                    <text>Analyses of the in vivo transcription of Agn-lacZ with two amino acids that have been mutated support this conclusion.</text>
                    <arg n="1">two amino acids</arg>
                </example>
                <example src="REPLACE" no="24">
                    <text>Analyses of the in vivo transcription of agn-lacZ with a gene that can be mutated support this conclusion.</text>
                    <arg n="1">a gene</arg>
                </example>
                <example src="REPLACE" no="25">
                    <text>Analyses of the in vivo transcription of agn-lacZ with a mutated gene that can be mutated support this conclusion.</text>
                    <arg n="1">a mutated gene</arg>
                </example>
                <example src="REPLACE" no="26">
                    <text>Analyses of the in vivo transcription of agn-lacZ with gen that can be mutated support this conclusion.</text>
                    <arg n="1">gen</arg>
                </example>
                <example src="REPLACE" no="27">
                    <text>Analyses of the in vivo transcription of agn-lacZ with pairs of waste positions that may have been mutated support this conclusion.</text>
                    <arg n="1">pairs of waste positions</arg>
                </example>
                <example src="REPLACE" no="28">
                    <text>Analyses of the in vivo transcription of agn-lacZ with parallel residue positions that can be mutated support this conclusion.</text>
                    <arg n="1">parallel residue positions</arg>
                </example>
                <example src="REPLACE" no="29">
                    <text>Analyses of the in vivo transcription of agn-lacZ with target sequences AG that can be mutated support this conclusion.</text>
                    <arg n="1">target sequences AG</arg>
                </example>
                <example src="REPLACE" no="30">
                    <text>For example, the A0 mutation (the C-terminal kinase sites of MAP (T235 and T239) essentially mutate to Lipfuscinosis slow inphantyl neural lipofuscinosis (CLN6) and in nclf mutant mice (figure 5C, bands 7 and 8).</text>
                    <arg n="2">Lipfuscinosis slow inphantyl neural lipofuscinosis (CLN6) and in nclf mutant mice</arg>
                </example>
                <example src="REPLACE" no="31">
                    <text>For example, the A0 mutation (the C-terminal kinase sites of MAP (T235 and T239) essentially mutate to above FEG-stimulated phosphorylation and FEG-induced mobility (figure 5C, bands 7 and 8).</text>
                    <arg n="2">above FEG-stimulated phosphorylation and FEG-induced mobility</arg>
                </example>
                <example src="REPLACE" no="32">
                    <text>For example, the A0 mutation (the C-terminal kinase sites of MAP (T235 and T239) essentially mutate to increasing above the increased phosphorylation stimulated by EGF and change of mobility induced by the EGF (figure 5C, bands 7 and 8).</text>
                    <arg n="2">increasing above the increased phosphorylation stimulated by EGF and change of mobility induced by the EGF</arg>
                </example>
                <example src="REPLACE" no="33">
                    <text>For example, the A0 mutation (the C-terminal kinase sites of MAP (T235 and T239) essentially mutate to late infectious variant neuronal lipofuscinosis (CLN6) and mutant nclf mice (figure 5C, bands 7 and 8).</text>
                    <arg n="2">late infectious variant neuronal lipofuscinosis (CLN6) and mutant nclf mice</arg>
                </example>
                <example src="REPLACE" no="34">
                    <text>For example, the A0 mutation (the C-terminal kinase sites of MAP (T235 and T239) essentially mutating to Lipfuscinosis of late infertile neural lipofuscinosis (CLN6) and in nclf mutant mice (figure 5C, bands 7 and 8).</text>
                    <arg n="2">Lipfuscinosis of late infertile neural lipofuscinosis (CLN6) and in nclf mutant mice</arg>
                </example>
                <example src="REPLACE" no="35">
                    <text>For example, the A0 mutation (the C-terminal kinase sites of MAP (T235 and T239) essentially mutating to increasing above the stimulated phosphorylation and change of mobility induced by FEG (figure 5C, bands 7 and 8).</text>
                    <arg n="2">increasing above the stimulated phosphorylation and change of mobility induced by FEG</arg>
                </example>
                <example src="REPLACE" no="36">
                    <text>For example, the A0 mutation (the C-terminal kinase sites of MAP (T235 and T239) essentially mutating to infectantyl lipofuscinosis neural lipofuscinosis (CLN6) and in nclf mutant mice (figure 5C, bands 7 and 8).</text>
                    <arg n="2">infectantyl lipofuscinosis neural lipofuscinosis (CLN6) and in nclf mutant mice</arg>
                </example>
                <example src="REPLACE" no="37">
                    <text>For example, the A0 mutation (the C-terminal kinase sites of MAP (T235 and T239)) is essentially the one that mutate to Lipfuscinosis of late infertile neural lipofuscinosis (CLN6) and in nclf mutant mice (figure 5C, bands 7 and 8).</text>
                    <arg n="2">Lipfuscinosis of late infertile neural lipofuscinosis (CLN6) and in nclf mutant mice</arg>
                </example>
                <example src="REPLACE" no="38">
                    <text>For example, the A0 mutation (the C-terminal kinase sites of MAP (T235 and T239)) is essentially the one that mutate to abolited increase of EGF and increased phosphorylation and mobility induced by EGF (figure 5C, bands 7 and 8).</text>
                    <arg n="2">abolited increase of EGF and increased phosphorylation and mobility induced by EGF</arg>
                </example>
                <example src="REPLACE" no="39">
                    <text>For example, the A0 mutation (the C-terminal kinase sites of MAP (T235 and T239)) is essentially the one that mutate to above the increased phosphorylation stimulated by FEG and reduced mobility induced by FEG (figure 5C, bands 7 and 8).</text>
                    <arg n="2">above the increased phosphorylation stimulated by FEG and reduced mobility induced by FEG</arg>
                </example>
                <example src="REPLACE" no="40">
                    <text>For example, the A0 mutation (the C-terminal kinase sites of MAP (T235 and T239)) is essentially the one that mutate to late infection variant neuronal neural lipofuscinosis (CLN6) and mutant nclf mice (figure 5C, bands 7 and 8).</text>
                    <arg n="2">late infection variant neuronal neural lipofuscinosis (CLN6) and mutant nclf mice</arg>
                </example>
                <example src="REPLACE" no="41">
                    <text>For example, the A0 mutation (the C-terminal kinase sites of MAP (T235 and T239)) is essentially the one that mutate to late infection variations in neuronal lipofuscinosis and nclf mice (figure 5C, bands 7 and 8).</text>
                    <arg n="2">late infection variations in neuronal lipofuscinosis and nclf mice</arg>
                </example>
                <example src="REPLACE" no="42">
                    <text>For example, the A0 mutation (the C-terminal kinase sites of MAP (T235 and T239)) is essentially the one that mutate to losing the transcriptional repression of the lacZ gene (figure 5C, bands 7 and 8).</text>
                    <arg n="2">losing the transcriptional repression of the lacZ gene</arg>
                </example>
                <example src="REPLACE" no="43">
                    <text>For example, the A0 mutation (the C-terminal-Kinase sites of MAP (T235 and T239) essentially mutate to Lipfuscinosis slow infertile neural lipofuscinosis (CLN6) and in nclf mutant mice (figure 5C, bands 7 and 8).</text>
                    <arg n="2">Lipfuscinosis slow infertile neural lipofuscinosis (CLN6) and in nclf mutant mice</arg>
                </example>
                <example src="REPLACE" no="44">
                    <text>For example, the A0 mutation (the C-terminal-Kinase sites of MAP (T235 and T239) essentially mutate to above the increased phosphorylation stimulated by FEG and reduced mobility induced by FEG (figure 5C, bands 7 and 8).</text>
                    <arg n="2">above the increased phosphorylation stimulated by FEG and reduced mobility induced by FEG</arg>
                </example>
                <example src="REPLACE" no="45">
                    <text>For example, the A0 mutation (the C-terminal-Kinase sites of MAP (T235 and T239) essentially mutate to increasing above increased phosphorylation stimulated by FEG and change of mobility induced by FEG (figure 5C, bands 7 and 8).</text>
                    <arg n="2">increasing above increased phosphorylation stimulated by FEG and change of mobility induced by FEG</arg>
                </example>
                <example src="REPLACE" no="46">
                    <text>For example, the A0 mutation (the C-terminal-Kinase sites of MAP (T235 and T239) essentially mutate to increasing above the EGF increase and increasing the phosphorylation and mobility induced by the EGF (figure 5C, bands 7 and 8).</text>
                    <arg n="2">increasing above the EGF increase and increasing the phosphorylation and mobility induced by the EGF</arg>
                </example>
                <example src="REPLACE" no="47">
                    <text>For example, the A0 mutation (the C-terminal-Kinase sites of MAP (T235 and T239) essentially mutate to late infection variations in neuronal lipofuscinosis and nclf mice (figure 5C, bands 7 and 8).</text>
                    <arg n="2">late infection variations in neuronal lipofuscinosis and nclf mice</arg>
                </example>
                <example src="REPLACE" no="48">
                    <text>For example, the A0 mutation (the C-terminal-Kinase sites of MAP (T235 and T239) essentially mutate to late neuronal lipofuscinosis and mutant nclf mice (figure 5C, bands 7 and 8).</text>
                    <arg n="2">late neuronal lipofuscinosis and mutant nclf mice</arg>
                </example>
                <example src="REPLACE" no="49">
                    <text>For example, the A0 mutation (the C-terminal-Kinase sites of MAP (T235 and T239) essentially mutating to Lipfuscinosis slow infertile neural lipofuscinosis (CLN6) and in nclf mutant mice (figure 5C, bands 7 and 8).</text>
                    <arg n="2">Lipfuscinosis slow infertile neural lipofuscinosis (CLN6) and in nclf mutant mice</arg>
                </example>
                <example src="REPLACE" no="50">
                    <text>For example, the A0 mutation (the C-terminal-Kinase sites of MAP (T235 and T239) essentially mutating to Liphofuscinosis slow inphantyl neural lipofuscinosis (CLN6) and in nclf mutant mice (figure 5C, bands 7 and 8).</text>
                    <arg n="2">Liphofuscinosis slow inphantyl neural lipofuscinosis (CLN6) and in nclf mutant mice</arg>
                </example>
                <example src="REPLACE" no="51">
                    <text>For example, the A0 mutation (the C-terminal-Kinase sites of MAP (T235 and T239) essentially mutating to abolited increase of FEG-stimulated phosphorylation and FEG-induced mobility change (figure 5C, bands 7 and 8).</text>
                    <arg n="2">abolited increase of FEG-stimulated phosphorylation and FEG-induced mobility change</arg>
                </example>
                <example src="REPLACE" no="52">
                    <text>For example, the A0 mutation (the C-terminal-Kinase sites of MAP (T235 and T239) essentially mutating to late infection variations in neuronal lipofuscinosis and nclf mice (figure 5C, bands 7 and 8).</text>
                    <arg n="2">late infection variations in neuronal lipofuscinosis and nclf mice</arg>
                </example>
                <example src="REPLACE" no="53">
                    <text>For example, the A0 mutation (the C-terminal-Kinase sites of MAP (T235 and T239) essentially mutating to late neuronal lipofuscinosis and mutant nclf mice (figure 5C, bands 7 and 8).</text>
                    <arg n="2">late neuronal lipofuscinosis and mutant nclf mice</arg>
                </example>
                <example src="REPLACE" no="54">
                    <text>For example, the A0 mutation (the C-terminal-Kinase sites of MAP (T235 and T239) essentially mutating to losing the transcriptional repression of the lacZ gene (figure 5C, bands 7 and 8).</text>
                    <arg n="2">losing the transcriptional repression of the lacZ gene</arg>
                </example>
                <example src="REPLACE" no="55">
                    <text>For example, the A0 mutation (the sites of the C-terminal kinase of MAP (T235 and T239) was essentially responsible for abolited increase of EGF and increased phosphorylation and mobility induced by EGF (figure 5C, mutating 7 and 8).</text>
                    <arg n="2">abolited increase of EGF and increased phosphorylation and mobility induced by EGF</arg>
                </example>
                <example src="REPLACE" no="56">
                    <text>For example, the A0 mutation (the sites of the C-terminal kinase of MAP (T235 and T239) was essentially responsible for abolited increase of FEG-stimulated phosphorylation and FEG-induced mobility change (figure 5C, mutating 7 and 8).</text>
                    <arg n="2">abolited increase of FEG-stimulated phosphorylation and FEG-induced mobility change</arg>
                </example>
                <example src="REPLACE" no="57">
                    <text>For example, the A0 mutation (the sites of the C-terminal kinase of MAP (T235 and T239) was essentially responsible for ceroid lipofuscinosis neural ceroid variation (CLN6) and in mutant mice nclf (figure 5C, mutating 7 and 8).</text>
                    <arg n="2">ceroid lipofuscinosis neural ceroid variation (CLN6) and in mutant mice nclf</arg>
                </example>
                <example src="REPLACE" no="58">
                    <text>For example, the A0 mutation (the sites of the C-terminal kinase of MAP (T235 and T239) was essentially responsible for increasing above the stimulated phosphorylation and change of mobility induced by FEG (figure 5C, mutating 7 and 8).</text>
                    <arg n="2">increasing above the stimulated phosphorylation and change of mobility induced by FEG</arg>
                </example>
                <example src="REPLACE" no="59">
                    <text>For example, the A0 mutation (the sites of the C-terminal kinase of MAP (T235 and T239) was essentially responsible for late infection variant neuronal neural lipofuscinosis (CLN6) and in mutant nclf mice (figure 5C, mutating 7 and 8).</text>
                    <arg n="2">late infection variant neuronal neural lipofuscinosis (CLN6) and in mutant nclf mice</arg>
                </example>
                <example src="REPLACE" no="60">
                    <text>However, the mutation of MAP-terminal p53 sites essentially mutating to a 7-fold induction (Figure 5C, lanes 7 and 8).</text>
                    <arg n="0">p53</arg>
                    <arg n="2">a 7-fold induction</arg>
                </example>
                <example src="REPLACE" no="61">
                    <text>However, the mutation of MAP-terminal the MAP-terminal T235 and T239 sites essentially mutating to abolition the stimulated increase of EGF in phosphorylation and avoidance of the change in mobility introduced by EGF (Figure 5C, lanes 7 and 8).</text>
                    <arg n="0">the MAP-terminal T235 and T239</arg>
                    <arg n="2">abolition the stimulated increase of EGF in phosphorylation and avoidance of the change in mobility introduced by EGF</arg>
                </example>
                <example src="REPLACE" no="62">
                    <text>However, the mutation of MAP-terminal the T235 and T239 sites sites essentially mutating to abolition of the FEG-stimulated increase in phosphorylation and prevention of FEG-induced mobility change (Figure 5C, lanes 7 and 8).</text>
                    <arg n="0">the T235 and T239 sites</arg>
                    <arg n="2">abolition of the FEG-stimulated increase in phosphorylation and prevention of FEG-induced mobility change</arg>
                </example>
                <example src="REPLACE" no="63">
                    <text>In COS-7 cell cotransfects with plasma expression PKA-Calfa and exon 8, PKA mutated the phosphorylation of the wild type SOX9, but did not affect the phosphorylation of a protein SOX9 in which acDR DNA of the alpha chain cDNA in the 1-cells.</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">acDR DNA of the alpha chain cDNA in the 1-cells</arg>
                </example>
                <example src="REPLACE" no="64">
                    <text>In COS-7 cells co-transfected with PKA-Calfa and exon 8 expression plasmids, PKA improved the phosphorylation of wild SOX9, but did not affect the phosphorylation of a protein SOX9 in which A1 (the two PKA phosphorylation sites (S (64) and S (211)) were observed to be significantly mutated.</text>
                    <arg n="0">exon 8</arg>
                </example>
                <example src="REPLACE" no="65">
                    <text>In COS-7 cells co-transfected with PKA-Calfa and the MAP-terminal T235 and T239 expression plasmids, PKA improved the phosphorylation of wild SOX9, but did not affect the phosphorylation of a protein SOX9 in which A1 (the two PKA phosphorylation sites (S (64) and S (211)) were observed to be significantly mutated.</text>
                    <arg n="0">the MAP-terminal T235 and T239</arg>
                </example>
                <example src="REPLACE" no="66">
                    <text>In COS-7 cotransfects with plasma expression PKA-Calfa and a preserved phenylalanine, PKA improved the phosphorylation of the wild type SOX9, but did not affect the phosphorylation of a protein SOX9 in which it was observed that A1 (the two phosphorylation sites PKA (S (64) and S (211) were significantly mutated.</text>
                    <arg n="0">a preserved phenylalanine</arg>
                </example>
                <example src="REPLACE" no="67">
                    <text>In COS-7 cotransfects with plasma expression PKA-Calfa and the T235 and T239 sites, PKA improved the phosphorylation of the wild type SOX9, but did not affect the phosphorylation of a protein SOX9 in which it was observed that A1 (the two phosphorylation sites PKA (S (64) and S (211) were significantly mutated.</text>
                    <arg n="0">the T235 and T239 sites</arg>
                </example>
                <example src="REPLACE" no="68">
                    <text>In contrast, A0 mutation (the C-terminal kinase sites of MAP (T235 and T239) essentially mutate to increasing above the EGF and increasing the phosphorylation and mobility induced by the EGF (figure 5C, bands 7 and 8).</text>
                    <arg n="2">increasing above the EGF and increasing the phosphorylation and mobility induced by the EGF</arg>
                </example>
                <example src="REPLACE" no="69">
                    <text>In contrast, A0 mutation (the C-terminal kinase sites of MAP (T235 and T239) essentially mutate to late infection variant ceroid neuronal lipofuscinosis (CLN6) and mutant nclf mice (figure 5C, bands 7 and 8).</text>
                    <arg n="2">late infection variant ceroid neuronal lipofuscinosis (CLN6) and mutant nclf mice</arg>
                </example>
                <example src="REPLACE" no="70">
                    <text>In contrast, A0 mutation (the C-terminal kinase sites of MAP (T235 and T239) essentially mutate to late infection variant neuronal neural lipofuscinosis (CLN6) and mutant nclf mice (figure 5C, bands 7 and 8).</text>
                    <arg n="2">late infection variant neuronal neural lipofuscinosis (CLN6) and mutant nclf mice</arg>
                </example>
                <example src="REPLACE" no="71">
                    <text>In contrast, A0 mutation (the C-terminal kinase sites of MAP (T235 and T239) essentially mutate to late infectious variant neuronal lipofuscinosis (CLN6) and mutant nclf mice (figure 5C, bands 7 and 8).</text>
                    <arg n="2">late infectious variant neuronal lipofuscinosis (CLN6) and mutant nclf mice</arg>
                </example>
                <example src="REPLACE" no="72">
                    <text>In contrast, A0 mutation (the C-terminal kinase sites of MAP (T235 and T239) essentially mutate to losing the transcriptional repression of the lacZ gene (figure 5C, bands 7 and 8).</text>
                    <arg n="2">losing the transcriptional repression of the lacZ gene</arg>
                </example>
                <example src="REPLACE" no="73">
                    <text>In cos-7 cells cotransfects with plasmid expression PKA-Calfa and SOX9, PKA improved the phosphorylation of wild type SOX9 but did not affect the phosphorylation of an a preserved phenylalanine in which A1 (the two phosphorylation sites PKA (S (64) and S (211) have the ability to be significantly mutated.</text>
                    <arg n="0">a preserved phenylalanine</arg>
                </example>
                <example src="REPLACE" no="74">
                    <text>In cos-7 cells cotransfects with plasmid expression PKA-Calfa and a preserved phenylalanine, PKA improved the phosphorylation of wild type SOX9 but did not affect the phosphorylation of an SOX9 in which A1 (the two phosphorylation sites PKA (S (64) and S (211) have the ability to be significantly mutated.</text>
                    <arg n="0">a preserved phenylalanine</arg>
                </example>
                <example src="REPLACE" no="75">
                    <text>In cos-7 cells cotransfects with plasmid expression PKA-Calfa and exon 8, PKA improved the phosphorylation of wild type SOX9 but did not affect the phosphorylation of an SOX9 in which A1 (the two phosphorylation sites PKA (S (64) and S (211) have the ability to be significantly mutated.</text>
                    <arg n="0">exon 8</arg>
                </example>
                <example src="REPLACE" no="76">
                    <text>In cos-7 cells cotransfects with plasmid expression PKA-Calfa and p53, PKA improved the phosphorylation of wild type SOX9 but did not affect the phosphorylation of an SOX9 in which A1 (the two phosphorylation sites PKA (S (64) and S (211) have the ability to be significantly mutated.</text>
                    <arg n="0">p53</arg>
                </example>
                <example src="REPLACE" no="77">
                    <text>In cos-7 cotransfect cells with plasma expression PKA-Calfa and a preserved phenylalanine, PKA improved the phosphorylation of the wild type SOX9, but did not affect the phosphorylation of a protein SOX9 in which A1 (the two phosphorylation sites PKA (S (64) and S (211) are significantly mutated.</text>
                    <arg n="0">a preserved phenylalanine</arg>
                </example>
                <example src="REPLACE" no="78">
                    <text>In cos-7 cotransfect cells with plasma expression PKA-Calfa and a preserved phenylalanine, PKA mutated the phosphorylation of the wild type SOX9, but did not affect the phosphorylation of a protein SOX9 in which the sequence eh1/GEH.</text>
                    <arg n="0">a preserved phenylalanine</arg>
                    <arg n="1">the sequence eh1/GEH</arg>
                </example>
                <example src="REPLACE" no="79">
                    <text>In cos-7 cotransfect cells with plasma expression PKA-Calfa and exon 8, PKA improved the phosphorylation of the wild type SOX9, but did not affect the phosphorylation of a protein SOX9 in which A1 (the two phosphorylation sites PKA (64) and S (211) have the ability to mutated.</text>
                    <arg n="0">exon 8</arg>
                </example>
                <example src="REPLACE" no="80">
                    <text>In cos-7 cotransfect cells with plasma expression PKA-Calfa and exon 8, PKA improved the phosphorylation of the wild type SOX9, but did not affect the phosphorylation of a protein SOX9 in which A1 (the two phosphorylation sites PKA (S (64) and S (211) are significantly mutated.</text>
                    <arg n="0">exon 8</arg>
                </example>
                <example src="REPLACE" no="81">
                    <text>In cos-7 cotransfect cells with plasma expression PKA-Calfa and exon 8, PKA mutated the phosphorylation of the wild type SOX9, but did not affect the phosphorylation of a protein SOX9 in which acDR DNA of alpha chain cDNA in COS-1 cells.</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">acDR DNA of alpha chain cDNA in COS-1 cells</arg>
                </example>
                <example src="REPLACE" no="82">
                    <text>In cos-7 cotransfect cells with plasma expression PKA-Calfa and exon 8, PKA mutated the phosphorylation of the wild type SOX9, but did not affect the phosphorylation of a protein SOX9 in which acDR DNA of the alpha chain cDNA in COS-1 cells.</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">acDR DNA of the alpha chain cDNA in COS-1 cells</arg>
                </example>
                <example src="REPLACE" no="83">
                    <text>In cos-7 cotransfect cells with plasma expression PKA-Calfa and exon 8, PKA mutated the phosphorylation of the wild type SOX9, but did not affect the phosphorylation of a protein SOX9 in which acDR-alpha in the alpha chain of cells 1.</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">acDR-alpha in the alpha chain of cells 1</arg>
                </example>
                <example src="REPLACE" no="84">
                    <text>In cos-7 cotransfect cells with plasma expression PKA-Calfa and the C-terminal MAP kinase sites (T235 and T239), PKA improved the phosphorylation of the wild type SOX9, but did not affect the phosphorylation of a protein SOX9 in which A1 (the two phosphorylation sites PKA (S (64) and S (211) are significantly mutated.</text>
                    <arg n="0">the C-terminal MAP kinase sites (T235 and T239)</arg>
                </example>
                <example src="REPLACE" no="85">
                    <text>In cos-7 cotransfects with plasma expression PKA-Calfa and a preserved phenylalanine, PKA improved the phosphorylation of the wild type SOX9, but did not affect the phosphorylation of a protein SOX9 in which A1 (the two phosphorylation sites PKA (S (64) and S (211) have already been significantly mutated.</text>
                    <arg n="0">a preserved phenylalanine</arg>
                </example>
                <example src="REPLACE" no="86">
                    <text>In cos-7 cotransfects with plasma expression PKA-Calfa and a preserved phenylalanine, PKA improved the phosphorylation of the wild type SOX9, but did not affect the phosphorylation of a protein SOX9 in which it was observed that A1 (the two phosphorylation sites PKA (S (64) and S (211) were mutated.</text>
                    <arg n="0">a preserved phenylalanine</arg>
                </example>
                <example src="REPLACE" no="87">
                    <text>In cos-7 cotransfects with plasma expression PKA-Calfa and a preserved phenylalanine, PKA improved the phosphorylation of the wild type SOX9, but did not affect the phosphorylation of a protein SOX9 where A1 (the two phosphorylation sites PKA (S (64) and S (211) can be mutated.</text>
                    <arg n="0">a preserved phenylalanine</arg>
                </example>
                <example src="REPLACE" no="88">
                    <text>In cos-7 cotransfects with plasma expression PKA-Calfa and exon 5, PKA improved the phosphorylation of the wild type SOX9, but did not affect the phosphorylation of a protein SOX9 where A1 (the two phosphorylation sites PKA (S (64) and S (211) can be significantly mutated.</text>
                    <arg n="0">exon 5</arg>
                </example>
                <example src="REPLACE" no="89">
                    <text>In cos-7 cotransfects with plasma expression PKA-Calfa and exon 5, PKA mutated the phosphorylation of the wild type SOX9, but did not affect the phosphorylation of a protein SOX9 where rice.</text>
                    <arg n="0">exon 5</arg>
                    <arg n="1">rice</arg>
                </example>
                <example src="REPLACE" no="90">
                    <text>In cos-7 cotransfects with plasma expression PKA-Calfa and exon 8, PKA improved the phosphorylation of the wild type SOX9, but did not affect the phosphorylation of a protein SOX9 in which A1 (the two phosphorylation sites PKA (S (64) and S (211) have already been significantly mutated.</text>
                    <arg n="0">exon 8</arg>
                </example>
                <example src="REPLACE" no="91">
                    <text>In cos-7 cotransfects with plasma expression PKA-Calfa and exon 8, PKA improved the phosphorylation of the wild type SOX9, but did not affect the phosphorylation of a protein SOX9 in which A1 (the two phosphorylation sites PKA (S (64) and S (211) were mutated.</text>
                    <arg n="0">exon 8</arg>
                </example>
                <example src="REPLACE" no="92">
                    <text>In cos-7 cotransfects with plasma expression PKA-Calfa and exon 8, PKA mutated the phosphorylation of the wild type SOX9, but did not affect the phosphorylation of a protein SOX9 where alpha strand cDNA in COS-1.</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha strand cDNA in COS-1</arg>
                </example>
                <example src="REPLACE" no="93">
                    <text>In cos-7 cotransfects with plasma expression PKA-Calfa and four of the sites, PKA improved the phosphorylation of the wild type SOX9, but did not affect the phosphorylation of a protein SOX9 in which A1 (the two phosphorylation sites PKA (S (64) and S (211) could have already been significantly mutated.</text>
                    <arg n="0">four of the sites</arg>
                </example>
                <example src="REPLACE" no="94">
                    <text>In cos-7 cotransfects with plasma expression PKA-Calfa and four of the sites, PKA improved the phosphorylation of the wild type SOX9, but did not affect the phosphorylation of a protein SOX9 in which it was observed that A1 (the two phosphorylation sites PKA (S (64) and S (211) were mutated.</text>
                    <arg n="0">four of the sites</arg>
                </example>
                <example src="REPLACE" no="95">
                    <text>In cos-7 cotransfects with plasma expression PKA-Calfa and the MAP-terminal T235 and T239, PKA improved the phosphorylation of the wild type SOX9, but did not affect the phosphorylation of a protein SOX9 in which A1 (the two phosphorylation sites PKA (S (64) and S (211) have already been significantly mutated.</text>
                    <arg n="0">the MAP-terminal T235 and T239</arg>
                </example>
                <example src="REPLACE" no="96">
                    <text>In cos-7 cotransfects with plasma expression PKA-Calfa and the MAP-terminal T235 and T239, PKA improved the phosphorylation of the wild type SOX9, but did not affect the phosphorylation of a protein SOX9 where A1 (the two phosphorylation sites PKA (S (64) and S (211) can be significantly mutated.</text>
                    <arg n="0">the MAP-terminal T235 and T239</arg>
                </example>
                <example src="REPLACE" no="97">
                    <text>In cos-7 cotransfects with plasma expression PKA-Calfa and the T235 and T239 sites, PKA improved the phosphorylation of the wild type SOX9, but did not affect the phosphorylation of a protein SOX9 in which A1 (the two phosphorylation sites PKA (S (64) and S (211) have already been significantly mutated.</text>
                    <arg n="0">the T235 and T239 sites</arg>
                </example>
                <example src="REPLACE" no="98">
                    <text>In cos-7 cotransfects with plasma expression PKA-Calfa and the T235 and T239 sites, PKA improved the phosphorylation of the wild type SOX9, but did not affect the phosphorylation of a protein SOX9 where A1 (the two phosphorylation sites PKA (S (64) and S (211) can be mutated.</text>
                    <arg n="0">the T235 and T239 sites</arg>
                </example>
                <example src="REPLACE" no="99">
                    <text>In cos-7 cotransfects with plasma expression PKA-Calfa and the sites T235 and T239, PKA improved the phosphorylation of the wild type SOX9, but did not affect the phosphorylation of a protein SOX9 in which A1 (the two phosphorylation sites PKA (S (64) and S (211) were mutated.</text>
                    <arg n="0">the sites T235 and T239</arg>
                </example>
                <example src="REPLACE" no="100">
                    <text>Induction of a mutation in the A0 gene (LacI), in contrast, has the ability to mutated in Lipfuscinosis of late infertile neural lipofuscinosis (CLN6) and in nclf mutant mice, which is the cell mutation.</text>
                    <arg n="2">Lipfuscinosis of late infertile neural lipofuscinosis (CLN6) and in nclf mutant mice</arg>
                </example>
                <example src="REPLACE" no="101">
                    <text>Induction of a mutation in the A0 gene (LacI), in contrast, has the ability to mutated in Lipfuscinosis slow inphantyl neural lipofuscinosis (CLN6) and in nclf mutant mice, which is the cell mutation.</text>
                    <arg n="2">Lipfuscinosis slow inphantyl neural lipofuscinosis (CLN6) and in nclf mutant mice</arg>
                </example>
                <example src="REPLACE" no="102">
                    <text>Induction of a mutation in the A0 gene (LacI), in contrast, has the ability to mutated in Liphofuscinosis slow inphantyl neural lipofuscinosis (CLN6) and in nclf mutant mice, which is the cell mutation.</text>
                    <arg n="2">Liphofuscinosis slow inphantyl neural lipofuscinosis (CLN6) and in nclf mutant mice</arg>
                </example>
                <example src="REPLACE" no="103">
                    <text>Induction of a mutation in the A0 gene (LacI), in contrast, has the ability to mutated in abolited increase of EGF and increased phosphorylation and mobility induced by EGF, which is the cell mutation.</text>
                    <arg n="2">abolited increase of EGF and increased phosphorylation and mobility induced by EGF</arg>
                </example>
                <example src="REPLACE" no="104">
                    <text>Induction of a mutation in the A0 gene (LacI), in contrast, has the ability to mutated in increasing above the EGF increase and increasing the phosphorylation and mobility induced by the EGF, which is the cell mutation.</text>
                    <arg n="2">increasing above the EGF increase and increasing the phosphorylation and mobility induced by the EGF</arg>
                </example>
                <example src="REPLACE" no="105">
                    <text>Induction of a mutation in the A0 gene (LacI), in contrast, has the ability to mutated in increasing above the increase in phosphorylation stimulated by FEG and change in mobility induced by FEG, which is the cell mutation.</text>
                    <arg n="2">increasing above the increase in phosphorylation stimulated by FEG and change in mobility induced by FEG</arg>
                </example>
                <example src="REPLACE" no="106">
                    <text>Induction of a mutation in the A0 gene (LacI), in contrast, has the ability to mutated in losing the transcriptional repression of the lacZ gene, which is the cell mutation.</text>
                    <arg n="2">losing the transcriptional repression of the lacZ gene</arg>
                </example>
                <example src="REPLACE" no="107">
                    <text>Induction of a mutation in the A0 gene (LacI), in contrast, will mutated in Lipfuscinosis of late infertile neural lipofuscinosis (CLN6) and in nclf mutant mice, which is the cell mutation.</text>
                    <arg n="2">Lipfuscinosis of late infertile neural lipofuscinosis (CLN6) and in nclf mutant mice</arg>
                </example>
                <example src="REPLACE" no="108">
                    <text>Induction of a mutation in the A0 gene (LacI), in contrast, will mutated in abolished the stimulated increase of EGF in phosphorylation and preventing the change in mobility introduced by EGF, which is the cell mutation.</text>
                    <arg n="2">abolished the stimulated increase of EGF in phosphorylation and preventing the change in mobility introduced by EGF</arg>
                </example>
                <example src="REPLACE" no="109">
                    <text>Induction of a mutation in the A0 gene (LacI), in contrast, will mutated in above FEG-stimulated phosphorylation and FEG-induced mobility, which is the cellular mutation.</text>
                    <arg n="2">above FEG-stimulated phosphorylation and FEG-induced mobility</arg>
                </example>
                <example src="REPLACE" no="110">
                    <text>Induction of a mutation in the A0 gene (LacI), in contrast, will mutated in ceroid variant of late infertile neural diffufuscinosis (CLN6) and in nclf mutant mice, which is the cell mutation.</text>
                    <arg n="2">ceroid variant of late infertile neural diffufuscinosis (CLN6) and in nclf mutant mice</arg>
                </example>
                <example src="REPLACE" no="111">
                    <text>Induction of a mutation in the A0 gene (LacI), in contrast, will mutated in infectantyl lipofuscinosis neural lipofuscinosis (CLN6) and in nclf mutant mice, which is the cell mutation.</text>
                    <arg n="2">infectantyl lipofuscinosis neural lipofuscinosis (CLN6) and in nclf mutant mice</arg>
                </example>
                <example src="REPLACE" no="112">
                    <text>Induction of a mutation in the A0 gene (LacI), in contrast, will mutated in infectantyl lipofuscinosis neural lipofuscinosis (CLN6) and in nclf mutant mice, which is the cellular mutation.</text>
                    <arg n="2">infectantyl lipofuscinosis neural lipofuscinosis (CLN6) and in nclf mutant mice</arg>
                </example>
                <example src="REPLACE" no="113">
                    <text>Induction of a mutation in the A0 gene (LacI), in contrast, will mutated in late infection variant ceroid neuronal lipofuscinosis (CLN6) and mutant nclf mice, which is the cell mutation.</text>
                    <arg n="2">late infection variant ceroid neuronal lipofuscinosis (CLN6) and mutant nclf mice</arg>
                </example>
                <example src="REPLACE" no="114">
                    <text>Induction of a mutation in the A0 gene (LacI), in contrast, will mutated in late infection variant ceroid neuronal lipofuscinosis (CLN6) and mutant nclf mice, which is the cellular mutation.</text>
                    <arg n="2">late infection variant ceroid neuronal lipofuscinosis (CLN6) and mutant nclf mice</arg>
                </example>
                <example src="REPLACE" no="115">
                    <text>Induction of a mutation in the A0 gene (LacI), in contrast, will mutated in late infection variant neuronal neural lipofuscinosis (CLN6) and mutant nclf mice, which is the cell mutation.</text>
                    <arg n="2">late infection variant neuronal neural lipofuscinosis (CLN6) and mutant nclf mice</arg>
                </example>
                <example src="REPLACE" no="116">
                    <text>Induction of a mutation in the A0 gene (LacI), in contrast, will mutated in late infection variations in neuronal lipofuscinosis and nclf mice, which is the cell mutation.</text>
                    <arg n="2">late infection variations in neuronal lipofuscinosis and nclf mice</arg>
                </example>
                <example src="REPLACE" no="117">
                    <text>Induction of a mutation in the A0 gene (LacI), on the other hand, has the ability to mutated in Lipfuscinosis of late infertile neural lipofuscinosis (CLN6) and in nclf mutant mice, which is the cellular mutation.</text>
                    <arg n="2">Lipfuscinosis of late infertile neural lipofuscinosis (CLN6) and in nclf mutant mice</arg>
                </example>
                <example src="REPLACE" no="118">
                    <text>Induction of a mutation in the A0 gene (LacI), on the other hand, has the ability to mutated in abolished the stimulated increase of EGF in phosphorylation and preventing the change in mobility introduced by EGF, which is the cellular mutation.</text>
                    <arg n="2">abolished the stimulated increase of EGF in phosphorylation and preventing the change in mobility introduced by EGF</arg>
                </example>
                <example src="REPLACE" no="119">
                    <text>Induction of a mutation in the A0 gene (LacI), on the other hand, has the ability to mutated in abolited increase of FEG-stimulated phosphorylation and FEG-induced mobility change, which is the cellular mutation.</text>
                    <arg n="2">abolited increase of FEG-stimulated phosphorylation and FEG-induced mobility change</arg>
                </example>
                <example src="REPLACE" no="120">
                    <text>Induction of a mutation in the A0 gene (LacI), on the other hand, has the ability to mutated in increasing above the EGF and increasing the phosphorylation and mobility induced by the EGF, which is the cellular mutation.</text>
                    <arg n="2">increasing above the EGF and increasing the phosphorylation and mobility induced by the EGF</arg>
                </example>
                <example src="REPLACE" no="121">
                    <text>Induction of a mutation in the A0 gene (LacI), on the other hand, has the ability to mutated in late infection variant neuronal neural lipofuscinosis (CLN6) and mutant nclf mice, which is the cellular mutation.</text>
                    <arg n="2">late infection variant neuronal neural lipofuscinosis (CLN6) and mutant nclf mice</arg>
                </example>
                <example src="REPLACE" no="122">
                    <text>Induction of a mutation in the A0 gene (LacI), on the other hand, has the ability to mutated in late infection variations in neuronal lipofuscinosis and nclf mice, which is the cellular mutation.</text>
                    <arg n="2">late infection variations in neuronal lipofuscinosis and nclf mice</arg>
                </example>
                <example src="REPLACE" no="123">
                    <text>It is likely that the exon 8 is significantly mutated by the acDR-alpha in the alpha chain of cells 1, adherence to Q62696 using the Swiss PDB display software (Guex and Peitsch, 1997).</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">acDR-alpha in the alpha chain of cells 1</arg>
                </example>
                <example src="REPLACE" no="124">
                    <text>It is likely that the exon 8 is significantly mutated by the alpha strand cDNA in COS-1, adherence to Q62696 using the Swiss PDB display software (Guex and Peitsch, 1997).</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha strand cDNA in COS-1</arg>
                </example>
                <example src="REPLACE" no="125">
                    <text>Muting A1 (EE(437 and 438) in increasing above the EGF increase and increasing the phosphorylation and mobility induced by the EGF has the ability to mutate the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">increasing above the EGF increase and increasing the phosphorylation and mobility induced by the EGF</arg>
                </example>
                <example src="REPLACE" no="126">
                    <text>Muting A1 (EE(437 and 438) in late infection variant neuronal neural lipofuscinosis (CLN6) and in mutant nclf mice has the ability to mutate the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">late infection variant neuronal neural lipofuscinosis (CLN6) and in mutant nclf mice</arg>
                </example>
                <example src="REPLACE" no="127">
                    <text>Muting A1 (EE(437 and 438) in late infection variant neuronal neural lipofuscinosis (CLN6) and mutant nclf mice has the ability to mutate the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">late infection variant neuronal neural lipofuscinosis (CLN6) and mutant nclf mice</arg>
                </example>
                <example src="REPLACE" no="128">
                    <text>Muting A1 (EE(437 and 438) in latest infertile neural lipofuscinosis (CLN6) and nclf mutant mice has the ability to mutate the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">latest infertile neural lipofuscinosis (CLN6) and nclf mutant mice</arg>
                </example>
                <example src="REPLACE" no="129">
                    <text>Muting A1 (EE(437 and 438) to Lipfuscinosis of late infertile neural lipofuscinosis (CLN6) and in nclf mutant mice would mutate the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">Lipfuscinosis of late infertile neural lipofuscinosis (CLN6) and in nclf mutant mice</arg>
                </example>
                <example src="REPLACE" no="130">
                    <text>Muting A1 (EE(437 and 438) to late infectious variant neuronal lipofuscinosis (CLN6) and mutant nclf mice would mutate the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">late infectious variant neuronal lipofuscinosis (CLN6) and mutant nclf mice</arg>
                </example>
                <example src="REPLACE" no="131">
                    <text>Our study showed that A0 mutation (the C-terminal sites of MAP kinase (T235 and T239) essentially mutate to abolited increase of EGF-stimulated phosphorylation and EGF-induced mobility change (figure 5C, bands 7 and 8).</text>
                    <arg n="2">abolited increase of EGF-stimulated phosphorylation and EGF-induced mobility change</arg>
                </example>
                <example src="REPLACE" no="132">
                    <text>Our study showed that A0 mutation (the C-terminal sites of MAP kinase (T235 and T239) essentially mutate to ceroid variant of late infertile neural diffufuscinosis (CLN6) and in nclf mutant mice (figure 5C, bands 7 and 8).</text>
                    <arg n="2">ceroid variant of late infertile neural diffufuscinosis (CLN6) and in nclf mutant mice</arg>
                </example>
                <example src="REPLACE" no="133">
                    <text>Our study showed that A0 mutation (the C-terminal sites of MAP kinase (T235 and T239) essentially mutate to late infection variant neuronal neural lipofuscinosis (CLN6) and mutant nclf mice (figure 5C, bands 7 and 8).</text>
                    <arg n="2">late infection variant neuronal neural lipofuscinosis (CLN6) and mutant nclf mice</arg>
                </example>
                <example src="REPLACE" no="134">
                    <text>Our study showed that A0 mutation (the C-terminal sites of MAP kinase (T235 and T239) essentially mutate to late neuronal lipofuscinosis and mutant nclf mice (figure 5C, bands 7 and 8).</text>
                    <arg n="2">late neuronal lipofuscinosis and mutant nclf mice</arg>
                </example>
                <example src="REPLACE" no="135">
                    <text>Our study showed that the A0 mutation (the C-terminal sites of MAP kinase (T235 and T239) is essentially the one that mutate to Lipfuscinosis of late infertile neural lipofuscinosis (CLN6) and in nclf mutant mice (figure 5C, bands 7 and 8).</text>
                    <arg n="2">Lipfuscinosis of late infertile neural lipofuscinosis (CLN6) and in nclf mutant mice</arg>
                </example>
                <example src="REPLACE" no="136">
                    <text>Our study showed that the A0 mutation (the C-terminal sites of MAP kinase (T235 and T239) is essentially the one that mutate to increasing above increased phosphorylation stimulated by FEG and change of mobility induced by FEG (figure 5C, bands 7 and 8).</text>
                    <arg n="2">increasing above increased phosphorylation stimulated by FEG and change of mobility induced by FEG</arg>
                </example>
                <example src="REPLACE" no="137">
                    <text>Our study showed that the A0 mutation (the C-terminal sites of MAP kinase (T235 and T239) is essentially the one that mutate to increasing above the increase in phosphorylation stimulated by FEG and change in mobility induced by FEG (figure 5C, bands 7 and 8).</text>
                    <arg n="2">increasing above the increase in phosphorylation stimulated by FEG and change in mobility induced by FEG</arg>
                </example>
                <example src="REPLACE" no="138">
                    <text>PDK1 phosphorylation has not been mutated by treatment of cells with a growth factor similar to insulin-I and four of the sites are mutations without loss of activity.</text>
                    <arg n="0">four of the sites</arg>
                </example>
                <example src="REPLACE" no="139">
                    <text>PDK1 phosphorylation was not mutated by the treatment of cells with a growth factor similar to insulin-I and a preserved phenylalanine will be changed with emphasis without loss of activity.</text>
                    <arg n="0">a preserved phenylalanine</arg>
                </example>
                <example src="REPLACE" no="140">
                    <text>PDK1 phosphorylation was not mutated by the treatment of cells with a growth factor similar to insulin-I and p53 will be changed with emphasis without loss of activity.</text>
                    <arg n="0">p53</arg>
                </example>
                <example src="REPLACE" no="141">
                    <text>PDK1 phosphorylation was not mutated by the treatment of cells with a growth factor similar to insulin-I and the MAP-terminal T235 and T239 will be changed with emphasis without loss of activity.</text>
                    <arg n="0">the MAP-terminal T235 and T239</arg>
                </example>
                <example src="REPLACE" no="142">
                    <text>PDK1 phosphorylation was not mutated by treatment of cells with a growth factor similar to insulin-I and exon 5 mutants are observed without loss of activity.</text>
                    <arg n="0">exon 5</arg>
                </example>
                <example src="REPLACE" no="143">
                    <text>PDK1 phosphorylation was not mutated by treatment of cells with a growth factor similar to insulin-I and the C-terminal MAP kinase sites (T235 and T239) mutants are observed without loss of activity.</text>
                    <arg n="0">the C-terminal MAP kinase sites (T235 and T239)</arg>
                </example>
                <example src="REPLACE" no="144">
                    <text>PDK1 phosphorylation was not mutated by treatment of cells with a growth factor similar to insulin-I and the sites T235 and T239 mutants are observed without loss of activity.</text>
                    <arg n="0">the sites T235 and T239</arg>
                </example>
                <example src="REPLACE" no="145">
                    <text>PDK1 phosphorylation was not mutated by treatment of cells with growth factor similar to insulin-I and four of the sites, as we predicted, has the ability to be changed remarkably without loss of activity.</text>
                    <arg n="0">four of the sites</arg>
                </example>
                <example src="REPLACE" no="146">
                    <text>PDK1 phosphorylation was not mutated by treatment of cells with growth factor similar to insulin-I and p53, as we predicted, has the ability to be changed remarkably without loss of activity.</text>
                    <arg n="0">p53</arg>
                </example>
                <example src="REPLACE" no="147">
                    <text>PDK1 phosphorylation was not mutated by treatment of cells with growth factor similar to insulin-I and the C-terminal MAP kinase sites (T235 and T239), as predicted, and it was able to be changed remarkably without loss of activity.</text>
                    <arg n="0">the C-terminal MAP kinase sites (T235 and T239)</arg>
                </example>
                <example src="REPLACE" no="148">
                    <text>PDK1 phosphorylation was not mutated with the treatment of cells with a growth factor similar to insulin I and four of the sites, as suggested by our study, they are observed to change without loss of activity.</text>
                    <arg n="0">four of the sites</arg>
                </example>
                <example src="REPLACE" no="149">
                    <text>PDK1 phosphorylation was not mutated with the treatment of cells with a growth factor similar to insulin I and the T235 and T239 sites, as suggested by our study, they are observed to change without loss of activity.</text>
                    <arg n="0">the T235 and T239 sites</arg>
                </example>
                <example src="REPLACE" no="150">
                    <text>The A0 mutation (the C-terminal-Kinase sites of MAP (T235 and T239), for example, essentially mutating to Lipfuscinosis slow infertile neural lipofuscinosis (CLN6) and in nclf mutant mice (figure 5C, bands 7 and 8).</text>
                    <arg n="2">Lipfuscinosis slow infertile neural lipofuscinosis (CLN6) and in nclf mutant mice</arg>
                </example>
                <example src="REPLACE" no="151">
                    <text>The A0 mutation (the C-terminal-Kinase sites of MAP (T235 and T239), for example, essentially mutating to Liphofuscinosis slow inphantyl neural lipofuscinosis (CLN6) and in nclf mutant mice (figure 5C, bands 7 and 8).</text>
                    <arg n="2">Liphofuscinosis slow inphantyl neural lipofuscinosis (CLN6) and in nclf mutant mice</arg>
                </example>
                <example src="REPLACE" no="152">
                    <text>The A0 mutation (the C-terminal-Kinase sites of MAP (T235 and T239), for example, essentially mutating to abolition of FEG-stimulated phosphorylation and prevented FEG-induced mobility (figure 5C, bands 7 and 8).</text>
                    <arg n="2">abolition of FEG-stimulated phosphorylation and prevented FEG-induced mobility</arg>
                </example>
                <example src="REPLACE" no="153">
                    <text>The A0 mutation (the C-terminal-Kinase sites of MAP (T235 and T239), for example, essentially mutating to losing the transcriptional repression of the lacZ gene (figure 5C, bands 7 and 8).</text>
                    <arg n="2">losing the transcriptional repression of the lacZ gene</arg>
                </example>
                <example src="REPLACE" no="154">
                    <text>The A0 mutation (the sites of the C-terminal kinase of MAP (T235 and T239), for example, essentially mutate to Lipfuscinosis of late infertile neural lipofuscinosis (CLN6) and in nclf mutant mice (figure 5C, bands 7 and 8).</text>
                    <arg n="2">Lipfuscinosis of late infertile neural lipofuscinosis (CLN6) and in nclf mutant mice</arg>
                </example>
                <example src="REPLACE" no="155">
                    <text>The A0 mutation (the sites of the C-terminal kinase of MAP (T235 and T239), for example, essentially mutate to Lipfuscinosis slow inphantyl neural lipofuscinosis (CLN6) and in nclf mutant mice (figure 5C, bands 7 and 8).</text>
                    <arg n="2">Lipfuscinosis slow inphantyl neural lipofuscinosis (CLN6) and in nclf mutant mice</arg>
                </example>
                <example src="REPLACE" no="156">
                    <text>The A0 mutation (the sites of the C-terminal kinase of MAP (T235 and T239), for example, essentially mutate to abolited increase of EGF and increased phosphorylation and mobility induced by EGF (figure 5C, bands 7 and 8).</text>
                    <arg n="2">abolited increase of EGF and increased phosphorylation and mobility induced by EGF</arg>
                </example>
                <example src="REPLACE" no="157">
                    <text>The A0 mutation (the sites of the C-terminal kinase of MAP (T235 and T239), for example, essentially mutate to increasing above the stimulated phosphorylation and change of mobility induced by FEG (figure 5C, bands 7 and 8).</text>
                    <arg n="2">increasing above the stimulated phosphorylation and change of mobility induced by FEG</arg>
                </example>
                <example src="REPLACE" no="158">
                    <text>The A0 mutation (the sites of the C-terminal kinase of MAP (T235 and T239), for example, essentially mutate to late infectious variant neuronal lipofuscinosis (CLN6) and mutant nclf mice (figure 5C, bands 7 and 8).</text>
                    <arg n="2">late infectious variant neuronal lipofuscinosis (CLN6) and mutant nclf mice</arg>
                </example>
                <example src="REPLACE" no="159">
                    <text>The A0 mutation (the sites of the C-terminal kinase of MAP (T235 and T239), in contrast, is mutating as one of the main responsible for Liphofuscinosis slow inphantyl neural lipofuscinosis (CLN6) and in nclf mutant mice (figure 5C, bands 7 and 8).</text>
                    <arg n="2">Liphofuscinosis slow inphantyl neural lipofuscinosis (CLN6) and in nclf mutant mice</arg>
                </example>
                <example src="REPLACE" no="160">
                    <text>The A0 mutation (the sites of the C-terminal kinase of MAP (T235 and T239), in contrast, is mutating as one of the main responsible for above FEG-stimulated phosphorylation and FEG-induced mobility (figure 5C, bands 7 and 8).</text>
                    <arg n="2">above FEG-stimulated phosphorylation and FEG-induced mobility</arg>
                </example>
                <example src="REPLACE" no="161">
                    <text>The A0 mutation (the sites of the C-terminal kinase of MAP (T235 and T239), in contrast, is mutating as one of the main responsible for above the increased phosphorylation stimulated by FEG and reduced mobility induced by FEG (figure 5C, bands 7 and 8).</text>
                    <arg n="2">above the increased phosphorylation stimulated by FEG and reduced mobility induced by FEG</arg>
                </example>
                <example src="REPLACE" no="162">
                    <text>The A0 mutation (the sites of the C-terminal kinase of MAP (T235 and T239), in contrast, is mutating as one of the main responsible for increasing above the EGF and increasing the phosphorylation and mobility induced by the EGF (figure 5C, bands 7 and 8).</text>
                    <arg n="2">increasing above the EGF and increasing the phosphorylation and mobility induced by the EGF</arg>
                </example>
                <example src="REPLACE" no="163">
                    <text>The A0 mutation (the sites of the C-terminal kinase of MAP (T235 and T239), in contrast, is mutating as one of the main responsible for infectantyl lipofuscinosis neural lipofuscinosis (CLN6) and in nclf mutant mice (figure 5C, bands 7 and 8).</text>
                    <arg n="2">infectantyl lipofuscinosis neural lipofuscinosis (CLN6) and in nclf mutant mice</arg>
                </example>
                <example src="REPLACE" no="164">
                    <text>The A1 gene that can be mutated in Lipfuscinosis slow inphantyl neural lipofuscinosis (CLN6) and in nclf mutant mice was a newly predicted transmembrane protein.</text>
                    <arg n="2">Lipfuscinosis slow inphantyl neural lipofuscinosis (CLN6) and in nclf mutant mice</arg>
                    <arg n="3">a newly predicted transmembrane protein</arg>
                </example>
                <example src="REPLACE" no="165">
                    <text>The A1 gene that can be mutated in ceroid variant of late infertile neural diffufuscinosis (CLN6) and in nclf mutant mice was a new predefined transmembrane protein.</text>
                    <arg n="2">ceroid variant of late infertile neural diffufuscinosis (CLN6) and in nclf mutant mice</arg>
                    <arg n="3">a new predefined transmembrane protein</arg>
                </example>
                <example src="REPLACE" no="166">
                    <text>The A1 gene that can be mutated in late neuronal lipofuscinosis and mutant nclf mice was a newly predicted transmembrane protein.</text>
                    <arg n="2">late neuronal lipofuscinosis and mutant nclf mice</arg>
                    <arg n="3">a newly predicted transmembrane protein</arg>
                </example>
                <example src="REPLACE" no="167">
                    <text>The A1 gene that can be mutated into Lipfuscinosis of late infertile neural lipofuscinosis (CLN6) and in nclf mutant mice codes a newly predicted transmembrane protein.</text>
                    <arg n="2">Lipfuscinosis of late infertile neural lipofuscinosis (CLN6) and in nclf mutant mice</arg>
                    <arg n="3">a newly predicted transmembrane protein</arg>
                </example>
                <example src="REPLACE" no="168">
                    <text>The A1 gene that can be mutated into ceroid variant of late infertile neural diffufuscinosis (CLN6) and in nclf mutant mice codified a new predefined transmembrane protein.</text>
                    <arg n="2">ceroid variant of late infertile neural diffufuscinosis (CLN6) and in nclf mutant mice</arg>
                    <arg n="3">a new predefined transmembrane protein</arg>
                </example>
                <example src="REPLACE" no="169">
                    <text>The A1 gene that can be mutated into late infection variant neuronal neural lipofuscinosis (CLN6) and mutant nclf mice codes a newly predicted transmembrane protein.</text>
                    <arg n="2">late infection variant neuronal neural lipofuscinosis (CLN6) and mutant nclf mice</arg>
                    <arg n="3">a newly predicted transmembrane protein</arg>
                </example>
                <example src="REPLACE" no="170">
                    <text>The A1 gene that can be mutated into late infection variant neuronal neural lipofuscinosis (CLN6) and mutant nclf mice codified a newly predicted transmembrane protein.</text>
                    <arg n="2">late infection variant neuronal neural lipofuscinosis (CLN6) and mutant nclf mice</arg>
                    <arg n="3">a newly predicted transmembrane protein</arg>
                </example>
                <example src="REPLACE" no="171">
                    <text>The A1 gene that can be mutated into late infection variations in neuronal lipofuscinosis and nclf mice codes a new predefined transmembrane protein.</text>
                    <arg n="2">late infection variations in neuronal lipofuscinosis and nclf mice</arg>
                    <arg n="3">a new predefined transmembrane protein</arg>
                </example>
                <example src="REPLACE" no="172">
                    <text>The A1 gene that can be mutated into late infectious variant neuronal lipofuscinosis (CLN6) and mutant nclf mice codified a new predefined transmembrane protein.</text>
                    <arg n="2">late infectious variant neuronal lipofuscinosis (CLN6) and mutant nclf mice</arg>
                    <arg n="3">a new predefined transmembrane protein</arg>
                </example>
                <example src="REPLACE" no="173">
                    <text>The A1 gene that has the ability to be mutated in Lipfuscinosis slow infertile neural lipofuscinosis (CLN6) and in nclf mutant mice codes a newly predicted transmembrane protein.</text>
                    <arg n="2">Lipfuscinosis slow infertile neural lipofuscinosis (CLN6) and in nclf mutant mice</arg>
                    <arg n="3">a newly predicted transmembrane protein</arg>
                </example>
                <example src="REPLACE" no="174">
                    <text>The A1 gene that has the ability to be mutated in late infection variant neuronal lipofuscinosis and mutant nclf mice codes a new predefined transmembrane protein.</text>
                    <arg n="2">late infection variant neuronal lipofuscinosis and mutant nclf mice</arg>
                    <arg n="3">a new predefined transmembrane protein</arg>
                </example>
                <example src="REPLACE" no="175">
                    <text>The A1 gene that has the ability to mutated in late infection variant neuronal neural lipofuscinosis (CLN6) and in mutant nclf mice codes a newly predicted transmembrane protein.</text>
                    <arg n="2">late infection variant neuronal neural lipofuscinosis (CLN6) and in mutant nclf mice</arg>
                    <arg n="3">a newly predicted transmembrane protein</arg>
                </example>
                <example src="REPLACE" no="176">
                    <text>The A1 gene that has the ability to mutated in late infection variant neuronal neural lipofuscinosis (CLN6) and mutant nclf mice codes a newly predicted transmembrane protein.</text>
                    <arg n="2">late infection variant neuronal neural lipofuscinosis (CLN6) and mutant nclf mice</arg>
                    <arg n="3">a newly predicted transmembrane protein</arg>
                </example>
                <example src="REPLACE" no="177">
                    <text>The A1 gene that has the ability to mutated in late infectious variant neuronal lipofuscinosis (CLN6) and mutant nclf mice codes a new predefined transmembrane protein.</text>
                    <arg n="2">late infectious variant neuronal lipofuscinosis (CLN6) and mutant nclf mice</arg>
                    <arg n="3">a new predefined transmembrane protein</arg>
                </example>
                <example src="REPLACE" no="178">
                    <text>The A1 gene that has the ability to mutated in latest infertile neural lipofuscinosis (CLN6) and nclf mutant mice codes a new predefined transmembrane protein.</text>
                    <arg n="2">latest infertile neural lipofuscinosis (CLN6) and nclf mutant mice</arg>
                    <arg n="3">a new predefined transmembrane protein</arg>
                </example>
                <example src="REPLACE" no="179">
                    <text>The A1 gene that has the ability to mutated into Lipfuscinosis of late infertile neural lipofuscinosis (CLN6) and in nclf mutant mice codified a newly predicted transmembrane protein.</text>
                    <arg n="2">Lipfuscinosis of late infertile neural lipofuscinosis (CLN6) and in nclf mutant mice</arg>
                    <arg n="3">a newly predicted transmembrane protein</arg>
                </example>
                <example src="REPLACE" no="180">
                    <text>The A1 gene that has the ability to mutated into Lipfuscinosis slow inphantyl neural lipofuscinosis (CLN6) and in nclf mutant mice codified a newly predicted transmembrane protein.</text>
                    <arg n="2">Lipfuscinosis slow inphantyl neural lipofuscinosis (CLN6) and in nclf mutant mice</arg>
                    <arg n="3">a newly predicted transmembrane protein</arg>
                </example>
                <example src="REPLACE" no="181">
                    <text>The A1 gene that has the ability to mutated into ceroid lipofuscinosis neural ceroid variation (CLN6) and in mutant mice nclf codified a new predefined transmembrane protein.</text>
                    <arg n="2">ceroid lipofuscinosis neural ceroid variation (CLN6) and in mutant mice nclf</arg>
                    <arg n="3">a new predefined transmembrane protein</arg>
                </example>
                <example src="REPLACE" no="182">
                    <text>The A1 gene that is able to be mutated into Lipfuscinosis slow inphantyl neural lipofuscinosis (CLN6) and in nclf mutant mice codes a newly predicted transmembrane protein.</text>
                    <arg n="2">Lipfuscinosis slow inphantyl neural lipofuscinosis (CLN6) and in nclf mutant mice</arg>
                    <arg n="3">a newly predicted transmembrane protein</arg>
                </example>
                <example src="REPLACE" no="183">
                    <text>The A1 gene that is able to be mutated into ceroid variant of late infertile neural diffufuscinosis (CLN6) and in nclf mutant mice codes a new predefined transmembrane protein.</text>
                    <arg n="2">ceroid variant of late infertile neural diffufuscinosis (CLN6) and in nclf mutant mice</arg>
                    <arg n="3">a new predefined transmembrane protein</arg>
                </example>
                <example src="REPLACE" no="184">
                    <text>The A1 gene that is able to be mutated into late infection variant neuronal lipofuscinosis and mutant nclf mice codes a new predefined transmembrane protein.</text>
                    <arg n="2">late infection variant neuronal lipofuscinosis and mutant nclf mice</arg>
                    <arg n="3">a new predefined transmembrane protein</arg>
                </example>
                <example src="REPLACE" no="185">
                    <text>The A1 gene that is able to be mutated into late infection variant neuronal neural lipofuscinosis (CLN6) and mutant nclf mice codes a newly predicted transmembrane protein.</text>
                    <arg n="2">late infection variant neuronal neural lipofuscinosis (CLN6) and mutant nclf mice</arg>
                    <arg n="3">a newly predicted transmembrane protein</arg>
                </example>
                <example src="REPLACE" no="186">
                    <text>The A1 gene that is able to be mutated into late infectious variant neuronal lipofuscinosis (CLN6) and mutant nclf mice codes a new predefined transmembrane protein.</text>
                    <arg n="2">late infectious variant neuronal lipofuscinosis (CLN6) and mutant nclf mice</arg>
                    <arg n="3">a new predefined transmembrane protein</arg>
                </example>
                <example src="REPLACE" no="187">
                    <text>The A1 gene that is mutated in ceroid lipofuscinosis neural ceroid variation (CLN6) and in mutant mice nclf was a new predefined transmembrane protein.</text>
                    <arg n="2">ceroid lipofuscinosis neural ceroid variation (CLN6) and in mutant mice nclf</arg>
                    <arg n="3">a new predefined transmembrane protein</arg>
                </example>
                <example src="REPLACE" no="188">
                    <text>The A1 gene that is mutated in ceroid variant of late infertile neural diffufuscinosis (CLN6) and in nclf mutant mice was a new predefined transmembrane protein.</text>
                    <arg n="2">ceroid variant of late infertile neural diffufuscinosis (CLN6) and in nclf mutant mice</arg>
                    <arg n="3">a new predefined transmembrane protein</arg>
                </example>
                <example src="REPLACE" no="189">
                    <text>The A1 gene that is mutated in late infection variant ceroid neuronal lipofuscinosis (CLN6) and mutant nclf mice was a newly predicted transmembrane protein.</text>
                    <arg n="2">late infection variant ceroid neuronal lipofuscinosis (CLN6) and mutant nclf mice</arg>
                    <arg n="3">a newly predicted transmembrane protein</arg>
                </example>
                <example src="REPLACE" no="190">
                    <text>The A1 gene that is mutated in late infection variant neuronal lipofuscinosis and mutant nclf mice was a new predefined transmembrane protein.</text>
                    <arg n="2">late infection variant neuronal lipofuscinosis and mutant nclf mice</arg>
                    <arg n="3">a new predefined transmembrane protein</arg>
                </example>
                <example src="REPLACE" no="191">
                    <text>The A1 gene that is mutated in late infection variant neuronal neural lipofuscinosis (CLN6) and mutant nclf mice was a newly predicted transmembrane protein.</text>
                    <arg n="2">late infection variant neuronal neural lipofuscinosis (CLN6) and mutant nclf mice</arg>
                    <arg n="3">a newly predicted transmembrane protein</arg>
                </example>
                <example src="REPLACE" no="192">
                    <text>The A1 gene that is mutated in late infectious variant neuronal lipofuscinosis (CLN6) and mutant nclf mice was a new predefined transmembrane protein.</text>
                    <arg n="2">late infectious variant neuronal lipofuscinosis (CLN6) and mutant nclf mice</arg>
                    <arg n="3">a new predefined transmembrane protein</arg>
                </example>
                <example src="REPLACE" no="193">
                    <text>The A1 gene that may have been mutated in Liphofuscinosis slow inphantyl neural lipofuscinosis (CLN6) and in nclf mutant mice codes a new predefined transmembrane protein.</text>
                    <arg n="2">Liphofuscinosis slow inphantyl neural lipofuscinosis (CLN6) and in nclf mutant mice</arg>
                    <arg n="3">a new predefined transmembrane protein</arg>
                </example>
                <example src="REPLACE" no="194">
                    <text>The A1 gene that may have been mutated in ceroid lipofuscinosis neural ceroid variation (CLN6) and in mutant mice nclf codes a new predefined transmembrane protein.</text>
                    <arg n="2">ceroid lipofuscinosis neural ceroid variation (CLN6) and in mutant mice nclf</arg>
                    <arg n="3">a new predefined transmembrane protein</arg>
                </example>
                <example src="REPLACE" no="195">
                    <text>The A1 mutation (EE amino acids(437 and 438) in abolished the stimulated increase of EGF in phosphorylation and preventing the change in mobility introduced by EGF mutating the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">abolished the stimulated increase of EGF in phosphorylation and preventing the change in mobility introduced by EGF</arg>
                </example>
                <example src="REPLACE" no="196">
                    <text>The A1 mutation (EE amino acids(437 and 438) in increasing above the EGF increase and increasing the phosphorylation and mobility induced by the EGF mutating the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">increasing above the EGF increase and increasing the phosphorylation and mobility induced by the EGF</arg>
                </example>
                <example src="REPLACE" no="197">
                    <text>The A1 mutation (EE amino acids(437 and 438) in increasing above the stimulated phosphorylation and change of mobility induced by FEG mutating the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">increasing above the stimulated phosphorylation and change of mobility induced by FEG</arg>
                </example>
                <example src="REPLACE" no="198">
                    <text>The A1 mutation (EE amino acids(437 and 438) in late infectious variant neuronal lipofuscinosis (CLN6) and mutant nclf mice mutating the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">late infectious variant neuronal lipofuscinosis (CLN6) and mutant nclf mice</arg>
                </example>
                <example src="REPLACE" no="199">
                    <text>The A1 mutation (EE amino acids(437 and 438) to above the increased phosphorylation stimulated by FEG and reduced mobility induced by FEG would mutate the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">above the increased phosphorylation stimulated by FEG and reduced mobility induced by FEG</arg>
                </example>
                <example src="REPLACE" no="200">
                    <text>The A1 mutation (EE amino acids(437 and 438) to ceroid variant of late infertile neural diffufuscinosis (CLN6) and in nclf mutant mice would mutate the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">ceroid variant of late infertile neural diffufuscinosis (CLN6) and in nclf mutant mice</arg>
                </example>
                <example src="REPLACE" no="201">
                    <text>The A1 mutation (EE amino acids(437 and 438) to increasing above the EGF increase and increasing the phosphorylation and mobility induced by the EGF mutate the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">increasing above the EGF increase and increasing the phosphorylation and mobility induced by the EGF</arg>
                </example>
                <example src="REPLACE" no="202">
                    <text>The A1 mutation (EE amino acids(437 and 438) to increasing above the EGF increase and increasing the phosphorylation and mobility induced by the EGF would mutate the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">increasing above the EGF increase and increasing the phosphorylation and mobility induced by the EGF</arg>
                </example>
                <example src="REPLACE" no="203">
                    <text>The A1 mutation (EE amino acids(437 and 438) to increasing above the stimulated phosphorylation and change of mobility induced by FEG would mutate the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">increasing above the stimulated phosphorylation and change of mobility induced by FEG</arg>
                </example>
                <example src="REPLACE" no="204">
                    <text>The A1 mutation (EE amino acids(437 and 438) to late infection variant neuronal lipofuscinosis and mutant nclf mice would mutate the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">late infection variant neuronal lipofuscinosis and mutant nclf mice</arg>
                </example>
                <example src="REPLACE" no="205">
                    <text>The A1 mutation (EE amino acids(437 and 438) to late infection variant neuronal neural lipofuscinosis (CLN6) and in mutant nclf mice mutate the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">late infection variant neuronal neural lipofuscinosis (CLN6) and in mutant nclf mice</arg>
                </example>
                <example src="REPLACE" no="206">
                    <text>The A1 mutation (EE amino acids(437 and 438) to late infection variations in neuronal lipofuscinosis and nclf mice mutate the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">late infection variations in neuronal lipofuscinosis and nclf mice</arg>
                </example>
                <example src="REPLACE" no="207">
                    <text>The A1 mutation (EE amino acids(437 and 438) to latest infertile neural lipofuscinosis (CLN6) and nclf mutant mice mutate the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">latest infertile neural lipofuscinosis (CLN6) and nclf mutant mice</arg>
                </example>
                <example src="REPLACE" no="208">
                    <text>The A1 mutation (EE amino acids(437 and 438)) to abolited increase of EGF-stimulated phosphorylation and EGF-induced mobility change is able to mutate the DNA-binding mutant (Stat5aEE-AA) of Stat5a.</text>
                    <arg n="2">abolited increase of EGF-stimulated phosphorylation and EGF-induced mobility change</arg>
                </example>
                <example src="REPLACE" no="209">
                    <text>The A1 mutation (EE amino acids(437 and 438)) to increasing above the stimulated phosphorylation and change of mobility induced by FEG is able to mutate the DNA-binding mutant (Stat5aEE-AA) of Stat5a.</text>
                    <arg n="2">increasing above the stimulated phosphorylation and change of mobility induced by FEG</arg>
                </example>
                <example src="REPLACE" no="210">
                    <text>The A1 mutation (EE amino acids(437 and 438)) to late infection variant neuronal neural lipofuscinosis (CLN6) and in mutant nclf mice is able to mutate the DNA-binding mutant (Stat5aEE-AA) of Stat5a.</text>
                    <arg n="2">late infection variant neuronal neural lipofuscinosis (CLN6) and in mutant nclf mice</arg>
                </example>
                <example src="REPLACE" no="211">
                    <text>The A1 mutation (EE(437 and 438) amino acids to abolited increase of EGF and increased phosphorylation and mobility induced by EGF mutate the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">abolited increase of EGF and increased phosphorylation and mobility induced by EGF</arg>
                </example>
                <example src="REPLACE" no="212">
                    <text>The A1 mutation (EE(437 and 438) amino acids to above the increased phosphorylation stimulated by FEG and reduced mobility induced by FEG mutate the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">above the increased phosphorylation stimulated by FEG and reduced mobility induced by FEG</arg>
                </example>
                <example src="REPLACE" no="213">
                    <text>The A1 mutation (EE(437 and 438) amino acids to ceroid variant of late infertile neural diffufuscinosis (CLN6) and in nclf mutant mice mutate the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">ceroid variant of late infertile neural diffufuscinosis (CLN6) and in nclf mutant mice</arg>
                </example>
                <example src="REPLACE" no="214">
                    <text>The A1 mutation (EE(437 and 438) amino acids to increasing above increased phosphorylation stimulated by FEG and change of mobility induced by FEG mutate the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">increasing above increased phosphorylation stimulated by FEG and change of mobility induced by FEG</arg>
                </example>
                <example src="REPLACE" no="215">
                    <text>The A1 mutation (EE(437 and 438) amino acids to increasing above the EGF increase and increasing the phosphorylation and mobility induced by the EGF mutate the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">increasing above the EGF increase and increasing the phosphorylation and mobility induced by the EGF</arg>
                </example>
                <example src="REPLACE" no="216">
                    <text>The A1 mutation (EE(437 and 438) amino acids to late infection variant neuronal neural lipofuscinosis (CLN6) and in mutant nclf mice mutate the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">late infection variant neuronal neural lipofuscinosis (CLN6) and in mutant nclf mice</arg>
                </example>
                <example src="REPLACE" no="217">
                    <text>The A1 mutation (EE(437 and 438) amino acids to late infection variations in neuronal lipofuscinosis and nclf mice mutate the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">late infection variations in neuronal lipofuscinosis and nclf mice</arg>
                </example>
                <example src="REPLACE" no="218">
                    <text>The A1 mutation (EE(437 and 438) amino acids to late infectious variant neuronal lipofuscinosis (CLN6) and mutant nclf mice mutate the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">late infectious variant neuronal lipofuscinosis (CLN6) and mutant nclf mice</arg>
                </example>
                <example src="REPLACE" no="219">
                    <text>The A1 mutation (EE(437 and 438) to Lipfuscinosis of late infertile neural lipofuscinosis (CLN6) and in nclf mutant mice amino acids) can mutating the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">Lipfuscinosis of late infertile neural lipofuscinosis (CLN6) and in nclf mutant mice</arg>
                </example>
                <example src="REPLACE" no="220">
                    <text>The A1 mutation (EE(437 and 438) to Lipfuscinosis of late infertile neural lipofuscinosis (CLN6) and in nclf mutant mice will mutating the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">Lipfuscinosis of late infertile neural lipofuscinosis (CLN6) and in nclf mutant mice</arg>
                </example>
                <example src="REPLACE" no="221">
                    <text>The A1 mutation (EE(437 and 438) to Lipfuscinosis slow inphantyl neural lipofuscinosis (CLN6) and in nclf mutant mice amino acids will mutate the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">Lipfuscinosis slow inphantyl neural lipofuscinosis (CLN6) and in nclf mutant mice</arg>
                </example>
                <example src="REPLACE" no="222">
                    <text>The A1 mutation (EE(437 and 438) to Liphofuscinosis slow inphantyl neural lipofuscinosis (CLN6) and in nclf mutant mice will mutating the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">Liphofuscinosis slow inphantyl neural lipofuscinosis (CLN6) and in nclf mutant mice</arg>
                </example>
                <example src="REPLACE" no="223">
                    <text>The A1 mutation (EE(437 and 438) to abolited increase of EGF and increased phosphorylation and mobility induced by EGF amino acids will mutate the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">abolited increase of EGF and increased phosphorylation and mobility induced by EGF</arg>
                </example>
                <example src="REPLACE" no="224">
                    <text>The A1 mutation (EE(437 and 438) to abolited increase of FEG-stimulated phosphorylation and FEG-induced mobility change will mutating the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">abolited increase of FEG-stimulated phosphorylation and FEG-induced mobility change</arg>
                </example>
                <example src="REPLACE" no="225">
                    <text>The A1 mutation (EE(437 and 438) to increasing above the EGF increase and increasing the phosphorylation and mobility induced by the EGF amino acids) can mutating the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">increasing above the EGF increase and increasing the phosphorylation and mobility induced by the EGF</arg>
                </example>
                <example src="REPLACE" no="226">
                    <text>The A1 mutation (EE(437 and 438) to increasing above the increased phosphorylation stimulated by EGF and change of mobility induced by the EGF will mutating the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">increasing above the increased phosphorylation stimulated by EGF and change of mobility induced by the EGF</arg>
                </example>
                <example src="REPLACE" no="227">
                    <text>The A1 mutation (EE(437 and 438) to late infection variant neuronal lipofuscinosis and mutant nclf mice amino acids) can mutating the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">late infection variant neuronal lipofuscinosis and mutant nclf mice</arg>
                </example>
                <example src="REPLACE" no="228">
                    <text>The A1 mutation (EE(437 and 438) to late infection variant neuronal neural lipofuscinosis (CLN6) and mutant nclf mice amino acids will mutate the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">late infection variant neuronal neural lipofuscinosis (CLN6) and mutant nclf mice</arg>
                </example>
                <example src="REPLACE" no="229">
                    <text>The A1 mutation (EE(437 and 438) to late infection variant neuronal neural lipofuscinosis (CLN6) and mutant nclf mice will mutating the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">late infection variant neuronal neural lipofuscinosis (CLN6) and mutant nclf mice</arg>
                </example>
                <example src="REPLACE" no="230">
                    <text>The A1 mutation (EE(437 and 438) to losing the transcriptional repression of the lacZ gene amino acids will mutate the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">losing the transcriptional repression of the lacZ gene</arg>
                </example>
                <example src="REPLACE" no="231">
                    <text>The A1 mutation (EE(437 and 438) to losing the transcriptional repression of the lacZ gene will mutating the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">losing the transcriptional repression of the lacZ gene</arg>
                </example>
                <example src="REPLACE" no="232">
                    <text>The A1 mutation (EE(437 and 438)) to Lipfuscinosis of late infertile neural lipofuscinosis (CLN6) and in nclf mutant mice could mutating the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">Lipfuscinosis of late infertile neural lipofuscinosis (CLN6) and in nclf mutant mice</arg>
                </example>
                <example src="REPLACE" no="233">
                    <text>The A1 mutation (EE(437 and 438)) to Lipfuscinosis of late infertile neural lipofuscinosis (CLN6) and in nclf mutant mice may mutate the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">Lipfuscinosis of late infertile neural lipofuscinosis (CLN6) and in nclf mutant mice</arg>
                </example>
                <example src="REPLACE" no="234">
                    <text>The A1 mutation (EE(437 and 438)) to Lipfuscinosis slow infertile neural lipofuscinosis (CLN6) and in nclf mutant mice is able to mutate the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">Lipfuscinosis slow infertile neural lipofuscinosis (CLN6) and in nclf mutant mice</arg>
                </example>
                <example src="REPLACE" no="235">
                    <text>The A1 mutation (EE(437 and 438)) to Lipfuscinosis slow inphantyl neural lipofuscinosis (CLN6) and in nclf mutant mice is able to mutate the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">Lipfuscinosis slow inphantyl neural lipofuscinosis (CLN6) and in nclf mutant mice</arg>
                </example>
                <example src="REPLACE" no="236">
                    <text>The A1 mutation (EE(437 and 438)) to Lipfuscinosis slow inphantyl neural lipofuscinosis (CLN6) and in nclf mutant mice may mutate the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">Lipfuscinosis slow inphantyl neural lipofuscinosis (CLN6) and in nclf mutant mice</arg>
                </example>
                <example src="REPLACE" no="237">
                    <text>The A1 mutation (EE(437 and 438)) to Liphofuscinosis slow inphantyl neural lipofuscinosis (CLN6) and in nclf mutant mice could mutating the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">Liphofuscinosis slow inphantyl neural lipofuscinosis (CLN6) and in nclf mutant mice</arg>
                </example>
                <example src="REPLACE" no="238">
                    <text>The A1 mutation (EE(437 and 438)) to Liphofuscinosis slow inphantyl neural lipofuscinosis (CLN6) and in nclf mutant mice may mutate the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">Liphofuscinosis slow inphantyl neural lipofuscinosis (CLN6) and in nclf mutant mice</arg>
                </example>
                <example src="REPLACE" no="239">
                    <text>The A1 mutation (EE(437 and 438)) to Liphofuscinosis slow inphantyl neural lipofuscinosis (CLN6) and in nclf mutant mice would mutating the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">Liphofuscinosis slow inphantyl neural lipofuscinosis (CLN6) and in nclf mutant mice</arg>
                </example>
                <example src="REPLACE" no="240">
                    <text>The A1 mutation (EE(437 and 438)) to abolished the stimulated increase of EGF in phosphorylation and preventing the change in mobility introduced by EGF could have mutating the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">abolished the stimulated increase of EGF in phosphorylation and preventing the change in mobility introduced by EGF</arg>
                </example>
                <example src="REPLACE" no="241">
                    <text>The A1 mutation (EE(437 and 438)) to abolished the stimulated increase of EGF in phosphorylation and preventing the change in mobility introduced by EGF may mutating the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">abolished the stimulated increase of EGF in phosphorylation and preventing the change in mobility introduced by EGF</arg>
                </example>
                <example src="REPLACE" no="242">
                    <text>The A1 mutation (EE(437 and 438)) to abolited increase of EGF and increased phosphorylation and mobility induced by EGF could mutate the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">abolited increase of EGF and increased phosphorylation and mobility induced by EGF</arg>
                </example>
                <example src="REPLACE" no="243">
                    <text>The A1 mutation (EE(437 and 438)) to abolited increase of EGF-stimulated phosphorylation and EGF-induced mobility change is able to mutate the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">abolited increase of EGF-stimulated phosphorylation and EGF-induced mobility change</arg>
                </example>
                <example src="REPLACE" no="244">
                    <text>The A1 mutation (EE(437 and 438)) to abolited increase of EGF-stimulated phosphorylation and EGF-induced mobility change is able to mutating the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">abolited increase of EGF-stimulated phosphorylation and EGF-induced mobility change</arg>
                </example>
                <example src="REPLACE" no="245">
                    <text>The A1 mutation (EE(437 and 438)) to abolited increase of EGF-stimulated phosphorylation and EGF-induced mobility change may mutate the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">abolited increase of EGF-stimulated phosphorylation and EGF-induced mobility change</arg>
                </example>
                <example src="REPLACE" no="246">
                    <text>The A1 mutation (EE(437 and 438)) to abolited increase of FEG-stimulated phosphorylation and FEG-induced mobility change may mutate the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">abolited increase of FEG-stimulated phosphorylation and FEG-induced mobility change</arg>
                </example>
                <example src="REPLACE" no="247">
                    <text>The A1 mutation (EE(437 and 438)) to abolited increase of FEG-stimulated phosphorylation and FEG-induced mobility change would mutating the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">abolited increase of FEG-stimulated phosphorylation and FEG-induced mobility change</arg>
                </example>
                <example src="REPLACE" no="248">
                    <text>The A1 mutation (EE(437 and 438)) to abolition of FEG-stimulated phosphorylation and prevented FEG-induced mobility is able to mutate the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">abolition of FEG-stimulated phosphorylation and prevented FEG-induced mobility</arg>
                </example>
                <example src="REPLACE" no="249">
                    <text>The A1 mutation (EE(437 and 438)) to above FEG-stimulated phosphorylation and FEG-induced mobility could mutating the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">above FEG-stimulated phosphorylation and FEG-induced mobility</arg>
                </example>
                <example src="REPLACE" no="250">
                    <text>The A1 mutation (EE(437 and 438)) to above FEG-stimulated phosphorylation and FEG-induced mobility is able to mutate the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">above FEG-stimulated phosphorylation and FEG-induced mobility</arg>
                </example>
                <example src="REPLACE" no="251">
                    <text>The A1 mutation (EE(437 and 438)) to above FEG-stimulated phosphorylation and FEG-induced mobility would mutating the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">above FEG-stimulated phosphorylation and FEG-induced mobility</arg>
                </example>
                <example src="REPLACE" no="252">
                    <text>The A1 mutation (EE(437 and 438)) to above the increased phosphorylation stimulated by FEG and reduced mobility induced by FEG could mutate the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">above the increased phosphorylation stimulated by FEG and reduced mobility induced by FEG</arg>
                </example>
                <example src="REPLACE" no="253">
                    <text>The A1 mutation (EE(437 and 438)) to ceroid variant of late infertile neural diffufuscinosis (CLN6) and in nclf mutant mice could mutate the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">ceroid variant of late infertile neural diffufuscinosis (CLN6) and in nclf mutant mice</arg>
                </example>
                <example src="REPLACE" no="254">
                    <text>The A1 mutation (EE(437 and 438)) to ceroid variant of late infertile neural diffufuscinosis (CLN6) and in nclf mutant mice may mutate the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">ceroid variant of late infertile neural diffufuscinosis (CLN6) and in nclf mutant mice</arg>
                </example>
                <example src="REPLACE" no="255">
                    <text>The A1 mutation (EE(437 and 438)) to increasing above increased phosphorylation stimulated by FEG and change of mobility induced by FEG may have mutate the DNA-binding mutant (Stat5aEE-AA of Stat5a may have been caused by the DNA mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">increasing above increased phosphorylation stimulated by FEG and change of mobility induced by FEG</arg>
                </example>
                <example src="REPLACE" no="256">
                    <text>The A1 mutation (EE(437 and 438)) to increasing above increased phosphorylation stimulated by FEG and change of mobility induced by FEG would mutating the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">increasing above increased phosphorylation stimulated by FEG and change of mobility induced by FEG</arg>
                </example>
                <example src="REPLACE" no="257">
                    <text>The A1 mutation (EE(437 and 438)) to increasing above the EGF and increasing the phosphorylation and mobility induced by the EGF could have mutating the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">increasing above the EGF and increasing the phosphorylation and mobility induced by the EGF</arg>
                </example>
                <example src="REPLACE" no="258">
                    <text>The A1 mutation (EE(437 and 438)) to increasing above the EGF and increasing the phosphorylation and mobility induced by the EGF is able to mutate the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">increasing above the EGF and increasing the phosphorylation and mobility induced by the EGF</arg>
                </example>
                <example src="REPLACE" no="259">
                    <text>The A1 mutation (EE(437 and 438)) to increasing above the EGF increase and increasing the phosphorylation and mobility induced by the EGF may mutate the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">increasing above the EGF increase and increasing the phosphorylation and mobility induced by the EGF</arg>
                </example>
                <example src="REPLACE" no="260">
                    <text>The A1 mutation (EE(437 and 438)) to increasing above the increase in phosphorylation stimulated by FEG and change in mobility induced by FEG could mutate the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">increasing above the increase in phosphorylation stimulated by FEG and change in mobility induced by FEG</arg>
                </example>
                <example src="REPLACE" no="261">
                    <text>The A1 mutation (EE(437 and 438)) to increasing above the increase in phosphorylation stimulated by FEG and change in mobility induced by FEG has the ability to mutating the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">increasing above the increase in phosphorylation stimulated by FEG and change in mobility induced by FEG</arg>
                </example>
                <example src="REPLACE" no="262">
                    <text>The A1 mutation (EE(437 and 438)) to increasing above the increase in phosphorylation stimulated by FEG and change in mobility induced by FEG may have mutate the DNA-binding mutant (Stat5aEE-AA of Stat5a may have been caused by the DNA mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">increasing above the increase in phosphorylation stimulated by FEG and change in mobility induced by FEG</arg>
                </example>
                <example src="REPLACE" no="263">
                    <text>The A1 mutation (EE(437 and 438)) to increasing above the increased phosphorylation stimulated by EGF and change of mobility induced by the EGF could have mutating the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">increasing above the increased phosphorylation stimulated by EGF and change of mobility induced by the EGF</arg>
                </example>
                <example src="REPLACE" no="264">
                    <text>The A1 mutation (EE(437 and 438)) to increasing above the stimulated phosphorylation and change of mobility induced by FEG could have mutating the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">increasing above the stimulated phosphorylation and change of mobility induced by FEG</arg>
                </example>
                <example src="REPLACE" no="265">
                    <text>The A1 mutation (EE(437 and 438)) to increasing above the stimulated phosphorylation and change of mobility induced by FEG is able to mutate the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">increasing above the stimulated phosphorylation and change of mobility induced by FEG</arg>
                </example>
                <example src="REPLACE" no="266">
                    <text>The A1 mutation (EE(437 and 438)) to increasing above the stimulated phosphorylation and change of mobility induced by FEG is able to mutating the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">increasing above the stimulated phosphorylation and change of mobility induced by FEG</arg>
                </example>
                <example src="REPLACE" no="267">
                    <text>The A1 mutation (EE(437 and 438)) to infectantyl lipofuscinosis neural lipofuscinosis (CLN6) and in nclf mutant mice could mutate the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">infectantyl lipofuscinosis neural lipofuscinosis (CLN6) and in nclf mutant mice</arg>
                </example>
                <example src="REPLACE" no="268">
                    <text>The A1 mutation (EE(437 and 438)) to infectantyl lipofuscinosis neural lipofuscinosis (CLN6) and in nclf mutant mice may mutating the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">infectantyl lipofuscinosis neural lipofuscinosis (CLN6) and in nclf mutant mice</arg>
                </example>
                <example src="REPLACE" no="269">
                    <text>The A1 mutation (EE(437 and 438)) to infectantyl lipofuscinosis neural lipofuscinosis (CLN6) and in nclf mutant mice would mutating the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">infectantyl lipofuscinosis neural lipofuscinosis (CLN6) and in nclf mutant mice</arg>
                </example>
                <example src="REPLACE" no="270">
                    <text>The A1 mutation (EE(437 and 438)) to late infection variant ceroid neuronal lipofuscinosis (CLN6) and mutant nclf mice could mutate the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">late infection variant ceroid neuronal lipofuscinosis (CLN6) and mutant nclf mice</arg>
                </example>
                <example src="REPLACE" no="271">
                    <text>The A1 mutation (EE(437 and 438)) to late infection variant ceroid neuronal lipofuscinosis (CLN6) and mutant nclf mice may have mutating the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">late infection variant ceroid neuronal lipofuscinosis (CLN6) and mutant nclf mice</arg>
                </example>
                <example src="REPLACE" no="272">
                    <text>The A1 mutation (EE(437 and 438)) to late infection variant ceroid neuronal lipofuscinosis (CLN6) and mutant nclf mice may mutating the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">late infection variant ceroid neuronal lipofuscinosis (CLN6) and mutant nclf mice</arg>
                </example>
                <example src="REPLACE" no="273">
                    <text>The A1 mutation (EE(437 and 438)) to late infection variant neuronal lipofuscinosis and mutant nclf mice could mutate the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">late infection variant neuronal lipofuscinosis and mutant nclf mice</arg>
                </example>
                <example src="REPLACE" no="274">
                    <text>The A1 mutation (EE(437 and 438)) to late infection variant neuronal lipofuscinosis and mutant nclf mice may have mutating the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">late infection variant neuronal lipofuscinosis and mutant nclf mice</arg>
                </example>
                <example src="REPLACE" no="275">
                    <text>The A1 mutation (EE(437 and 438)) to late infection variant neuronal neural lipofuscinosis (CLN6) and in mutant nclf mice is observed to mutate the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">late infection variant neuronal neural lipofuscinosis (CLN6) and in mutant nclf mice</arg>
                </example>
                <example src="REPLACE" no="276">
                    <text>The A1 mutation (EE(437 and 438)) to late infection variant neuronal neural lipofuscinosis (CLN6) and in mutant nclf mice mutating the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">late infection variant neuronal neural lipofuscinosis (CLN6) and in mutant nclf mice</arg>
                </example>
                <example src="REPLACE" no="277">
                    <text>The A1 mutation (EE(437 and 438)) to late infection variant neuronal neural lipofuscinosis (CLN6) and mutant nclf mice mutating the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">late infection variant neuronal neural lipofuscinosis (CLN6) and mutant nclf mice</arg>
                </example>
                <example src="REPLACE" no="278">
                    <text>The A1 mutation (EE(437 and 438)) to late infection variations in neuronal lipofuscinosis and nclf mice could have mutating the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">late infection variations in neuronal lipofuscinosis and nclf mice</arg>
                </example>
                <example src="REPLACE" no="279">
                    <text>The A1 mutation (EE(437 and 438)) to late infection variations in neuronal lipofuscinosis and nclf mice has the ability to mutating the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">late infection variations in neuronal lipofuscinosis and nclf mice</arg>
                </example>
                <example src="REPLACE" no="280">
                    <text>The A1 mutation (EE(437 and 438)) to late infection variations in neuronal lipofuscinosis and nclf mice is observed to mutate the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">late infection variations in neuronal lipofuscinosis and nclf mice</arg>
                </example>
                <example src="REPLACE" no="281">
                    <text>The A1 mutation (EE(437 and 438)) to late infection variations in neuronal lipofuscinosis and nclf mice may have mutating the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">late infection variations in neuronal lipofuscinosis and nclf mice</arg>
                </example>
                <example src="REPLACE" no="282">
                    <text>The A1 mutation (EE(437 and 438)) to late infection variations in neuronal lipofuscinosis and nclf mice would mutating the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">late infection variations in neuronal lipofuscinosis and nclf mice</arg>
                </example>
                <example src="REPLACE" no="283">
                    <text>The A1 mutation (EE(437 and 438)) to late infectious variant neuronal lipofuscinosis (CLN6) and mutant nclf mice could mutating the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">late infectious variant neuronal lipofuscinosis (CLN6) and mutant nclf mice</arg>
                </example>
                <example src="REPLACE" no="284">
                    <text>The A1 mutation (EE(437 and 438)) to late infectious variant neuronal lipofuscinosis (CLN6) and mutant nclf mice may have mutate the DNA-binding mutant (Stat5aEE-AA of Stat5a may have been caused by the DNA mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">late infectious variant neuronal lipofuscinosis (CLN6) and mutant nclf mice</arg>
                </example>
                <example src="REPLACE" no="285">
                    <text>The A1 mutation (EE(437 and 438)) to latest infertile neural lipofuscinosis (CLN6) and nclf mutant mice may mutating the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">latest infertile neural lipofuscinosis (CLN6) and nclf mutant mice</arg>
                </example>
                <example src="REPLACE" no="286">
                    <text>The A1 mutation (EE(437 and 438)) to latest infertile neural lipofuscinosis (CLN6) and nclf mutant mice mutating the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">latest infertile neural lipofuscinosis (CLN6) and nclf mutant mice</arg>
                </example>
                <example src="REPLACE" no="287">
                    <text>The A1 mutation (EE(437 and 438)) to losing the transcriptional repression of the lacZ gene is able to mutate the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">losing the transcriptional repression of the lacZ gene</arg>
                </example>
                <example src="REPLACE" no="288">
                    <text>The A1 mutation (EE(437 and 438)) to losing the transcriptional repression of the lacZ gene may have mutate the DNA-binding mutant (Stat5aEE-AA of Stat5a may have been caused by the DNA mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">losing the transcriptional repression of the lacZ gene</arg>
                </example>
                <example src="REPLACE" no="289">
                    <text>The DNA-binding mutant (Stat5aEE-abolited increase of EGF and increased phosphorylation and mobility induced by EGF) of Stat5a is observed to be mutating by the A1 mutation (EE amino acids(437 and 438)) to AA.</text>
                    <arg n="2">abolited increase of EGF and increased phosphorylation and mobility induced by EGF</arg>
                </example>
                <example src="REPLACE" no="290">
                    <text>The DNA-binding mutant (Stat5aEE-abolited increase of EGF-stimulated phosphorylation and EGF-induced mobility change) of Stat5a is observed to be mutating by the A1 mutation (EE amino acids(437 and 438)) to AA.</text>
                    <arg n="2">abolited increase of EGF-stimulated phosphorylation and EGF-induced mobility change</arg>
                </example>
                <example src="REPLACE" no="291">
                    <text>The DNA-binding mutant (Stat5aEE-abolited increase of FEG-stimulated phosphorylation and FEG-induced mobility change) of Stat5a can be mutating by the A1 mutation (EE amino acids(437 and 438)) to AA.</text>
                    <arg n="2">abolited increase of FEG-stimulated phosphorylation and FEG-induced mobility change</arg>
                </example>
                <example src="REPLACE" no="292">
                    <text>The DNA-binding mutant (Stat5aEE-above FEG-stimulated phosphorylation and FEG-induced mobility) of Stat5a is observed to be mutating by the A1 mutation (EE amino acids(437 and 438)) to AA.</text>
                    <arg n="2">above FEG-stimulated phosphorylation and FEG-induced mobility</arg>
                </example>
                <example src="REPLACE" no="293">
                    <text>The DNA-binding mutant (Stat5aEE-increasing above the EGF increase and increasing the phosphorylation and mobility induced by the EGF) of Stat5a can be mutating by the A1 mutation (EE amino acids(437 and 438)) to AA.</text>
                    <arg n="2">increasing above the EGF increase and increasing the phosphorylation and mobility induced by the EGF</arg>
                </example>
                <example src="REPLACE" no="294">
                    <text>The DNA-binding mutant (Stat5aEE-increasing above the increased phosphorylation stimulated by EGF and change of mobility induced by the EGF) of Stat5a can be mutating by the A1 mutation (EE amino acids(437 and 438)) to AA.</text>
                    <arg n="2">increasing above the increased phosphorylation stimulated by EGF and change of mobility induced by the EGF</arg>
                </example>
                <example src="REPLACE" no="295">
                    <text>The DNA-binding mutant (Stat5aEE-late infection variant ceroid neuronal lipofuscinosis (CLN6) and mutant nclf mice) of Stat5a can be mutating by the A1 mutation (EE amino acids(437 and 438)) to AA.</text>
                    <arg n="2">late infection variant ceroid neuronal lipofuscinosis (CLN6) and mutant nclf mice</arg>
                </example>
                <example src="REPLACE" no="296">
                    <text>The DNA-binding mutant (Stat5aEE-late infection variant neuronal neural lipofuscinosis (CLN6) and in mutant nclf mice) of Stat5a is observed to be mutating by the A1 mutation (EE amino acids(437 and 438)) to AA.</text>
                    <arg n="2">late infection variant neuronal neural lipofuscinosis (CLN6) and in mutant nclf mice</arg>
                </example>
                <example src="REPLACE" no="297">
                    <text>The DNA-binding mutant (Stat5aEE-late infection variant neuronal neural lipofuscinosis (CLN6) and in mutant nclf mice) of Stat5a was mutating by the A1 mutant (EE(437 and 438) of AA.</text>
                    <arg n="2">late infection variant neuronal neural lipofuscinosis (CLN6) and in mutant nclf mice</arg>
                </example>
                <example src="REPLACE" no="298">
                    <text>The DNA-binding mutant (Stat5aEE-latest infertile neural lipofuscinosis (CLN6) and nclf mutant mice) of Stat5a is observed to be mutating by the A1 mutation (EE amino acids(437 and 438)) to AA.</text>
                    <arg n="2">latest infertile neural lipofuscinosis (CLN6) and nclf mutant mice</arg>
                </example>
                <example src="REPLACE" no="299">
                    <text>The DNA-binding mutant (Stat5aEE-losing the transcriptional repression of the lacZ gene) of Stat5a could have been mutating by the A1 mutation (EE amino acids(437 and 438)) to AA.</text>
                    <arg n="2">losing the transcriptional repression of the lacZ gene</arg>
                </example>
                <example src="REPLACE" no="300">
                    <text>The DNA-binding mutant (Stat5aEE-losing the transcriptional repression of the lacZ gene) of Stat5a was mutating by the A1 mutant (EE(437 and 438) of AA.</text>
                    <arg n="2">losing the transcriptional repression of the lacZ gene</arg>
                </example>
                <example src="REPLACE" no="301">
                    <text>The a preserved phenylalanine was significantly mutated by the the sequence eh1/GEH, adherence to Q62696 using the Swiss PDB display software (Guex and Peitsch, 1997).</text>
                    <arg n="0">a preserved phenylalanine</arg>
                    <arg n="1">the sequence eh1/GEH</arg>
                </example>
                <example src="REPLACE" no="302">
                    <text>The analyses of in vivo transcription of agn-lacZ with a gene that can be mutated support this conclusion.</text>
                    <arg n="1">a gene</arg>
                </example>
                <example src="REPLACE" no="303">
                    <text>The analyses of in vivo transcription of agn-lacZ with parallel residue positions that may have mutated mutations support this conclusion.</text>
                    <arg n="1">parallel residue positions</arg>
                </example>
                <example src="REPLACE" no="304">
                    <text>The analyses of in vivo transcription of agn-lacZ with pars of residue positions that may have mutated mutations support this conclusion.</text>
                    <arg n="1">pars of residue positions</arg>
                </example>
                <example src="REPLACE" no="305">
                    <text>The analyses of in vivo transcription of agn-lacZ with the two phosphorylation sites PKA (S 64) and S (211) may have been mutated that can be mutated support this conclusion.</text>
                    <arg n="1">the two phosphorylation sites PKA (S 64) and S (211) may have been mutated</arg>
                </example>
                <example src="REPLACE" no="306">
                    <text>The analyses of in vivo transcription of agn-lacZ with two amino acids that may have mutated mutations support this conclusion.</text>
                    <arg n="1">two amino acids</arg>
                </example>
                <example src="REPLACE" no="307">
                    <text>The exon 5 A1 mutation (the eh1/GEH sequence) termination of premature translation mutating the binding of the snail (Jimnez et al., 1999).</text>
                    <arg n="0">exon 5</arg>
                    <arg n="2">termination of premature translation</arg>
                </example>
                <example src="REPLACE" no="308">
                    <text>The exon 5 had the ability to silence alele with termination of premature translation and mutate in severe Hex A deficiency.</text>
                    <arg n="0">exon 5</arg>
                    <arg n="1">alele</arg>
                    <arg n="2">termination of premature translation</arg>
                    <arg n="3">severe Hex A deficiency</arg>
                </example>
                <example src="REPLACE" no="309">
                    <text>The exon 5 had the ability to silence rice with premature translation abbreviation and mutate in deficiency of each Hex A.</text>
                    <arg n="0">exon 5</arg>
                    <arg n="1">rice</arg>
                    <arg n="2">premature translation abbreviation</arg>
                    <arg n="3">deficiency of each Hex A</arg>
                </example>
                <example src="REPLACE" no="310">
                    <text>The exon 5 may have been significantly mutated by the alele, adhering to Q62696 using the Swiss PDB display software (Guex and Peitsch, 1997).</text>
                    <arg n="0">exon 5</arg>
                    <arg n="1">alele</arg>
                </example>
                <example src="REPLACE" no="311">
                    <text>The exon 5 may have been significantly mutated by the allele, adhering to Q62696 using the Swiss PDB display software (Guex and Peitsch, 1997).</text>
                    <arg n="0">exon 5</arg>
                    <arg n="1">allele</arg>
                </example>
                <example src="REPLACE" no="312">
                    <text>The exon 5 was able to silence rice with premature translation termination and mutate in severe Hex A deficiency.</text>
                    <arg n="0">exon 5</arg>
                    <arg n="1">rice</arg>
                    <arg n="2">premature translation termination</arg>
                    <arg n="3">severe Hex A deficiency</arg>
                </example>
                <example src="REPLACE" no="313">
                    <text>The exon 5 was mutated by the rice, adherence to Q62696 using the Swiss PDB display software (Guex and Peitsch, 1997).</text>
                    <arg n="0">exon 5</arg>
                    <arg n="1">rice</arg>
                </example>
                <example src="REPLACE" no="314">
                    <text>The exon 5 would be significantly mutated to the allele, adhesion to Q62696 using the Swiss PDB display program (Guex and Peitsch, 1997).</text>
                    <arg n="0">exon 5</arg>
                    <arg n="1">allele</arg>
                </example>
                <example src="REPLACE" no="315">
                    <text>The exon 8 could have been significantly mutated by the acDR DNA of the alpha chain cDNA in the 1-cells, the adherence no.D62696 using the Swiss PDB display program (Guex and Peitsch, 1997).</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">acDR DNA of the alpha chain cDNA in the 1-cells</arg>
                </example>
                <example src="REPLACE" no="316">
                    <text>The exon 8 could have been significantly mutated by the acDR-alpha in the alpha chain of cells 1, the adherence no.D62696 using the Swiss PDB display program (Guex and Peitsch, 1997).</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">acDR-alpha in the alpha chain of cells 1</arg>
                </example>
                <example src="REPLACE" no="317">
                    <text>The exon 8 could have been significantly mutated by the alpha cDNA chain in COS-1, the adherence no.D62696 using the Swiss PDB display program (Guex and Peitsch, 1997).</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha cDNA chain in COS-1</arg>
                </example>
                <example src="REPLACE" no="318">
                    <text>The exon 8 could have been significantly mutated by the alpha strand cDNA in the COS-1 cells, the adherence no.D62696 using the Swiss PDB display program (Guex and Peitsch, 1997).</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha strand cDNA in the COS-1 cells</arg>
                </example>
                <example src="REPLACE" no="319">
                    <text>The exon 8 could have been significantly mutated by the alpha-chain cDNA into COS-1 cells, the adherence no.D62696 using the Swiss PDB display program (Guex and Peitsch, 1997).</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha-chain cDNA into COS-1 cells</arg>
                </example>
                <example src="REPLACE" no="320">
                    <text>The exon 8 could have been significantly mutated by the cDNA alpha chain in COS-1 cells, the adherence no.D62696 using the Swiss PDB display program (Guex and Peitsch, 1997).</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">cDNA alpha chain in COS-1 cells</arg>
                </example>
                <example src="REPLACE" no="321">
                    <text>The exon 8 may have been mutated by the acDR DNA of alpha chain cDNA in COS-1 cells, adherence to Q62696 using the Swiss PDB display software (Guex and Peitsch, 1997).</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">acDR DNA of alpha chain cDNA in COS-1 cells</arg>
                </example>
                <example src="REPLACE" no="322">
                    <text>The exon 8 may have been mutated by the alpha strand cDNA in the COS-1 cells, adherence to Q62696 using the Swiss PDB display program (Guex and Peitsch, 1997).</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha strand cDNA in the COS-1 cells</arg>
                </example>
                <example src="REPLACE" no="323">
                    <text>The exon 8 may have been significantly mutated by the alpha strand cDNA DNA in COS-1 cells, adhering to Q62696 using the Swiss PDB display software (Guex and Peitsch, 1997).</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha strand cDNA DNA in COS-1 cells</arg>
                </example>
                <example src="REPLACE" no="324">
                    <text>The exon 8 was mutated by the alpha chain cDNA in COS-1 cells, adherence to Q62696 using the Swiss PDB display software (Guex and Peitsch, 1997).</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha chain cDNA in COS-1 cells</arg>
                </example>
                <example src="REPLACE" no="325">
                    <text>The exon 8 was significantly mutated by the alpha chain cDNA in COS-1 cells, adherence to Q62696 using the Swiss PDB display software (Guex and Peitsch, 1997).</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha chain cDNA in COS-1 cells</arg>
                </example>
                <example src="REPLACE" no="326">
                    <text>The exon 8 will be mutated by the alpha strand cDNA in COS-1, adherence to Q62696 using the Swiss PDB display program (Guex and Peitsch, 1997).</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha strand cDNA in COS-1</arg>
                </example>
                <example src="REPLACE" no="327">
                    <text>The exon 8 will be mutated by the alpha strand cDNA in the COS-1 cells, adherence to Q62696 using the Swiss PDB display program (Guex and Peitsch, 1997).</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha strand cDNA in the COS-1 cells</arg>
                </example>
                <example src="REPLACE" no="328">
                    <text>The exon 8 will be mutated by the alpha-chain cDNA into COS-1 cells, adherence to Q62696 using the Swiss PDB display program (Guex and Peitsch, 1997).</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha-chain cDNA into COS-1 cells</arg>
                </example>
                <example src="REPLACE" no="329">
                    <text>The exon 8 would be mutated by the acDR DNA of alpha chain cDNA in COS-1 cells, adherence to Q62696 using the Swiss PDB display software (Guex and Peitsch, 1997).</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">acDR DNA of alpha chain cDNA in COS-1 cells</arg>
                </example>
                <example src="REPLACE" no="330">
                    <text>The exon 8 would be mutated by the alpha strand cDNA in the COS-1 cells, adherence to Q62696 using the Swiss PDB display software (Guex and Peitsch, 1997).</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha strand cDNA in the COS-1 cells</arg>
                </example>
                <example src="REPLACE" no="331">
                    <text>The exon 8 would be mutated by the alpha-acDR in the alpha chain in 1-BODY cells, adherence to Q62696 using the Swiss PDB display software (Guex and Peitsch, 1997).</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha-acDR in the alpha chain in 1-BODY cells</arg>
                </example>
                <example src="REPLACE" no="332">
                    <text>The exon 8 would be mutated by the cDNA alpha chain in COS-1 cells, adherence to Q62696 using the Swiss PDB display software (Guex and Peitsch, 1997).</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">cDNA alpha chain in COS-1 cells</arg>
                </example>
                <example src="REPLACE" no="333">
                    <text>The exon 8 would be significantly mutated to the alpha cDNA chain in COS-1 cells, adhesion to Q62696 using the Swiss PDB display program (Guex and Peitsch, 1997).</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha cDNA chain in COS-1 cells</arg>
                </example>
                <example src="REPLACE" no="334">
                    <text>The in vivo transcription analyses of Agn-lacZ with pairs of waste positions mutated this conclusion.</text>
                    <arg n="1">pairs of waste positions</arg>
                </example>
                <example src="REPLACE" no="335">
                    <text>The in vivo transcription analyses of Agn-lacZ with pars of residue positions mutated this conclusion.</text>
                    <arg n="1">pars of residue positions</arg>
                </example>
                <example src="REPLACE" no="336">
                    <text>The in vivo transcription analyses of Agn-lacZ with target sequences AG mutated this conclusion.</text>
                    <arg n="1">target sequences AG</arg>
                </example>
                <example src="REPLACE" no="337">
                    <text>The in vivo transcription analyses of agn-lacZ with parallel of residue positions mutated in line with this conclusion.</text>
                    <arg n="1">parallel of residue positions</arg>
                </example>
                <example src="REPLACE" no="338">
                    <text>The in vivo transcription analyses of agn-lacZ with parallel positions of residues that are mutations mutated this conclusion.</text>
                    <arg n="1">parallel positions of residues</arg>
                </example>
                <example src="REPLACE" no="339">
                    <text>The in vivo transcription analyses of agn-lacZ with parallel residue positions that mutated mutations support this conclusion.</text>
                    <arg n="1">parallel residue positions</arg>
                </example>
                <example src="REPLACE" no="340">
                    <text>The in vivo transcription analyses of agn-lacZ with pars of residue positions mutated in line with this conclusion.</text>
                    <arg n="1">pars of residue positions</arg>
                </example>
                <example src="REPLACE" no="341">
                    <text>The in vivo transcription analyses of agn-lacZ with parts of residue positions that are mutations mutated this conclusion.</text>
                    <arg n="1">parts of residue positions</arg>
                </example>
                <example src="REPLACE" no="342">
                    <text>The induction of a mutation in the A0 gene (LacI) has the ability to mutated in Lipfuscinosis slow inphantyl neural lipofuscinosis (CLN6) and in nclf mutant mice, which is the cell mutation.</text>
                    <arg n="2">Lipfuscinosis slow inphantyl neural lipofuscinosis (CLN6) and in nclf mutant mice</arg>
                </example>
                <example src="REPLACE" no="343">
                    <text>The induction of a mutation in the A0 gene (LacI) has the ability to mutated in abolited increase of EGF and increased phosphorylation and mobility induced by EGF, which is the cell mutation.</text>
                    <arg n="2">abolited increase of EGF and increased phosphorylation and mobility induced by EGF</arg>
                </example>
                <example src="REPLACE" no="344">
                    <text>The induction of a mutation in the A0 gene (LacI) has the ability to mutated in abolited increase of FEG-stimulated phosphorylation and FEG-induced mobility change, which is the cell mutation.</text>
                    <arg n="2">abolited increase of FEG-stimulated phosphorylation and FEG-induced mobility change</arg>
                </example>
                <example src="REPLACE" no="345">
                    <text>The induction of a mutation in the A0 gene (LacI) has the ability to mutated in increasing above the stimulated phosphorylation and change of mobility induced by FEG, which is the cell mutation.</text>
                    <arg n="2">increasing above the stimulated phosphorylation and change of mobility induced by FEG</arg>
                </example>
                <example src="REPLACE" no="346">
                    <text>The induction of a mutation in the A0 gene (LacI) has the ability to mutated in late infection variant neuronal lipofuscinosis and mutant nclf mice, which is the cell mutation.</text>
                    <arg n="2">late infection variant neuronal lipofuscinosis and mutant nclf mice</arg>
                </example>
                <example src="REPLACE" no="347">
                    <text>The induction of a mutation in the A0 gene (LacI) has the ability to mutated in late infection variations in neuronal lipofuscinosis and nclf mice, which is the cell mutation.</text>
                    <arg n="2">late infection variations in neuronal lipofuscinosis and nclf mice</arg>
                </example>
                <example src="REPLACE" no="348">
                    <text>The induction of a mutation in the A0 gene (LacI) has the ability to mutated in losing the transcriptional repression of the lacZ gene, which is the cell mutation.</text>
                    <arg n="2">losing the transcriptional repression of the lacZ gene</arg>
                </example>
                <example src="REPLACE" no="349">
                    <text>The induction of a mutation in the A0 gene (LacI) will mutated in Liphofuscinosis slow inphantyl neural lipofuscinosis (CLN6) and in nclf mutant mice, which is the cell mutation.</text>
                    <arg n="2">Liphofuscinosis slow inphantyl neural lipofuscinosis (CLN6) and in nclf mutant mice</arg>
                </example>
                <example src="REPLACE" no="350">
                    <text>The induction of a mutation in the A0 gene (LacI) will mutated in above the increased phosphorylation stimulated by FEG and reduced mobility induced by FEG, which is the cell mutation.</text>
                    <arg n="2">above the increased phosphorylation stimulated by FEG and reduced mobility induced by FEG</arg>
                </example>
                <example src="REPLACE" no="351">
                    <text>The induction of a mutation in the A0 gene (LacI) will mutated in increasing above the EGF and increasing the phosphorylation and mobility induced by the EGF, which is the cell mutation.</text>
                    <arg n="2">increasing above the EGF and increasing the phosphorylation and mobility induced by the EGF</arg>
                </example>
                <example src="REPLACE" no="352">
                    <text>The induction of a mutation in the A0 gene (LacI) will mutated in late neuronal lipofuscinosis and mutant nclf mice, which is the cell mutation.</text>
                    <arg n="2">late neuronal lipofuscinosis and mutant nclf mice</arg>
                </example>
                <example src="REPLACE" no="353">
                    <text>The induction of a mutation in the A0 gene (LacI), for example, has the ability to mutated in Liphofuscinosis slow inphantyl neural lipofuscinosis (CLN6) and in nclf mutant mice, which is the cell mutation.</text>
                    <arg n="2">Liphofuscinosis slow inphantyl neural lipofuscinosis (CLN6) and in nclf mutant mice</arg>
                </example>
                <example src="REPLACE" no="354">
                    <text>The induction of a mutation in the A0 gene (LacI), for example, has the ability to mutated in abolited increase of EGF and increased phosphorylation and mobility induced by EGF, which is the cell mutation.</text>
                    <arg n="2">abolited increase of EGF and increased phosphorylation and mobility induced by EGF</arg>
                </example>
                <example src="REPLACE" no="355">
                    <text>The induction of a mutation in the A0 gene (LacI), for example, has the ability to mutated in abolition of FEG-stimulated phosphorylation and prevented FEG-induced mobility, which is the cell mutation.</text>
                    <arg n="2">abolition of FEG-stimulated phosphorylation and prevented FEG-induced mobility</arg>
                </example>
                <example src="REPLACE" no="356">
                    <text>The induction of a mutation in the A0 gene (LacI), for example, has the ability to mutated in above FEG-stimulated phosphorylation and FEG-induced mobility, which is the cell mutation.</text>
                    <arg n="2">above FEG-stimulated phosphorylation and FEG-induced mobility</arg>
                </example>
                <example src="REPLACE" no="357">
                    <text>The induction of a mutation in the A0 gene (LacI), for example, has the ability to mutated in late infection variations in neuronal lipofuscinosis and nclf mice, which is the cell mutation.</text>
                    <arg n="2">late infection variations in neuronal lipofuscinosis and nclf mice</arg>
                </example>
                <example src="REPLACE" no="358">
                    <text>The induction of a mutation in the A0 gene (LacI), for example, will mutated in abolited increase of EGF-stimulated phosphorylation and EGF-induced mobility change, which is the cell mutation.</text>
                    <arg n="2">abolited increase of EGF-stimulated phosphorylation and EGF-induced mobility change</arg>
                </example>
                <example src="REPLACE" no="359">
                    <text>The induction of a mutation in the A0 gene (LacI), for example, will mutated in ceroid lipofuscinosis neural ceroid variation (CLN6) and in mutant mice nclf, which is the cell mutation.</text>
                    <arg n="2">ceroid lipofuscinosis neural ceroid variation (CLN6) and in mutant mice nclf</arg>
                </example>
                <example src="REPLACE" no="360">
                    <text>The induction of a mutation in the A0 gene (LacI), for example, will mutated in increasing above the EGF and increasing the phosphorylation and mobility induced by the EGF, which is the cell mutation.</text>
                    <arg n="2">increasing above the EGF and increasing the phosphorylation and mobility induced by the EGF</arg>
                </example>
                <example src="REPLACE" no="361">
                    <text>The induction of a mutation in the A0 gene (LacI), for example, will mutated in increasing above the stimulated phosphorylation and change of mobility induced by FEG, which is the cell mutation.</text>
                    <arg n="2">increasing above the stimulated phosphorylation and change of mobility induced by FEG</arg>
                </example>
                <example src="REPLACE" no="362">
                    <text>The induction of a mutation in the A0 gene (LacI), for example, will mutated in late infection variant neuronal neural lipofuscinosis (CLN6) and mutant nclf mice, which is the cell mutation.</text>
                    <arg n="2">late infection variant neuronal neural lipofuscinosis (CLN6) and mutant nclf mice</arg>
                </example>
                <example src="REPLACE" no="363">
                    <text>The induction of a mutation in the A0 gene (LacI), for example, will mutated in latest infertile neural lipofuscinosis (CLN6) and nclf mutant mice, which is the cell mutation.</text>
                    <arg n="2">latest infertile neural lipofuscinosis (CLN6) and nclf mutant mice</arg>
                </example>
                <example src="REPLACE" no="364">
                    <text>The mutated A1 gene in abolished the stimulated increase of EGF in phosphorylation and preventing the change in mobility introduced by EGF was the A3 gene (a recently predicted transmembrane protein).</text>
                    <arg n="2">abolished the stimulated increase of EGF in phosphorylation and preventing the change in mobility introduced by EGF</arg>
                </example>
                <example src="REPLACE" no="365">
                    <text>The mutated A1 gene in abolited increase of EGF-stimulated phosphorylation and EGF-induced mobility change was the A3 gene (a recently predicted transmembrane protein).</text>
                    <arg n="2">abolited increase of EGF-stimulated phosphorylation and EGF-induced mobility change</arg>
                </example>
                <example src="REPLACE" no="366">
                    <text>The mutated A1 gene in increasing above the EGF and increasing the phosphorylation and mobility induced by the EGF was the A3 gene (a recently predicted transmembrane protein).</text>
                    <arg n="2">increasing above the EGF and increasing the phosphorylation and mobility induced by the EGF</arg>
                </example>
                <example src="REPLACE" no="367">
                    <text>The mutated A1 gene in increasing above the stimulated phosphorylation and change of mobility induced by FEG was the A3 gene (a recently predicted transmembrane protein).</text>
                    <arg n="2">increasing above the stimulated phosphorylation and change of mobility induced by FEG</arg>
                </example>
                <example src="REPLACE" no="368">
                    <text>The mutated A1 gene in losing the transcriptional repression of the lacZ gene was the A3 gene (a recently predicted transmembrane protein).</text>
                    <arg n="2">losing the transcriptional repression of the lacZ gene</arg>
                </example>
                <example src="REPLACE" no="369">
                    <text>The mutation A1 (EE(437 and 438) to Lipfuscinosis of late infertile neural lipofuscinosis (CLN6) and in nclf mutant mice mutate the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">Lipfuscinosis of late infertile neural lipofuscinosis (CLN6) and in nclf mutant mice</arg>
                </example>
                <example src="REPLACE" no="370">
                    <text>The mutation A1 (EE(437 and 438) to Lipfuscinosis slow infertile neural lipofuscinosis (CLN6) and in nclf mutant mice could mutate the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">Lipfuscinosis slow infertile neural lipofuscinosis (CLN6) and in nclf mutant mice</arg>
                </example>
                <example src="REPLACE" no="371">
                    <text>The mutation A1 (EE(437 and 438) to Lipfuscinosis slow infertile neural lipofuscinosis (CLN6) and in nclf mutant mice may have mutate the DNA-binding mutant (Stat5aEE-AA of Stat5a may have been caused by the DNA mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">Lipfuscinosis slow infertile neural lipofuscinosis (CLN6) and in nclf mutant mice</arg>
                </example>
                <example src="REPLACE" no="372">
                    <text>The mutation A1 (EE(437 and 438) to Lipfuscinosis slow infertile neural lipofuscinosis (CLN6) and in nclf mutant mice mutating the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">Lipfuscinosis slow infertile neural lipofuscinosis (CLN6) and in nclf mutant mice</arg>
                </example>
                <example src="REPLACE" no="373">
                    <text>The mutation A1 (EE(437 and 438) to Lipfuscinosis slow infertile neural lipofuscinosis (CLN6) and in nclf mutant mice will mutating the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">Lipfuscinosis slow infertile neural lipofuscinosis (CLN6) and in nclf mutant mice</arg>
                </example>
                <example src="REPLACE" no="374">
                    <text>The mutation A1 (EE(437 and 438) to Lipfuscinosis slow inphantyl neural lipofuscinosis (CLN6) and in nclf mutant mice may have mutate the DNA-binding mutant (Stat5aEE-AA of Stat5a may have been caused by the DNA mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">Lipfuscinosis slow inphantyl neural lipofuscinosis (CLN6) and in nclf mutant mice</arg>
                </example>
                <example src="REPLACE" no="375">
                    <text>The mutation A1 (EE(437 and 438) to Liphofuscinosis slow inphantyl neural lipofuscinosis (CLN6) and in nclf mutant mice could mutate the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">Liphofuscinosis slow inphantyl neural lipofuscinosis (CLN6) and in nclf mutant mice</arg>
                </example>
                <example src="REPLACE" no="376">
                    <text>The mutation A1 (EE(437 and 438) to abolished the stimulated increase of EGF in phosphorylation and preventing the change in mobility introduced by EGF is observed to mutate the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">abolished the stimulated increase of EGF in phosphorylation and preventing the change in mobility introduced by EGF</arg>
                </example>
                <example src="REPLACE" no="377">
                    <text>The mutation A1 (EE(437 and 438) to abolished the stimulated increase of EGF in phosphorylation and preventing the change in mobility introduced by EGF will mutate the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">abolished the stimulated increase of EGF in phosphorylation and preventing the change in mobility introduced by EGF</arg>
                </example>
                <example src="REPLACE" no="378">
                    <text>The mutation A1 (EE(437 and 438) to abolished the stimulated increase of EGF in phosphorylation and preventing the change in mobility introduced by EGF will mutating the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">abolished the stimulated increase of EGF in phosphorylation and preventing the change in mobility introduced by EGF</arg>
                </example>
                <example src="REPLACE" no="379">
                    <text>The mutation A1 (EE(437 and 438) to abolited increase of EGF and increased phosphorylation and mobility induced by EGF may have mutating the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">abolited increase of EGF and increased phosphorylation and mobility induced by EGF</arg>
                </example>
                <example src="REPLACE" no="380">
                    <text>The mutation A1 (EE(437 and 438) to abolited increase of EGF and increased phosphorylation and mobility induced by EGF will mutating the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">abolited increase of EGF and increased phosphorylation and mobility induced by EGF</arg>
                </example>
                <example src="REPLACE" no="381">
                    <text>The mutation A1 (EE(437 and 438) to abolited increase of EGF-stimulated phosphorylation and EGF-induced mobility change will mutate the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">abolited increase of EGF-stimulated phosphorylation and EGF-induced mobility change</arg>
                </example>
                <example src="REPLACE" no="382">
                    <text>The mutation A1 (EE(437 and 438) to abolited increase of FEG-stimulated phosphorylation and FEG-induced mobility change can mutating the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">abolited increase of FEG-stimulated phosphorylation and FEG-induced mobility change</arg>
                </example>
                <example src="REPLACE" no="383">
                    <text>The mutation A1 (EE(437 and 438) to abolited increase of FEG-stimulated phosphorylation and FEG-induced mobility change may have mutating the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">abolited increase of FEG-stimulated phosphorylation and FEG-induced mobility change</arg>
                </example>
                <example src="REPLACE" no="384">
                    <text>The mutation A1 (EE(437 and 438) to abolition of FEG-stimulated phosphorylation and prevented FEG-induced mobility can mutating the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">abolition of FEG-stimulated phosphorylation and prevented FEG-induced mobility</arg>
                </example>
                <example src="REPLACE" no="385">
                    <text>The mutation A1 (EE(437 and 438) to abolition of FEG-stimulated phosphorylation and prevented FEG-induced mobility has the ability to mutating the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">abolition of FEG-stimulated phosphorylation and prevented FEG-induced mobility</arg>
                </example>
                <example src="REPLACE" no="386">
                    <text>The mutation A1 (EE(437 and 438) to abolition of FEG-stimulated phosphorylation and prevented FEG-induced mobility would mutating the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">abolition of FEG-stimulated phosphorylation and prevented FEG-induced mobility</arg>
                </example>
                <example src="REPLACE" no="387">
                    <text>The mutation A1 (EE(437 and 438) to above FEG-stimulated phosphorylation and FEG-induced mobility can mutating the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">above FEG-stimulated phosphorylation and FEG-induced mobility</arg>
                </example>
                <example src="REPLACE" no="388">
                    <text>The mutation A1 (EE(437 and 438) to above FEG-stimulated phosphorylation and FEG-induced mobility may have mutate the DNA-binding mutant (Stat5aEE-AA of Stat5a may have been caused by the DNA mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">above FEG-stimulated phosphorylation and FEG-induced mobility</arg>
                </example>
                <example src="REPLACE" no="389">
                    <text>The mutation A1 (EE(437 and 438) to above the increased phosphorylation stimulated by FEG and reduced mobility induced by FEG is observed to mutate the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">above the increased phosphorylation stimulated by FEG and reduced mobility induced by FEG</arg>
                </example>
                <example src="REPLACE" no="390">
                    <text>The mutation A1 (EE(437 and 438) to ceroid lipofuscinosis neural ceroid variation (CLN6) and in mutant mice nclf could mutate the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">ceroid lipofuscinosis neural ceroid variation (CLN6) and in mutant mice nclf</arg>
                </example>
                <example src="REPLACE" no="391">
                    <text>The mutation A1 (EE(437 and 438) to ceroid lipofuscinosis neural ceroid variation (CLN6) and in mutant mice nclf may have mutate the DNA-binding mutant (Stat5aEE-AA of Stat5a may have been caused by the DNA mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">ceroid lipofuscinosis neural ceroid variation (CLN6) and in mutant mice nclf</arg>
                </example>
                <example src="REPLACE" no="392">
                    <text>The mutation A1 (EE(437 and 438) to ceroid variant of late infertile neural diffufuscinosis (CLN6) and in nclf mutant mice could mutate the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">ceroid variant of late infertile neural diffufuscinosis (CLN6) and in nclf mutant mice</arg>
                </example>
                <example src="REPLACE" no="393">
                    <text>The mutation A1 (EE(437 and 438) to ceroid variant of late infertile neural diffufuscinosis (CLN6) and in nclf mutant mice has the ability to mutating the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">ceroid variant of late infertile neural diffufuscinosis (CLN6) and in nclf mutant mice</arg>
                </example>
                <example src="REPLACE" no="394">
                    <text>The mutation A1 (EE(437 and 438) to increasing above increased phosphorylation stimulated by FEG and change of mobility induced by FEG is observed to mutate the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">increasing above increased phosphorylation stimulated by FEG and change of mobility induced by FEG</arg>
                </example>
                <example src="REPLACE" no="395">
                    <text>The mutation A1 (EE(437 and 438) to increasing above increased phosphorylation stimulated by FEG and change of mobility induced by FEG mutating the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">increasing above increased phosphorylation stimulated by FEG and change of mobility induced by FEG</arg>
                </example>
                <example src="REPLACE" no="396">
                    <text>The mutation A1 (EE(437 and 438) to increasing above the EGF and increasing the phosphorylation and mobility induced by the EGF could mutate the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">increasing above the EGF and increasing the phosphorylation and mobility induced by the EGF</arg>
                </example>
                <example src="REPLACE" no="397">
                    <text>The mutation A1 (EE(437 and 438) to increasing above the EGF increase and increasing the phosphorylation and mobility induced by the EGF will mutating the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">increasing above the EGF increase and increasing the phosphorylation and mobility induced by the EGF</arg>
                </example>
                <example src="REPLACE" no="398">
                    <text>The mutation A1 (EE(437 and 438) to increasing above the increase in phosphorylation stimulated by FEG and change in mobility induced by FEG may have mutating the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">increasing above the increase in phosphorylation stimulated by FEG and change in mobility induced by FEG</arg>
                </example>
                <example src="REPLACE" no="399">
                    <text>The mutation A1 (EE(437 and 438) to increasing above the increase in phosphorylation stimulated by FEG and change in mobility induced by FEG mutate the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">increasing above the increase in phosphorylation stimulated by FEG and change in mobility induced by FEG</arg>
                </example>
                <example src="REPLACE" no="400">
                    <text>The mutation A1 (EE(437 and 438) to increasing above the increased phosphorylation stimulated by EGF and change of mobility induced by the EGF can mutating the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">increasing above the increased phosphorylation stimulated by EGF and change of mobility induced by the EGF</arg>
                </example>
                <example src="REPLACE" no="401">
                    <text>The mutation A1 (EE(437 and 438) to increasing above the increased phosphorylation stimulated by EGF and change of mobility induced by the EGF will mutate the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">increasing above the increased phosphorylation stimulated by EGF and change of mobility induced by the EGF</arg>
                </example>
                <example src="REPLACE" no="402">
                    <text>The mutation A1 (EE(437 and 438) to infectantyl lipofuscinosis neural lipofuscinosis (CLN6) and in nclf mutant mice could mutate the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">infectantyl lipofuscinosis neural lipofuscinosis (CLN6) and in nclf mutant mice</arg>
                </example>
                <example src="REPLACE" no="403">
                    <text>The mutation A1 (EE(437 and 438) to late infection variant ceroid neuronal lipofuscinosis (CLN6) and mutant nclf mice can mutating the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">late infection variant ceroid neuronal lipofuscinosis (CLN6) and mutant nclf mice</arg>
                </example>
                <example src="REPLACE" no="404">
                    <text>The mutation A1 (EE(437 and 438) to late infection variant ceroid neuronal lipofuscinosis (CLN6) and mutant nclf mice may have mutate the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">late infection variant ceroid neuronal lipofuscinosis (CLN6) and mutant nclf mice</arg>
                </example>
                <example src="REPLACE" no="405">
                    <text>The mutation A1 (EE(437 and 438) to late infection variant neuronal neural lipofuscinosis (CLN6) and mutant nclf mice may have mutate the DNA-binding mutant (Stat5aEE-AA of Stat5a may have been caused by the DNA mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">late infection variant neuronal neural lipofuscinosis (CLN6) and mutant nclf mice</arg>
                </example>
                <example src="REPLACE" no="406">
                    <text>The mutation A1 (EE(437 and 438) to late infection variant neuronal neural lipofuscinosis (CLN6) and mutant nclf mice will mutate the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">late infection variant neuronal neural lipofuscinosis (CLN6) and mutant nclf mice</arg>
                </example>
                <example src="REPLACE" no="407">
                    <text>The mutation A1 (EE(437 and 438) to late infection variant neuronal neural lipofuscinosis (CLN6) and mutant nclf mice would mutating the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">late infection variant neuronal neural lipofuscinosis (CLN6) and mutant nclf mice</arg>
                </example>
                <example src="REPLACE" no="408">
                    <text>The mutation A1 (EE(437 and 438) to late infection variations in neuronal lipofuscinosis and nclf mice can mutating the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">late infection variations in neuronal lipofuscinosis and nclf mice</arg>
                </example>
                <example src="REPLACE" no="409">
                    <text>The mutation A1 (EE(437 and 438) to late infectious variant neuronal lipofuscinosis (CLN6) and mutant nclf mice may have mutating the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">late infectious variant neuronal lipofuscinosis (CLN6) and mutant nclf mice</arg>
                </example>
                <example src="REPLACE" no="410">
                    <text>The mutation A1 (EE(437 and 438) to late neuronal lipofuscinosis and mutant nclf mice could mutating the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">late neuronal lipofuscinosis and mutant nclf mice</arg>
                </example>
                <example src="REPLACE" no="411">
                    <text>The mutation A1 (EE(437 and 438) to latest infertile neural lipofuscinosis (CLN6) and nclf mutant mice may have mutating the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">latest infertile neural lipofuscinosis (CLN6) and nclf mutant mice</arg>
                </example>
                <example src="REPLACE" no="412">
                    <text>The mutation A1 (EE(437 and 438) to latest infertile neural lipofuscinosis (CLN6) and nclf mutant mice will mutating the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">latest infertile neural lipofuscinosis (CLN6) and nclf mutant mice</arg>
                </example>
                <example src="REPLACE" no="413">
                    <text>The mutation A1 (EE(437 and 438) to losing the transcriptional repression of the lacZ gene has the ability to mutating the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">losing the transcriptional repression of the lacZ gene</arg>
                </example>
                <example src="REPLACE" no="414">
                    <text>The mutation A1 (EE(437 and 438) to losing the transcriptional repression of the lacZ gene mutate the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">losing the transcriptional repression of the lacZ gene</arg>
                </example>
                <example src="REPLACE" no="415">
                    <text>The the MAP-terminal T235 and T239 A1 mutation (the eh1/GEH sequence) abolition the stimulated increase of EGF in phosphorylation and preventing the change in mobility introduced by EGF mutate the binding of the snail (Jimnez et al., 1999).</text>
                    <arg n="0">the MAP-terminal T235 and T239</arg>
                    <arg n="2">abolition the stimulated increase of EGF in phosphorylation and preventing the change in mobility introduced by EGF</arg>
                </example>
                <example src="REPLACE" no="416">
                    <text>The the sites T235 and T239 A1 mutation (the eh1/GEH sequence) abolition the stimulated increase in EGF phosphorylation and preventing the change in mobility introduced by the EGF mutating the binding of the snail (Jimnez et al., 1999).</text>
                    <arg n="0">the sites T235 and T239</arg>
                    <arg n="2">abolition the stimulated increase in EGF phosphorylation and preventing the change in mobility introduced by the EGF</arg>
                </example>
                <example src="REPLACE" no="417">
                    <text>The transient expression of exon 8 may have significant mutation of acDR DNA of alpha chain cDNA in COS-1 cells, mutated in enzymatic deficiency.</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">acDR DNA of alpha chain cDNA in COS-1 cells</arg>
                    <arg n="3">enzymatic deficiency</arg>
                </example>
                <example src="REPLACE" no="418">
                    <text>The transient expression of mutants exon 8 alpha strand cDNA DNA in COS-1 cells mutates in enzyme deficiency.</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha strand cDNA DNA in COS-1 cells</arg>
                    <arg n="3">enzyme deficiency</arg>
                </example>
                <example src="REPLACE" no="419">
                    <text>The transient expression of mutants exon 8 alpha-chain cDNA into COS-1 cells mutates in enzyme deficiency.</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha-chain cDNA into COS-1 cells</arg>
                    <arg n="3">enzyme deficiency</arg>
                </example>
                <example src="REPLACE" no="420">
                    <text>To determine how activators interact with the complex and examine the importance of these interactions, in relation to other potential driving mechanisms, for the SWI/SNF function, a gene was identified and mutated.</text>
                    <arg n="1">a gene</arg>
                </example>
                <example src="REPLACE" no="421">
                    <text>To determine how activators interact with the complex and examine the importance of these interactions, in relation to other potential driving mechanisms, for the SWI/SNF function, gen was identified and mutated.</text>
                    <arg n="1">gen</arg>
                </example>
                <example src="REPLACE" no="422">
                    <text>To determine how activators interact with the complex and examine the importance of these interactions, in relation to other potential driving mechanisms, for the SWI/SNF function, pars of residue positions was identified and mutated.</text>
                    <arg n="1">pars of residue positions</arg>
                </example>
                <example src="REPLACE" no="423">
                    <text>To determine how activators interact with the complex and examine the importance of these interactions, in relation to other potential driving mechanisms, for the SWI/SNF function, two amino acids was identified and mutated.</text>
                    <arg n="1">two amino acids</arg>
                </example>
                <example src="REPLACE" no="424">
                    <text>To determine how activators interact with the complex and examine the importance of these interactions, in relation to other potential driving mechanisms, for the SWI/SNF function, we mutated and change genus.</text>
                    <arg n="1">genus</arg>
                </example>
                <example src="REPLACE" no="425">
                    <text>To determine how activators interact with the complex and examine the importance of these interactions, in relation to other potential orientation mechanisms, for the SWI/SNF function, genus have been identified and mutated.</text>
                    <arg n="1">genus</arg>
                </example>
                <example src="REPLACE" no="426">
                    <text>To determine how activators interact with the complex and examine the importance of these interactions, in relation to other potential orientation mechanisms, for the SWI/SNF function, parts of residue positions have been identified and mutated.</text>
                    <arg n="1">parts of residue positions</arg>
                </example>
                <example src="REPLACE" no="427">
                    <text>To determine how activators interact with the complex and examine the importance of these interactions, in relation to other potential orientation mechanisms, for the SWI/SNF function, parts of residue positions will be identified and mutated.</text>
                    <arg n="1">parts of residue positions</arg>
                </example>
                <example src="REPLACE" no="428">
                    <text>To determine how activators interact with the complex and examine the importance of these interactions, in relation to other potential orientation mechanisms, for the SWI/SNF function, we found to identify and mutate a gene.</text>
                    <arg n="1">a gene</arg>
                </example>
                <example src="REPLACE" no="429">
                    <text>To determine how activators interact with the complex and examine the importance of these interactions, in relation to other potential orientation mechanisms, for the SWI/SNF function, we found to identify and mutate gen.</text>
                    <arg n="1">gen</arg>
                </example>
                <example src="REPLACE" no="430">
                    <text>To determine how activators interact with the complex and examine the importance of these interactions, in relation to other potential orientation mechanisms, for the SWI/SNF function, we found to identify and mutate parallel residue positions.</text>
                    <arg n="1">parallel residue positions</arg>
                </example>
                <example src="REPLACE" no="431">
                    <text>To determine how activators interact with the complex and examine the importance of these interactions, in relation to other potential orientation mechanisms, for the SWI/SNF function, we found to identify and mutate settlement pairs.</text>
                    <arg n="1">settlement pairs</arg>
                </example>
                <example src="REPLACE" no="432">
                    <text>To determine how activators interact with the complex and examine the importance of these interactions, in relation to other potential orientation mechanisms, for the SWI/SNF function, we found to identify and mutate target sequences AG.</text>
                    <arg n="1">target sequences AG</arg>
                </example>
                <example src="REPLACE" no="433">
                    <text>To determine how activators interact with the complex and examine the importance of these interactions, in relation to other potential orientation mechanisms, for the SWI/SNF function, we have identified and mutated a gene.</text>
                    <arg n="1">a gene</arg>
                </example>
                <example src="REPLACE" no="434">
                    <text>To determine how activators interact with the complex and examine the importance of these interactions, in relation to other potential orientation mechanisms, for the SWI/SNF function, we have identified and mutated parallel position of waste.</text>
                    <arg n="1">parallel position of waste</arg>
                </example>
                <example src="REPLACE" no="435">
                    <text>To determine how activators interact with the complex and examine the importance of these interactions, in relation to other potential orientation mechanisms, for the SWI/SNF function, we have identified and mutated the two phosphorylation sites PKA (S 64) and S (211) have already been mutated.</text>
                    <arg n="1">the two phosphorylation sites PKA (S 64) and S (211) have already been mutated</arg>
                </example>
                <example src="REPLACE" no="436">
                    <text>To determine how activators interact with the complex and examine the importance of these interactions, in relation to other potential orientation mechanisms, for the SWI/SNF function, we identify and mutate a mutated gene.</text>
                    <arg n="1">a mutated gene</arg>
                </example>
                <example src="REPLACE" no="437">
                    <text>To determine how activators interact with the complex and examine the importance of these interactions, in relation to other potential orientation mechanisms, for the SWI/SNF function, we identify and mutate pairs of waste positions.</text>
                    <arg n="1">pairs of waste positions</arg>
                </example>
                <example src="REPLACE" no="438">
                    <text>To determine how activators interact with the complex and examine the importance of these interactions, in relation to other potential orientation mechanisms, for the SWI/SNF function, we identify and mutated a mutated gene.</text>
                    <arg n="1">a mutated gene</arg>
                </example>
                <example src="REPLACE" no="439">
                    <text>To determine how activators interact with the complex and examine the importance of these interactions, in relation to other potential orientation mechanisms, for the SWI/SNF function, we identify and mutated the two phosphorylation sites PKA (S 64) and S (211) have already been mutated.</text>
                    <arg n="1">the two phosphorylation sites PKA (S 64) and S (211) have already been mutated</arg>
                </example>
                <example src="REPLACE" no="440">
                    <text>To determine how activators interact with the complex and examine the importance of these interactions, in relation to other potential orientation mechanisms, for the SWI/SNF function, we will identify and mutate a gene.</text>
                    <arg n="1">a gene</arg>
                </example>
                <example src="REPLACE" no="441">
                    <text>To determine how activators interact with the complex and examine the importance of these interactions, in relation to other potential orientation mechanisms, for the SWI/SNF function, we will identify and mutate a mutated gene.</text>
                    <arg n="1">a mutated gene</arg>
                </example>
                <example src="REPLACE" no="442">
                    <text>To determine how activators interact with the complex and examine the importance of these interactions, in relation to other potential orientation mechanisms, for the SWI/SNF function, we will identify and mutate pairs of waste positions.</text>
                    <arg n="1">pairs of waste positions</arg>
                </example>
                <example src="REPLACE" no="443">
                    <text>To determine how activators interact with the complex and examine the importance of these interactions, in relation to other potential orientation mechanisms, for the SWI/SNF function, we will identify and mutate parallel of residue positions.</text>
                    <arg n="1">parallel of residue positions</arg>
                </example>
                <example src="REPLACE" no="444">
                    <text>To determine how activators interact with the complex and examine the importance of these interactions, in relation to other potential orientation mechanisms, for the SWI/SNF function, we will identify and mutate parallel residue positions.</text>
                    <arg n="1">parallel residue positions</arg>
                </example>
                <example src="REPLACE" no="445">
                    <text>We have identified alele in exon 5 (Leu40, Ile70, Val73, Leu75, and Pro77) which, when completely mutated to premature translation termination, severe Hex A deficiency.</text>
                    <arg n="0">exon 5</arg>
                    <arg n="1">alele</arg>
                    <arg n="2">premature translation termination</arg>
                    <arg n="3">severe Hex A deficiency</arg>
                </example>
                <example src="REPLACE" no="446">
                    <text>We have identified allele in exon 5 (Leu40, Ile70, Val73, Leu75, and Pro77) which, when completely mutated to termination of premature translation, serious Hex A deficiency.</text>
                    <arg n="0">exon 5</arg>
                    <arg n="1">allele</arg>
                    <arg n="2">termination of premature translation</arg>
                    <arg n="3">serious Hex A deficiency</arg>
                </example>
                <example src="REPLACE" no="447">
                    <text>We have identified allele in exon 5 (Leu40, Ile70, Val73, Leu75, and Pro77) which, when significantly mutated to termination of premature translation, serious Hex A deficiency.</text>
                    <arg n="0">exon 5</arg>
                    <arg n="1">allele</arg>
                    <arg n="2">termination of premature translation</arg>
                    <arg n="3">serious Hex A deficiency</arg>
                </example>
                <example src="REPLACE" no="448">
                    <text>We have identified rice in exon 5 (Leu40, Ile70, Val73, Leu75, and Pro77) which, when completely mutated to premature translation abbreviation, deficiency of each Hex A.</text>
                    <arg n="0">exon 5</arg>
                    <arg n="1">rice</arg>
                    <arg n="2">premature translation abbreviation</arg>
                    <arg n="3">deficiency of each Hex A</arg>
                </example>
                <example src="REPLACE" no="449">
                    <text>We have identified rice in exon 5 (Leu40, Ile70, Val73, Leu75, and Pro77) which, when completely mutated to premature translation abbreviation, severe Hex A deficiency.</text>
                    <arg n="0">exon 5</arg>
                    <arg n="1">rice</arg>
                    <arg n="2">premature translation abbreviation</arg>
                    <arg n="3">severe Hex A deficiency</arg>
                </example>
                <example src="REPLACE" no="450">
                    <text>We have identified rice in exon 5 (Leu40, Ile70, Val73, Leu75, and Pro77) which, when completely mutated to premature translation termination, severe Hex A deficiency.</text>
                    <arg n="0">exon 5</arg>
                    <arg n="1">rice</arg>
                    <arg n="2">premature translation termination</arg>
                    <arg n="3">severe Hex A deficiency</arg>
                </example>
                <example src="REPLACE" no="451">
                    <text>a gene that is mutated in late neural lipofuscinosis variant (LLC6) and nclf mutant mice codes a new predefined transmembrane protein.</text>
                    <arg n="1">a gene</arg>
                    <arg n="2">late neural lipofuscinosis variant (LLC6) and nclf mutant mice</arg>
                    <arg n="3">a new predefined transmembrane protein</arg>
                </example>
                <example src="REPLACE" no="452">
                    <text>a gene was mutated into late neural lipofuscinosis variant (LLC6) and nclf mutant mice coding a new predefined transmembrane protein.</text>
                    <arg n="1">a gene</arg>
                    <arg n="2">late neural lipofuscinosis variant (LLC6) and nclf mutant mice</arg>
                    <arg n="3">a new predefined transmembrane protein</arg>
                </example>
                <example src="REPLACE" no="453">
                    <text>a preserved phenylalanine are able to be significantly mutated by the sequence eh1/GEH, adherence no.Q62696 using the Swiss PDB Viewer program (Guex and Peitsch, 1997).</text>
                    <arg n="0">a preserved phenylalanine</arg>
                    <arg n="1">the sequence eh1/GEH</arg>
                </example>
                <example src="REPLACE" no="454">
                    <text>a preserved phenylalanine are observed significantly mutated by the sequence eh1/GEH, adherence to Q62696 using the Swiss PDB display software (Guex and Peitsch, 1997).</text>
                    <arg n="0">a preserved phenylalanine</arg>
                    <arg n="1">the sequence eh1/GEH</arg>
                </example>
                <example src="REPLACE" no="455">
                    <text>a preserved phenylalanine can be significantly mutated by the sequence eh1/GEH, adherence in Q62696 using the Swiss PDB Viewer software (Guex and Peitsch, 1997).</text>
                    <arg n="0">a preserved phenylalanine</arg>
                    <arg n="1">the sequence eh1/GEH</arg>
                </example>
                <example src="REPLACE" no="456">
                    <text>a preserved phenylalanine can be significantly mutated by the sequence the sequence eh1/GEH, adherence no.D62696 using the Swiss PDB Viewer program (Guex and Peitsch, 1997).</text>
                    <arg n="0">a preserved phenylalanine</arg>
                    <arg n="1">the sequence eh1/GEH</arg>
                </example>
                <example src="REPLACE" no="457">
                    <text>a preserved phenylalanine is likely to be significantly mutated by the sequence eh1/GEH, ascension No.D62696 using the Swiss PDB Viewer program (Guex and Peitsch, 1997).</text>
                    <arg n="0">a preserved phenylalanine</arg>
                    <arg n="1">the sequence eh1/GEH</arg>
                </example>
                <example src="REPLACE" no="458">
                    <text>a preserved phenylalanine will be mutated by the sequence eh1/GEH, adherence in Q62696 using the Swiss PDB Viewer program (Guex and Peitsch, 1997).</text>
                    <arg n="0">a preserved phenylalanine</arg>
                    <arg n="1">the sequence eh1/GEH</arg>
                </example>
                <example src="REPLACE" no="459">
                    <text>a preserved phenylalanine will be significantly mutated for the sequence eh1/GEH, No.D62696 adhesion using the Swiss PDB Viewer program (Guex and Peitsch, 1997).</text>
                    <arg n="0">a preserved phenylalanine</arg>
                    <arg n="1">the sequence eh1/GEH</arg>
                </example>
                <example src="REPLACE" no="460">
                    <text>a preserved phenylalanine would be significantly mutated by the sequence eh1/GEH, adherence in Q62696 using the Swiss PDB Viewer program (Guex and Peitsch, 1997).</text>
                    <arg n="0">a preserved phenylalanine</arg>
                    <arg n="1">the sequence eh1/GEH</arg>
                </example>
                <example src="REPLACE" no="461">
                    <text>exon 5 are able to be significantly mutated by allele, adherence no.Q62696 using the Swiss PDB Viewer program (Guex and Peitsch, 1997).</text>
                    <arg n="0">exon 5</arg>
                    <arg n="1">allele</arg>
                </example>
                <example src="REPLACE" no="462">
                    <text>exon 5 are observed mutated by alele, adhering to Q62696 using the Swiss PDB display software (Guex and Peitsch, 1997).</text>
                    <arg n="0">exon 5</arg>
                    <arg n="1">alele</arg>
                </example>
                <example src="REPLACE" no="463">
                    <text>exon 5 are observed significantly mutated by rice, adherence to Q62696 using the Swiss PDB display software (Guex and Peitsch, 1997).</text>
                    <arg n="0">exon 5</arg>
                    <arg n="1">rice</arg>
                </example>
                <example src="REPLACE" no="464">
                    <text>exon 5 are significantly mutated by alele, adherence to Q62696 using the Swiss PDB display software (Guex and Peitsch, 1997).</text>
                    <arg n="0">exon 5</arg>
                    <arg n="1">alele</arg>
                </example>
                <example src="REPLACE" no="465">
                    <text>exon 5 can be mutated by allele, No.D62696 adhesion using the Swiss PDB Viewer program (Guex and Peitsch, 1997).</text>
                    <arg n="0">exon 5</arg>
                    <arg n="1">allele</arg>
                </example>
                <example src="REPLACE" no="466">
                    <text>exon 5 can be mutated by rice, No.D62696 adhesion using the Swiss PDB Viewer program (Guex and Peitsch, 1997).</text>
                    <arg n="0">exon 5</arg>
                    <arg n="1">rice</arg>
                </example>
                <example src="REPLACE" no="467">
                    <text>exon 5 can be mutated by the sequence allele, adherence no.D62696 using the Swiss PDB Viewer software (Guex and Peitsch, 1997).</text>
                    <arg n="0">exon 5</arg>
                    <arg n="1">allele</arg>
                </example>
                <example src="REPLACE" no="468">
                    <text>exon 5 can be significantly mutated by alele, adhesion in Q62696 using the Swiss PDB display software (Guex and Peitsch, 1997).</text>
                    <arg n="0">exon 5</arg>
                    <arg n="1">alele</arg>
                </example>
                <example src="REPLACE" no="469">
                    <text>exon 5 can be significantly mutated by allele, adhesion in Q62696 using the Swiss PDB display software (Guex and Peitsch, 1997).</text>
                    <arg n="0">exon 5</arg>
                    <arg n="1">allele</arg>
                </example>
                <example src="REPLACE" no="470">
                    <text>exon 5 can be significantly mutated by the sequence allele, adherence no.D62696 using the Swiss PDB Viewer program (Guex and Peitsch, 1997).</text>
                    <arg n="0">exon 5</arg>
                    <arg n="1">allele</arg>
                </example>
                <example src="REPLACE" no="471">
                    <text>exon 5 could be muted for allele, No.D62696 adhesion mutated the Swiss PDB Viewer program (Guex and Peitsch, 1997).</text>
                    <arg n="0">exon 5</arg>
                    <arg n="1">allele</arg>
                </example>
                <example src="REPLACE" no="472">
                    <text>exon 5 could be muted for rice, No.D62696 adhesion mutated the Swiss PDB Viewer program (Guex and Peitsch, 1997).</text>
                    <arg n="0">exon 5</arg>
                    <arg n="1">rice</arg>
                </example>
                <example src="REPLACE" no="473">
                    <text>exon 5 is able to be mutated by rice, adherence in Q62696 using the Swiss PDB Viewer program (Guex and Peitsch, 1997).</text>
                    <arg n="0">exon 5</arg>
                    <arg n="1">rice</arg>
                </example>
                <example src="REPLACE" no="474">
                    <text>exon 5 would be mutated by rice , adherence in Q62696 using the Swiss PDB Viewer software (Guex and Peitsch, 1997).</text>
                    <arg n="0">exon 5</arg>
                    <arg n="1">rice</arg>
                </example>
                <example src="REPLACE" no="475">
                    <text>exon 5 would be significantly mutated by allele, adherence in Q62696 using the Swiss PDB Viewer program (Guex and Peitsch, 1997).</text>
                    <arg n="0">exon 5</arg>
                    <arg n="1">allele</arg>
                </example>
                <example src="REPLACE" no="476">
                    <text>exon 8 are able to be significantly mutated by alpha strand cDNA in the COS-1 cells, adherence no.Q62696 using the Swiss PDB Viewer program (Guex and Peitsch, 1997).</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha strand cDNA in the COS-1 cells</arg>
                </example>
                <example src="REPLACE" no="477">
                    <text>exon 8 are mutated by acDR DNA of alpha chain cDNA in COS-1 cells, adhesion in Q62696 using the Swiss PDB display software (Guex and Peitsch, 1997).</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">acDR DNA of alpha chain cDNA in COS-1 cells</arg>
                </example>
                <example src="REPLACE" no="478">
                    <text>exon 8 are mutated by alpha cDNA chain in COS-1 cells, adherence in Q62696 using the Swiss PDB Viewer software (Guex and Peitsch, 1997).</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha cDNA chain in COS-1 cells</arg>
                </example>
                <example src="REPLACE" no="479">
                    <text>exon 8 are mutated by alpha strand cDNA in COS-1 cells, adhesion in Q62696 using the Swiss PDB display software (Guex and Peitsch, 1997).</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha strand cDNA in COS-1 cells</arg>
                </example>
                <example src="REPLACE" no="480">
                    <text>exon 8 are mutated by alpha-acDR in the alpha chain in 1-BODY cells, adhesion in Q62696 using the Swiss PDB display software (Guex and Peitsch, 1997).</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha-acDR in the alpha chain in 1-BODY cells</arg>
                </example>
                <example src="REPLACE" no="481">
                    <text>exon 8 are mutated by alpha-chain cDNA into COS-1 cells, adherence in Q62696 using the Swiss PDB Viewer software (Guex and Peitsch, 1997).</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha-chain cDNA into COS-1 cells</arg>
                </example>
                <example src="REPLACE" no="482">
                    <text>exon 8 are mutated by cDNA alpha chain in COS-1 cells, adherence in Q62696 using the Swiss PDB Viewer software (Guex and Peitsch, 1997).</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">cDNA alpha chain in COS-1 cells</arg>
                </example>
                <example src="REPLACE" no="483">
                    <text>exon 8 are mutated by cDNA alpha chain in COS-1 cells, adhesion in Q62696 using the Swiss PDB display software (Guex and Peitsch, 1997).</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">cDNA alpha chain in COS-1 cells</arg>
                </example>
                <example src="REPLACE" no="484">
                    <text>exon 8 are observed as mutated by acDR DNA of the alpha chain cDNA in COS-1 cells, adherence to Q62696 using the Swiss PDB Viewer software (Guex and Peitsch, 1997).</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">acDR DNA of the alpha chain cDNA in COS-1 cells</arg>
                </example>
                <example src="REPLACE" no="485">
                    <text>exon 8 are observed as mutated by alpha strand cDNA in COS-1 cells, adherence to Q62696 using the Swiss PDB Viewer software (Guex and Peitsch, 1997).</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha strand cDNA in COS-1 cells</arg>
                </example>
                <example src="REPLACE" no="486">
                    <text>exon 8 are observed as mutated by alpha-chain cDNA into COS-1 cells, adherence to Q62696 using the Swiss PDB Viewer software (Guex and Peitsch, 1997).</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha-chain cDNA into COS-1 cells</arg>
                </example>
                <example src="REPLACE" no="487">
                    <text>exon 8 are observed mutated by acDR DNA of the alpha chain cDNA in the 1-cells, adhering to Q62696 using the Swiss PDB display software (Guex and Peitsch, 1997).</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">acDR DNA of the alpha chain cDNA in the 1-cells</arg>
                </example>
                <example src="REPLACE" no="488">
                    <text>exon 8 are observed mutated by alpha strand cDNA in the COS-1 cells, adhering to Q62696 using the Swiss PDB display software (Guex and Peitsch, 1997).</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha strand cDNA in the COS-1 cells</arg>
                </example>
                <example src="REPLACE" no="489">
                    <text>exon 8 are observed significantly mutated by acDR DNA of alpha chain cDNA in COS-1 cells, ascension No.D62696 using the Swiss PDB Viewer program (Guex and Peitsch, 1997).</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">acDR DNA of alpha chain cDNA in COS-1 cells</arg>
                </example>
                <example src="REPLACE" no="490">
                    <text>exon 8 are observed significantly mutated by acDR DNA of the alpha chain cDNA in the 1-cells, adherence to Q62696 using the Swiss PDB display software (Guex and Peitsch, 1997).</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">acDR DNA of the alpha chain cDNA in the 1-cells</arg>
                </example>
                <example src="REPLACE" no="491">
                    <text>exon 8 are observed significantly mutated by alpha cDNA chain in COS-1, adherence to Q62696 using the Swiss PDB display software (Guex and Peitsch, 1997).</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha cDNA chain in COS-1</arg>
                </example>
                <example src="REPLACE" no="492">
                    <text>exon 8 are observed significantly mutated by alpha strand cDNA DNA in COS-1 cells, adherence to Q62696 using the Swiss PDB display software (Guex and Peitsch, 1997).</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha strand cDNA DNA in COS-1 cells</arg>
                </example>
                <example src="REPLACE" no="493">
                    <text>exon 8 are observed significantly mutated by alpha strand cDNA in COS-1, adherence to Q62696 using the Swiss PDB display software (Guex and Peitsch, 1997).</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha strand cDNA in COS-1</arg>
                </example>
                <example src="REPLACE" no="494">
                    <text>exon 8 are observed significantly mutated by alpha-chain cDNA into COS-1 cells, ascension No.D62696 using the Swiss PDB Viewer program (Guex and Peitsch, 1997).</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha-chain cDNA into COS-1 cells</arg>
                </example>
                <example src="REPLACE" no="495">
                    <text>exon 8 are observed significantly mutated by cDNA alpha chain in COS-1 cells, adherence to Q62696 using the Swiss PDB display software (Guex and Peitsch, 1997).</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">cDNA alpha chain in COS-1 cells</arg>
                </example>
                <example src="REPLACE" no="496">
                    <text>exon 8 are significantly mutated by acDR DNA of alpha chain cDNA in COS-1 cells, adherence to Q62696 using the Swiss PDB display software (Guex and Peitsch, 1997).</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">acDR DNA of alpha chain cDNA in COS-1 cells</arg>
                </example>
                <example src="REPLACE" no="497">
                    <text>exon 8 are significantly mutated by acDR DNA of the alpha chain cDNA in COS-1 cells, adherence to Q62696 using the Swiss PDB display software (Guex and Peitsch, 1997).</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">acDR DNA of the alpha chain cDNA in COS-1 cells</arg>
                </example>
                <example src="REPLACE" no="498">
                    <text>exon 8 are significantly mutated by alpha strand cDNA DNA in COS-1 cells, adherence in Q62696 using the Swiss PDB Viewer software (Guex and Peitsch, 1997).</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha strand cDNA DNA in COS-1 cells</arg>
                </example>
                <example src="REPLACE" no="499">
                    <text>exon 8 are significantly mutated by alpha strand cDNA in COS-1 cells, adherence in Q62696 using the Swiss PDB Viewer software (Guex and Peitsch, 1997).</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha strand cDNA in COS-1 cells</arg>
                </example>
                <example src="REPLACE" no="500">
                    <text>exon 8 are significantly mutated by cDNA alpha chain in COS-1 cells, adherence to Q62696 using the Swiss PDB display software (Guex and Peitsch, 1997).</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">cDNA alpha chain in COS-1 cells</arg>
                </example>
                <example src="REPLACE" no="501">
                    <text>exon 8 can be mutated by acDR DNA of the alpha chain cDNA in the 1-cells, No.D62696 adhesion using the Swiss PDB Viewer program (Guex and Peitsch, 1997).</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">acDR DNA of the alpha chain cDNA in the 1-cells</arg>
                </example>
                <example src="REPLACE" no="502">
                    <text>exon 8 can be mutated by alpha cDNA chain in COS-1 cells, adherence in Q62696 using the Swiss PDB Viewer program (Guex and Peitsch, 1997).</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha cDNA chain in COS-1 cells</arg>
                </example>
                <example src="REPLACE" no="503">
                    <text>exon 8 can be mutated by alpha cDNA chain in COS-1, adherence in Q62696 using the Swiss PDB Viewer program (Guex and Peitsch, 1997).</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha cDNA chain in COS-1</arg>
                </example>
                <example src="REPLACE" no="504">
                    <text>exon 8 can be mutated by alpha strand cDNA DNA in COS-1 cells, No.D62696 adhesion using the Swiss PDB Viewer program (Guex and Peitsch, 1997).</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha strand cDNA DNA in COS-1 cells</arg>
                </example>
                <example src="REPLACE" no="505">
                    <text>exon 8 can be mutated by alpha strand cDNA in COS-1 cells, No.D62696 adhesion using the Swiss PDB Viewer program (Guex and Peitsch, 1997).</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha strand cDNA in COS-1 cells</arg>
                </example>
                <example src="REPLACE" no="506">
                    <text>exon 8 can be mutated by alpha strand cDNA in the COS-1 cells, adherence in Q62696 using the Swiss PDB Viewer program (Guex and Peitsch, 1997).</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha strand cDNA in the COS-1 cells</arg>
                </example>
                <example src="REPLACE" no="507">
                    <text>exon 8 can be mutated by alpha-chain cDNA into COS-1 cells, adhesion to Q62696 using the Swiss PDB display program (Guex and Peitsch, 1997).</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha-chain cDNA into COS-1 cells</arg>
                </example>
                <example src="REPLACE" no="508">
                    <text>exon 8 can be mutated by the sequence alpha strand cDNA in COS-1 cells, adherence no.D62696 using the Swiss PDB Viewer software (Guex and Peitsch, 1997).</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha strand cDNA in COS-1 cells</arg>
                </example>
                <example src="REPLACE" no="509">
                    <text>exon 8 can be mutated by the sequence alpha-chain cDNA into COS-1 cells, adherence no.D62696 using the Swiss PDB Viewer software (Guex and Peitsch, 1997).</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha-chain cDNA into COS-1 cells</arg>
                </example>
                <example src="REPLACE" no="510">
                    <text>exon 8 can be significantly mutated by acDR DNA of alpha chain cDNA in COS-1 cells, adherence in Q62696 using the Swiss PDB Viewer software (Guex and Peitsch, 1997).</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">acDR DNA of alpha chain cDNA in COS-1 cells</arg>
                </example>
                <example src="REPLACE" no="511">
                    <text>exon 8 can be significantly mutated by acDR-alpha in the alpha chain of cells 1, adherence in Q62696 using the Swiss PDB Viewer software (Guex and Peitsch, 1997).</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">acDR-alpha in the alpha chain of cells 1</arg>
                </example>
                <example src="REPLACE" no="512">
                    <text>exon 8 can be significantly mutated by alpha chain cDNA in COS-1 cells, adherence in Q62696 using the Swiss PDB Viewer software (Guex and Peitsch, 1997).</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha chain cDNA in COS-1 cells</arg>
                </example>
                <example src="REPLACE" no="513">
                    <text>exon 8 can be significantly mutated by alpha strand cDNA DNA in COS-1 cells, adhesion in Q62696 using the Swiss PDB display software (Guex and Peitsch, 1997).</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha strand cDNA DNA in COS-1 cells</arg>
                </example>
                <example src="REPLACE" no="514">
                    <text>exon 8 can be significantly mutated by the sequence acDR-alpha in the alpha chain of cells 1, adherence no.D62696 using the Swiss PDB Viewer program (Guex and Peitsch, 1997).</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">acDR-alpha in the alpha chain of cells 1</arg>
                </example>
                <example src="REPLACE" no="515">
                    <text>exon 8 can be significantly mutated by the sequence alpha-chain cDNA into COS-1 cells, adherence no.D62696 using the Swiss PDB Viewer program (Guex and Peitsch, 1997).</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha-chain cDNA into COS-1 cells</arg>
                </example>
                <example src="REPLACE" no="516">
                    <text>exon 8 could be mutated by alpha strand cDNA in the COS-1 cells , adherence in Q62696 using the Swiss PDB Viewer program (Guex and Peitsch, 1997).</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha strand cDNA in the COS-1 cells</arg>
                </example>
                <example src="REPLACE" no="517">
                    <text>exon 8 could be muted for alpha strand cDNA in COS-1 cells, No.D62696 adhesion mutated the Swiss PDB Viewer program (Guex and Peitsch, 1997).</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha strand cDNA in COS-1 cells</arg>
                </example>
                <example src="REPLACE" no="518">
                    <text>exon 8 could be significantly mutated by acDR DNA of the alpha chain cDNA in COS-1 cells, adherence to Q62696 using the Swiss PDB display program (Guex and Peitsch, 1997).</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">acDR DNA of the alpha chain cDNA in COS-1 cells</arg>
                </example>
                <example src="REPLACE" no="519">
                    <text>exon 8 could be significantly mutated by acDR DNA of the alpha chain cDNA in the 1-cells, adherence to Q62696 using the Swiss PDB display program (Guex and Peitsch, 1997).</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">acDR DNA of the alpha chain cDNA in the 1-cells</arg>
                </example>
                <example src="REPLACE" no="520">
                    <text>exon 8 could be significantly mutated by alpha strand cDNA in COS-1 cells, adherence to Q62696 using the Swiss PDB display program (Guex and Peitsch, 1997).</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha strand cDNA in COS-1 cells</arg>
                </example>
                <example src="REPLACE" no="521">
                    <text>exon 8 could be significantly mutated by alpha strand cDNA in COS-1, adherence to Q62696 using the Swiss PDB display program (Guex and Peitsch, 1997).</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha strand cDNA in COS-1</arg>
                </example>
                <example src="REPLACE" no="522">
                    <text>exon 8 could have been mutated by acDR DNA of the alpha chain cDNA in the 1-cells, adherence in Q62696 using the Swiss PDB Viewer program (Guex and Peitsch, 1997).</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">acDR DNA of the alpha chain cDNA in the 1-cells</arg>
                </example>
                <example src="REPLACE" no="523">
                    <text>exon 8 could have been mutated by alpha cDNA chain in COS-1, adherence in Q62696 using the Swiss PDB Viewer program (Guex and Peitsch, 1997).</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha cDNA chain in COS-1</arg>
                </example>
                <example src="REPLACE" no="524">
                    <text>exon 8 could have been mutated by alpha strand cDNA in COS-1 cells, adherence in Q62696 using the Swiss PDB Viewer program (Guex and Peitsch, 1997).</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha strand cDNA in COS-1 cells</arg>
                </example>
                <example src="REPLACE" no="525">
                    <text>exon 8 could have been significantly mutated by alpha chain cDNA in COS-1 cells, adherence no.Q62696 using the Swiss PDB Viewer program (Guex and Peitsch, 1997).</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha chain cDNA in COS-1 cells</arg>
                </example>
                <example src="REPLACE" no="526">
                    <text>exon 8 has the probability of being mutations by acDR DNA of the alpha chain cDNA in COS-1 cells, adherence to Q62696 mutated the Swiss PDB Viewer software (Guex and Peitsch, 1997).</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">acDR DNA of the alpha chain cDNA in COS-1 cells</arg>
                </example>
                <example src="REPLACE" no="527">
                    <text>exon 8 have been mutated by alpha cDNA chain in the COS-1 cells, Adhesion No.D62696 using the Swiss PDB Viewer program (Guex and Peitsch, 1997).</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha cDNA chain in the COS-1 cells</arg>
                </example>
                <example src="REPLACE" no="528">
                    <text>exon 8 have been mutated by alpha chain cDNA in COS-1 cells, Adhesion No.D62696 using the Swiss PDB Viewer program (Guex and Peitsch, 1997).</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha chain cDNA in COS-1 cells</arg>
                </example>
                <example src="REPLACE" no="529">
                    <text>exon 8 have been mutated by alpha strand cDNA DNA in COS-1 cells, Adhesion No.D62696 using the Swiss PDB Viewer program (Guex and Peitsch, 1997).</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha strand cDNA DNA in COS-1 cells</arg>
                </example>
                <example src="REPLACE" no="530">
                    <text>exon 8 have been significantly mutated by alpha chain cDNA in COS-1 cells, ascent No. 62696 using the Swiss PDB Viewer program (Guex and Peitsch, 1997).</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha chain cDNA in COS-1 cells</arg>
                </example>
                <example src="REPLACE" no="531">
                    <text>exon 8 is able to be mutated by acDR DNA of the alpha chain cDNA in the 1-cells, adherence in Q62696 using the Swiss PDB Viewer program (Guex and Peitsch, 1997).</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">acDR DNA of the alpha chain cDNA in the 1-cells</arg>
                </example>
                <example src="REPLACE" no="532">
                    <text>exon 8 is able to be mutated by alpha cDNA chain in COS-1 cells, adherence in Q62696 using the Swiss PDB Viewer program (Guex and Peitsch, 1997).</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha cDNA chain in COS-1 cells</arg>
                </example>
                <example src="REPLACE" no="533">
                    <text>exon 8 is able to be mutated by alpha cDNA chain in COS-1, adherence in Q62696 using the Swiss PDB Viewer program (Guex and Peitsch, 1997).</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha cDNA chain in COS-1</arg>
                </example>
                <example src="REPLACE" no="534">
                    <text>exon 8 is able to be mutated by alpha strand cDNA DNA in COS-1 cells, adherence in Q62696 using the Swiss PDB Viewer program (Guex and Peitsch, 1997).</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha strand cDNA DNA in COS-1 cells</arg>
                </example>
                <example src="REPLACE" no="535">
                    <text>exon 8 is likely to be mutated by acDR DNA of alpha chain cDNA in COS-1 cells, ascension No.D62696 using the Swiss PDB Viewer program (Guex and Peitsch, 1997).</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">acDR DNA of alpha chain cDNA in COS-1 cells</arg>
                </example>
                <example src="REPLACE" no="536">
                    <text>exon 8 is likely to be mutated by alpha strand cDNA in COS-1, ascension No.D62696 using the Swiss PDB Viewer program (Guex and Peitsch, 1997).</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha strand cDNA in COS-1</arg>
                </example>
                <example src="REPLACE" no="537">
                    <text>exon 8 is likely to be significantly mutated by alpha strand cDNA DNA in cells-1, ascension No.D62696 using the Swiss PDB Viewer program (Guex and Peitsch, 1997).</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha strand cDNA DNA in cells-1</arg>
                </example>
                <example src="REPLACE" no="538">
                    <text>exon 8 is likely to be significantly mutated by alpha strand cDNA in COS-1, ascension No.D62696 using the Swiss PDB Viewer program (Guex and Peitsch, 1997).</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha strand cDNA in COS-1</arg>
                </example>
                <example src="REPLACE" no="539">
                    <text>exon 8 is likely to be significantly mutated by alpha-acDR in the alpha chain in 1-BODY cells, ascension No.D62696 using the Swiss PDB Viewer program (Guex and Peitsch, 1997).</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha-acDR in the alpha chain in 1-BODY cells</arg>
                </example>
                <example src="REPLACE" no="540">
                    <text>exon 8 may have been mutated by alpha strand cDNA DNA in COS-1 cells, Adhesion No.D62696 using the Swiss PDB Viewer program (Guex and Peitsch, 1997).</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha strand cDNA DNA in COS-1 cells</arg>
                </example>
                <example src="REPLACE" no="541">
                    <text>exon 8 may have been mutated by alpha strand cDNA in COS-1 cells, Adhesion No.D62696 using the Swiss PDB Viewer program (Guex and Peitsch, 1997).</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha strand cDNA in COS-1 cells</arg>
                </example>
                <example src="REPLACE" no="542">
                    <text>exon 8 may have been mutated by alpha strand cDNA in the COS-1 cells, Adhesion No.D62696 using the Swiss PDB Viewer program (Guex and Peitsch, 1997).</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha strand cDNA in the COS-1 cells</arg>
                </example>
                <example src="REPLACE" no="543">
                    <text>exon 8 may have been significantly mutated by alpha chain cDNA in COS-1 cells, adherence to Q62696 using the Swiss PDB Viewer software (Guex and Peitsch, 1997).</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha chain cDNA in COS-1 cells</arg>
                </example>
                <example src="REPLACE" no="544">
                    <text>exon 8 will be significantly mutated by alpha strand cDNA DNA in cells-1, adherence in Q62696 using the Swiss PDB Viewer program (Guex and Peitsch, 1997).</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha strand cDNA DNA in cells-1</arg>
                </example>
                <example src="REPLACE" no="545">
                    <text>exon 8 will be significantly mutated for acDR DNA of the alpha chain cDNA in COS-1 cells, No.D62696 adhesion using the Swiss PDB Viewer program (Guex and Peitsch, 1997).</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">acDR DNA of the alpha chain cDNA in COS-1 cells</arg>
                </example>
                <example src="REPLACE" no="546">
                    <text>exon 8 will be significantly mutated for alpha cDNA chain in COS-1 cells, No.D62696 adhesion using the Swiss PDB Viewer program (Guex and Peitsch, 1997).</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha cDNA chain in COS-1 cells</arg>
                </example>
                <example src="REPLACE" no="547">
                    <text>exon 8 will be significantly mutated for alpha strand cDNA in COS-1 cells, No.D62696 adhesion using the Swiss PDB Viewer program (Guex and Peitsch, 1997).</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha strand cDNA in COS-1 cells</arg>
                </example>
                <example src="REPLACE" no="548">
                    <text>exon 8 will be significantly mutated for alpha-acDR in the alpha chain in 1-BODY cells, No.D62696 adhesion using the Swiss PDB Viewer program (Guex and Peitsch, 1997).</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha-acDR in the alpha chain in 1-BODY cells</arg>
                </example>
                <example src="REPLACE" no="549">
                    <text>exon 8 will be significantly mutated for alpha-chain cDNA into COS-1 cells, No.D62696 adhesion using the Swiss PDB Viewer program (Guex and Peitsch, 1997).</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha-chain cDNA into COS-1 cells</arg>
                </example>
                <example src="REPLACE" no="550">
                    <text>exon 8 would be mutated by cDNA alpha chain in COS-1 cells , adherence in Q62696 using the Swiss PDB Viewer software (Guex and Peitsch, 1997).</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">cDNA alpha chain in COS-1 cells</arg>
                </example>
                <example src="REPLACE" no="551">
                    <text>exon 8 would be significantly mutated by alpha chain cDNA in COS-1 cells, adherence in Q62696 using the Swiss PDB Viewer program (Guex and Peitsch, 1997).</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha chain cDNA in COS-1 cells</arg>
                </example>
                <example src="REPLACE" no="552">
                    <text>exon 8 would be significantly mutated by alpha strand cDNA DNA in cells-1, adherence in Q62696 using the Swiss PDB Viewer program (Guex and Peitsch, 1997).</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha strand cDNA DNA in cells-1</arg>
                </example>
                <example src="REPLACE" no="553">
                    <text>exon 8 would be significantly mutated by alpha strand cDNA in the COS-1 cells, adherence in Q62696 using the Swiss PDB Viewer program (Guex and Peitsch, 1997).</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha strand cDNA in the COS-1 cells</arg>
                </example>
                <example src="REPLACE" no="554">
                    <text>exon 8 would be significantly mutated by alpha-chain cDNA into COS-1 cells, adherence in Q62696 using the Swiss PDB Viewer program (Guex and Peitsch, 1997).</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha-chain cDNA into COS-1 cells</arg>
                </example>
                <example src="REPLACE" no="555">
                    <text>gen mutated in late infectious variant lipofuscinosis neuronal lipofuscinosis (CLN6) and in mutant nclf mice was A3 (a newly predicted transmembrane protein.</text>
                    <arg n="1">gen</arg>
                    <arg n="2">late infectious variant lipofuscinosis neuronal lipofuscinosis (CLN6) and in mutant nclf mice</arg>
                </example>
                <example src="REPLACE" no="556">
                    <text>gen that has been mutated into late infectious variant lipofuscinosis neuronal lipofuscinosis (CLN6) and in mutant nclf mice codes a newly predicted transmembrane protein.</text>
                    <arg n="1">gen</arg>
                    <arg n="2">late infectious variant lipofuscinosis neuronal lipofuscinosis (CLN6) and in mutant nclf mice</arg>
                    <arg n="3">a newly predicted transmembrane protein</arg>
                </example>
                <example src="REPLACE" no="557">
                    <text>gen that has been mutated into variant of late infantyl neural lipofuscinosis (CLN6) and nclf mutant mice codes a new predefined transmembrane protein.</text>
                    <arg n="1">gen</arg>
                    <arg n="2">variant of late infantyl neural lipofuscinosis (CLN6) and nclf mutant mice</arg>
                    <arg n="3">a new predefined transmembrane protein</arg>
                </example>
                <example src="REPLACE" no="558">
                    <text>gen that is mutated in late infectious variant lipofuscinosis neuronal lipofuscinosis (CLN6) and in mutant nclf mice codes a newly predicted transmembrane protein.</text>
                    <arg n="1">gen</arg>
                    <arg n="2">late infectious variant lipofuscinosis neuronal lipofuscinosis (CLN6) and in mutant nclf mice</arg>
                    <arg n="3">a newly predicted transmembrane protein</arg>
                </example>
                <example src="REPLACE" no="559">
                    <text>gen that is mutated into Liphofuscinosis late infertile neural lipofuscinosis (CLN6) and in nclf mutant mice codes a newly predicted transmembrane protein.</text>
                    <arg n="1">gen</arg>
                    <arg n="2">Liphofuscinosis late infertile neural lipofuscinosis (CLN6) and in nclf mutant mice</arg>
                    <arg n="3">a newly predicted transmembrane protein</arg>
                </example>
                <example src="REPLACE" no="560">
                    <text>gen that is observed to be mutated in variant of late infantyl neural lipofuscinosis (CLN6) and nclf mutant mice codes a new predefined transmembrane protein.</text>
                    <arg n="1">gen</arg>
                    <arg n="2">variant of late infantyl neural lipofuscinosis (CLN6) and nclf mutant mice</arg>
                    <arg n="3">a new predefined transmembrane protein</arg>
                </example>
                <example src="REPLACE" no="561">
                    <text>gen that may have been mutated in Liphofuscinosis late infertile neural lipofuscinosis (CLN6) and in nclf mutant mice was A3 (a new transmembrane protein predicted.</text>
                    <arg n="1">gen</arg>
                    <arg n="2">Liphofuscinosis late infertile neural lipofuscinosis (CLN6) and in nclf mutant mice</arg>
                </example>
                <example src="REPLACE" no="562">
                    <text>gen that was mutated into Lipfuscinosis late infertile neural lipofuscinosis (CLN6) and in nclf mutant mice codes a new predefined transmembrane protein.</text>
                    <arg n="1">gen</arg>
                    <arg n="2">Lipfuscinosis late infertile neural lipofuscinosis (CLN6) and in nclf mutant mice</arg>
                    <arg n="3">a new predefined transmembrane protein</arg>
                </example>
                <example src="REPLACE" no="563">
                    <text>gen that was mutated into late infectious variant lipofuscinosis neuronal lipofuscinosis (CLN6) and in mutant nclf mice was a newly predicted transmembrane protein.</text>
                    <arg n="1">gen</arg>
                    <arg n="2">late infectious variant lipofuscinosis neuronal lipofuscinosis (CLN6) and in mutant nclf mice</arg>
                    <arg n="3">a newly predicted transmembrane protein</arg>
                </example>
            </roleset>
        </predicate>
    </framesest>
</PASBIO>
